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Adrenal corticosteroid effects are mediated predominantly through intracellular
receptors of two types, mineralocorticoid (MR) and glucocorticoid (GR). In vitro, MR
bind aldosterone and the physiological glucocorticoids Cortisol and corticosterone with
equivalent affinities. However in kidney distal convoluted tubules and cortical
collecting ducts, MR selectively bind aldosterone although circulating levels of
glucocorticoids are 100 to 1000-fold in excess of aldosterone. This selectivity is due to
the intracellular enzyme llB-hydroxysteroid dehydrogenase (11B-OHSD) which
catalyses the reversible conversion of physiological glucocorticoids (but not
mineralocorticoids) to inactive products (cortisone and 11-dehydrocorticosterone), thus
regulating their access to MR and perhaps GR. This thesis describes the tissue-specific
regulation of 11B-OHSD using an enzyme assay for total 11B-OHSD activity, and
northern analysis using a cDNA cloned from a rat liver library.
I have found that 11B-OHSD activity and mRNA expression are regulated by
glucocorticoids, but not mineralocorticoids, in rat hippocampus and liver, but not
kidney. Hippocampal 11B-OHSD activity and mRNA expression are elevated by
dexamethasone and stress suggesting a role for 11B-OHSD in modulating glucocorticoid
access to neuronal MR. In agreement with this hypothesis, development of a double in-
situ hybridisation technique demonstrated cellular co-localisation of 11B-OHSD mRNA
with MR and GR mRNAs in rat hippocampus.
I have also demonstrated that 11B-OHSD activity exhibits a sexually-dimorphic
pattern of expression in rat liver due to oestrogen repression in female rats which could
not be explained by a direct action of oestrogen. However, hepatic 11B-OHSD in dwarf
rats exhibits attenuated sexual dimorphism suggesting that oestradiol effects may be
mediated through secretory patterns of growth hormone (GH) which differ in male and
female rats. Furthermore, continuous (female-type) administration of GH led to a
decrease in hepatic 11B-OHSD activity and mRNA expression which was not observed
following pulsatile (male-type) GH treatment. Hippocampal 11B-OHSD activity and
mRNA expression were not affected by oestradiol or GH treatments supporting an
indirect mechanism of oestradiol action, since sex steroids have free access to the brain,
but GH, like many peptides, is unable to cross the blood-brain barrier.
Hypophysectomy followed by oestradiol treatment revealed an additional direct action
of oestradiol on hepatic 11B-OHSD activity and mRNA expression which was not
additive to the repression of hepatic 11B-OHSD by GH. Hippocampal 11B-OHSD was
not affected by oestradiol treatment following hypophysectomy indicating that there are,
as yet undetermined differences between hepatic and hippocampal 11B-OHSD. In rat
kidney, 11B-0HSD activity and mRNA expression were inversely regulated by sex
steroids. Oestradiol treatment of male and female rats led to a marked increase in 11B-
OHSD activity in concurrence with almost complete suppression of 11B-OHSD mRNA
expression, providing evidence for the existence of a second dehydrogenase in rat
kidney which is regulated in a complex manner by oestradiol and continuous but not
pulsatile GH.
In order to understand the cellular role of the 'liver-type' 11B-OHSD, a plasmid
containing the coding region of the rat liver 11B-OHSD cDNA linked to an SV40
promoter was transfected into COS-7 and CV-1 cells, and the conversion of [3H]
corticosterone to [3H] 11-dehydrocorticosterone or [3H] 11-dehydrocorticosterone to
[3H] corticosterone, monitored in the medium over a 24 hour period. Interestingly, it
was found that in intact cells, the 'liver-type' 11B-OHSD did not act as a dehydrogenase,
but instead as a reductase (activating glucocorticoids), and therefore is highly unlikely
to be the enzyme responsible for protecting MR in kidney tubules from exposure to
glucocorticoids. This was confirmed at a molecular level using cells transfected with
11B-OHSD, GR and MMTV-LTR luciferase reporter plasmids, which showed
activation of otherwise inert 11-dehydrocorticosterone to induce the GR-dependent
reporter gene. In conclusion, this thesis demonstrates tissue-specific regulation of 11B-
OHSD by adrenal steroids, sex steroids and growth hormone, provides evidence for the
existence of a second dehydrogenase in rat kidney, and indicates that the 'liver-type'
11B-OHSD is unlikely to be responsible for protecting renal MR from exposure to
glucocorticoids.
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Steroid hormones are all derived from cholesterol, are synthesised in three tissues -
the adrenal glands, the testis and the ovaries, and form four major classes - androgens,
oestrogens, progestins and corticosteroids. Corticosteroids consist of mineralocorticoids
and glucocorticoids, both of which are synthesised in the adrenal cortex and are
metabolised in many other tissues. Mineralocorticoid and glucocorticoid levels are
regulated at various levels including synthesis, metabolism, and exerting effects through
two types of receptor - mineralocorticoid and glucocorticoid receptors. 116-
hydroxysteroid dehydrogenase (116-OHSD) is also a tissue-specific regulator of
corticosteroid levels, and is the subject of this thesis.
1.1.1 The Adrenal Cortex
Biosynthesis of glucocorticoids, mineralocorticoids and adrenal androgens occurs in
the adrenal cortex which has been subdivided into three morphologically distinct zones,
based on differences in vascular and connective tissues (Arnold et al., 1866). The
outermost region, called the zona glomerulosa, lies just underneath the adrenal capsule
and consists of clusters of compact cells which are involved in the synthesis of the major
mineralocorticoid aldosterone. Cells in the middle layer, the zona fasiculata, are larger
due to many lipid inclusions. Cells in the zona fasiculata may have extensions
penetrating into the zona glomerulosa, and thus these two regions are not clearly
demarcated. The innermost layer is the zona reticularis, which is clearly separated from
the other two zones, and is comprised of loosely packed small cells which contain few
lipid inclusions. The two innermost layers, although morphologically distinct, are both
involved in the synthesis of the glucocorticoids Cortisol and/or corticosterone, as well as
producing relatively large amounts of the adrenal androgen dehydroepiandrosterone
(DHEA) and its sulphate DHEAS.
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1.1.2 Steroid Hormone Biosynthesis
The steroid hormones produced by the adrenal cortex are all derived from cholesterol,
the basic structure of which is maintained throughout the steroid biosynthetic pathways
(Fig. 1.1). Some of the steps involved in the pathways leading to synthesis of
mineralocorticoids, glucocorticoids and adrenal androgens are shown in Fig. 1.2.
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atoms.
Four cytochrome P-450 enzymes, and an additional microsomal enzyme are involved
in corticosteroid biosynthesis from cholesterol. Each enzymatic step is
compartmentalised within the cell depending on the subcellular localisation of the
enzyme involved. Firstly, cholesterol must be transported from the cytosol to the inner
mitochondrial membrane, the site of cytochrome P-450scc (side chain cleavage) which
cleaves the side chain of cholesterol at position C21 to form pregnenolone. This is the
rate limiting step in steroidogenesis. Microsomal 36-hydroxysteroid dehydrogenase
(which is probably not a cytochrome P-450 enzyme), is responsible for the conversion of
the newly synthesised pregnenolone to progesterone. Pregnenolone and progesterone are
substrates for two further enzymes associated with the smooth endoplasmic reticulum;
P450ci7 (17a-hydroxylase) and P450c2l (21-hydroxylase) which catalyse hydroxylations
at positions C17 and C21 respectively. Mitochondrial P-450cii is responsible for
hydroxylation of deoxycorticosterone and deoxycortisol to produce corticosterone and
Cortisol respectively. Thus the end products of corticosteroid biosynthesis fall into two
main categories, the C21 steroids which have a two carbon side chain located at position




















Steroid biosynthetic pathways in the adrenal cortex. The pathways for
mineralocorticoids, glucocorticoids and adrenal androgens are shown. 3B-HSD=3B-
hydroxysteroid dehydrogenase. Taken from Orth et al., 1991.
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C21 steroids possess mineralocorticoid and glucocorticoid activities with only small
structural differences determining which activity predominates (Fig. 1.2).
Mineralocorticoids are synthesised in the zona glomerulosa from deoxycorticosterone,
which is converted to aldosterone in three steps, by the action of a single enzyme - P-
450cii (aldosterone synthase). A related but separate gene product (1 lB-hydroxylase) is
also involved in the synthesis of glucocorticoids in the zona fasiculata (John et al., 1985;
Chua et al., 1987).
C19 steroids which possess weak androgenic activity are also produced by the
adrenal cortex. In fact dehydroepiandrosterone (DHEA) and its sulphate DHEAS are the
most abundant products of the adrenal cortex. They are formed from 17a-
hydroxypregnenolone and 17a-progesterone (Fig. 1.2) by the action of P-450cl7. The
products of this reaction, dehydroepiandrosterone and androstenedione are subsequently
converted to testosterone in the periphery; adrenal testosterone synthesis is minimal.
Removal of a further carbon atom (CI9) by the microsomal enzyme P-450 aromatase
produces CI 8 compounds with weak oestrogenic properties. Only small amounts of
oestrogens are produced from the adrenal glands, but DHEA, DHEAS and
androstenedione are substrates for oestrogen production by peripheral tissues such as
adipose tissue which contain P-450 aromatase activity (Nimrod & Ryan, 1975).
1.1.3 Steroid Release and Circulation
Adrenal steroid hormones are released immediately following synthesis, with only
small amounts stored in the gland. Circulating steroid hormones are largely bound to
plasma proteins. The major binding proteins are corticosteroid binding globulin (CBG),
testosterone binding globulin (also known as sex steroid binding globulin) and albumin.
3-4% of plasma Cortisol and corticosterone typically circulates 'free' in the absence of
binding globulins; approximately 90% Cortisol and 80% corticosterone is found
associated with CBG, with remaining glucocorticoids normally associated with albumin
(Dunn et al., 1981). In contrast, aldosterone is only weakly associated with CBG (20%)
and albumin (40%), the rest being non-protein bound or 'free'.
1.1.4 Regulation of Glucocorticoid Secretion
Glucocorticoid secretion is regulated by interactions between hormones of the
hypothalamus, the pituitary, and the adrenal glands, and by neural stimuli. Neural stimuli
from the brain in response to stress for example, cause release of corticotrophin releasing
hormone (CRH) and arginine vasopressin (AVP) from paraventricular parvicellular
neurones into the hypophyseal portal blood. These hormones are carried in the portal
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vessels to the anterior pituitary where they stimulate adrenal corticotrophic hormone
(ACTH) secretion into the systemic blood. ACTH acts on the adrenal cortex to stimulate
synthesis and release of glucocorticoids from the zona fasiculata and zona glomerulosa.
Adrenal activity is subsequently "down-regulated" by the feedback inhibitory actions of
glucocorticoids which inhibit CRH and AVP release from the hypothalamus, and ACTH
release from the pituitary in a negative feedback mechanism. These regulatory systems
are depicted in Fig. 1.3, and reviewed in Orth et al. (1991).
1.1.4.1 ACTH
ACTH is synthesised in the anterior pituitary from a large precursor, pro¬
opiomelanocortin (POMC) (Eipper & Mains, 1980). ACTH binds to selective cell-
surface receptors resulting in activation of adenylate cyclase, thus increasing levels of
cyclic AMP (cAMP) which in turn activates cAMP-dependent protein kinase (protein
kinase A) and phosphorylation of several proteins ultimately resulting in stimulated
steroidogenesis. The acute phase of ACTH action (within minutes) involves an increase
in the conversion of cholesterol to pregnenolone (Simpson & Waterman, 1988). There is
also a chronic phase of ACTH action occurring within hours to days of secretion, which
involves increased synthesis of most of the enzymes involved in the biosynthesis of
corticosteroids, including all of the P-450 enzymes involved (Simpson & Waterman,
1988). ACTH also induces synthesis of other proteins involved in steroidogenesis such
as (i) the low density lipoprotein (LDL) receptor which is required for the uptake of
circulating cholesterol, (ii) adrenodoxin, a protein in the electron transport system
involved in electron transfer by the P-450 enzymes and (iii) sterol carrier protein 2 which
is required for the transfer of cholesterol from intracellular lipid stores to mitochondria.
In addition to a regulatory role in corticosteroid biosynthesis, ACTH is involved in
the maintenance of adrenal weight Thus, supraphysiological ACTH administration leads
to adrenal hypertrophy and hyperplasia, while the absence of ACTH results in adrenal
atrophy (Gill, 1972).
1.1.4.2 Regulation ofACTH Secretion
Although CRH and AVP are the most important physiological regulators of ACTH
secretion, several other hormones such as catecholamines, angiotensin II, serotonin,
oxytocin, atrial natriuretic factor (ANF), cholesystokinin, vasoactive intestinal peptide,
PHI-27 (a gastrointestinal and hypothalamic peptide) and gastrin-releasing peptide have
also been implicated (reviewed in Antoni, 1986).
AVP that participates in the regulation of ACTH release is produced two groups of
neurones in the hypothalamus; the parvicellular cells of the paraventricular nucleus which


























Control of glucocorticoid synthesis and secretion; the hypothalamic-pituitary-adrenal
axis. + = stimulation; - = inhibition.
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nuclei. AVP binds to selective receptors resulting in the hydrolysis of
phosphatidylinositol 4,5-bisphosphate and mobilisation of intracellular calcium stores.
AVP control of ACTH secretion is reviewed in Antoni (1993).
CRH is a 41 amino acid peptide that is probably the major regulator of ACTH
secretion. Similarly to ACTH, CRH mediates its effects by binding to selective cell-
surface receptors which promote activation of adenylate cyclase and cAMP- dependent
protein kinase A. Within seconds, this results in ACTH secretion from the anterior
pituitary corticotropes, and subsequently increased POMC gene transcription.
1.1.4.3 OtherRegulatory Systems
Glucocorticoid secretion is potentially regulated by three control and response
systems which may operate simultaneously, (i) The hypothalamic-pituitary-adrenal axis
in humans and other species, is regulated by a circadian ("about a day") rhythm. The
circadian rhythm of ACTH and glucocorticoid secretion is modified by light and sleep
patterns, such that both ACTH and glucocorticoids reach a maximum in the last few
hours before and after wakening, and then decline throughout the morning and are
minimal in the evening. The mechanisms responsible for the circadian rhythm are
unclear; a diurnal rhythm of CRH release has been reported by some (Watabe et al.,
1987), but not by others (Cunnah et al., 1987) suggesting that other factors must be
involved in maintenance of the circadian rhythm of ACTH and glucocorticoid secretion,
(ii) Stress activates the hypothalamic-pituitary-adrenal axis. Physical and psychological
stressors such as exercise, trauma, surgery, cold exposure, fear and depression all
stimulate the hypothalamus to release ACTH secretagogues such as CRF and AVP. (iii)
Glucocorticoid feedback occurs both at the level of the hypothalamus, and the pituitary.
In the anterior pituitary, glucocorticoids inhibit ACTH secretion and POMC gene
transcription resulting in reduced POMC synthesis (Lundbland & Roberts, 1988).
Glucocorticoids also decrease CRF and AVP mRNA and peptide levels in the
paraventricular nucleus of the hypothalamus.
1.1.5 Regulation of Mineralocorticoid Secretion
Aldosterone secretion is largely controlled by the renin-angiotensin system and
potassium ions. In addition, ACTH and other POMC-derived peptides, sodium ions,
AVP, dopamine, ANF, serotonin and somatostatin may have minor regulatory roles
(Quinn & Williams, 1988).
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1.1.5.1 The Renin-Angiotensin-System
Renin is an enzyme synthesised by the juxtaglomerular cells of the renal cortex,
which catalyses the conversion of liver synthesised angiotensinogen to angiotensin I (Fig.
1.4) (Goodfriend et al., 1984). Angiotensin I is rapidly converted to angiotensin II by the
angiotensin converting enzyme (ACE) predominantly in the lungs and vasculature.
Angiotensin II and in addition angiotensin III, (produced by cleavage of the amino
terminal asparagine from angiotensin II) are responsible for stimulating aldosterone
secretion (Goodfriend et al., 1984). In contrast, angiotensin I has no known biological
action. The actions of angiotensins II and III on the zona glomerulosa are mediated by
cell surface receptors linked to activation of phospholipase C via one or more GTP-
binding proteins. Release of intracellular and extracellular calcium ions through the
phosphoinositol pathway then promotes conversion of cholesterol to pregnenolone, and
corticosterone to aldosterone (Kramer et al., 1980).
Renin secretion and release from the kidney is controlled by renal arterial blood
pressure and sodium levels in the renal tubular fluid (Gibbons et al., 1984). Thus factors
which increase blood pressure such as high salt intake will result in a decrease renin
secretion, while factors which decrease blood pressure such as haemorrhage and
dehydration will increase renin secretion. In addition, angiotensin II inhibits renin
release by negative feedback.
Figure 1.4:
Control of aldosterone secretion by the renin-angiotensin-aldosterone pathway. ACE =
angiotensin converting enzyme; Al, All, AIII = angiotensins I, II and III.
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1.1.5.2 Potassium
Regulation of aldosterone secretion by potassium ions also involves calcium ions as a
second messenger system. Potassium directly increases aldosterone secretion from the
adrenal cortex by depolarizing the plasma membrane which activates voltage-dependent
calcium channels, resulting in an influx of extracellular calcium (Quinn & Williams,
1988) which subsequently increases the activity of steroidogenic enzymes, and thus
promotes conversion of cholesterol to pregnenolone and corticosterone to aldosterone in
the same way as angiotnesin II (McKenna et al., 1978).
1.1.6 Effects of Glucocorticoids
Glucocorticoids have profound effects on development and in the adult, both
peripherally and centrally. For example, glucocorticoids regulate homeostasis, affect
mood and behaviour, are involved in the inflammatory response, and have profound
effects in development; in fact excess glucocorticoid exposure during development leads
to growth retardation, and possibly increases the risk of high blood pressure and
ischaemic heart disease mortality (section 1.3.6.1). A deficiency in corticosteroid
production leads to Addison's disease which is characterised by muscular weakness, low
blood pressure, depression and weight loss. Conversely, Cushing's syndrome occurs as a
result of overproduction of glucocorticoids which may lead to hypertension, poor wound
healing, and redistribution of body fat. The effects of glucocorticoids discussed briefly
below, are reviewed in detail by Orth et al. (1991).
1.1.6.1 Fuel Metabolism
Glucocorticoids play an important role in energy production from proteins,
carbohydrates and fats. Glucocorticoids increase gluconeogenesis in the liver by
increasing the supply of gluconeogenic amino acids from breakdown of muscle proteins,
and by activation of gluconeogenic enzymes such as glucose-6-phosphate (G-6-P) and
phosphoenol pyruvate carboxykinase (PEPCK) (Exton, 1979). In conjunction with
increased gluconeogensis, glucocorticoids also inhibit glucose uptake and peripheral
tissue glucose utilisation in part by direct inhibition of glucose transport into cells (Munk,
1962). Glucocorticoids increase glycogen storage in the liver which may be due to
insulin secretion in response to the increase in blood sugar. There is also increased
protein breakdown and decreased protein synthesis, particularly in muscle in response to
glucocorticoids. Glucocorticoids acutely activate lipolysis in adipose tissue (Fain, 1979),
and lead to redistribution of body fat in situations of glucocorticoid excess possibly in
response to hyperinsulinaemia (Hausberger, 1958). Finally glucocorticoids appear to
have a permissive role in mediating the effects of other gluconeogenic enzymes such as
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glucagon and catecholamines which are ineffective in the absence of glucocorticoids.
Thus glucocorticoids affect fat metabolism by enhancing the sensitivity of lipolysis to
catecholamines (Exton, 1979).
1.1.6.2 Immunological Function and Inflammatory Processes
When given therapeutically, glucocorticoids have powerful anti-inflammatory and
immunosupressive effects (Graham & Tucker, 1984). Local inflammatory responses are
mediated by movement of cells and fluid from the intravascular compartment to the site
of inflammation. Glucocorticoids inhibit this process (Zweifach et al., 1953) possibly by
inhibiting prostaglandin synthesis (Hong & Levine, 1976). Glucocorticoids also inhibit
the actions of inflammatory mediators such as histamine which is a potent vasoactive
agent (Facui, 1979).
Probably the major effect of glucocorticoids on immune cells is to influence their
movement to and from the peripheral circulation. Thus glucocorticoids appear to deplete
T-cells and B-cells by redistribution from the intravascular compartment to the spleen,
lymph nodes and bone marrow (Facui & Dale, 1974; Yu et al., 1974). Glucocorticoids
also have immunosupressive effects on T-cells and B-cells by inhibiting their
proliferation (Gillis et al., 1979; Cupps et al., 1985). In addition, glucocorticoids inhibit
the phagocytic and cytotoxic functions ofmacrophages (Rinehartet al., 1982).
1.1.6.3 Musculoskeletal and Connective Tissues
Chronic glucocorticoid excess causes osteoporosis implicating direct steroid effects
on bone cells. Glucocorticoids inhibit osteoblast function and increase osteoclast
number, leading to a reduction in new bone formation (Hahn et al., 1979).
Glucocorticoids also appear to mediate indirect effects on bone by inhibiting intestinal
calcium reabsorption (Hahn et al., 1979; Wajchenberg et al., 1969).
Fibroblast proliferation is inhibited by glucocorticoids. Glucocorticoids also inhibit
synthesis of the extracellular matrix components collagen and hyaluronidase which
collectively result in impaired wound healing and fragile connective tissues (Leibovich &
Ross, 1975).
1.1.6.4 Fluid and Electrolyte Homeostasis
Evidence of glucocorticoid modulation of blood pressure comes mainly from patients
with glucocorticoids excess or deficiency. Patients with glucocorticoid excess usually
suffer from hypertension, often without increased levels of mineralocorticoids, kaliuresis
or suppressed plasma renin activity (Krakoff et al., 1975; Saruta et al., 1986). However
whether glucocorticoids exert a direct mineralocorticoid response is unclear. Other
glucocorticoid effects have been implicated in the modulation of blood pressure. For
10
example, glucocorticoids induce hepatic production of angiotensinogen, but the
mechanism is unclear, as is the issue of whether increased circulating angiotensinogen
levels leads to increased angiotensin II production. In addition, decreased levels of the
vasodilators prostaglandin E2 and kallikrein are found in the urine of animals and humans
with glucocorticoid excess (Saruta et al., 1986; Handa et al., 1983). Thus the basis for
hypertension in patients with glucocorticoid excess is poorly understood.
A decrease in free water clearance in patients with glucocorticoid deficiency is
associated with increased plasma AVP concentrations (Slessor, 1951; Garrod & Burston,
1952). In addition, glucocorticoid receptors are present in AVP producing cells of the
parvicellular division of the paraventricular hypothalamus (Uht et al., 1988), and
glucocorticoid deficiency leads to increased AVP mRNA levels in the paraventricular
nucleus (Widmaier et al., 1988). In addition, increased circulating AVP levels may play
a role in maintaining blood pressure in adrenal insufficiency (Schwartz et al., 1983).
Animals which have had their adrenal glands removed apart from the adrenal capsule
and zona glomerulosa appear unable to secrete excess salt (Gaunt et al., 1967; 1968).
Glucocorticoid replacement reverses this effect by inducing the synthesis and secretion of
ANF from cardiac myocytes (Garcia et al., 1985). The ANF gene contains putative
glucocorticoid response elements on its regulatory region (Greenberg et al., 1984;
Seidman et al., 1984; Argentin et al., 1985) suggesting that the effects of glucocorticoids
may be direct.
1.1.6.5 Neuropsychiatry and Behavioural Effects
Glucocorticoids affect mood and sleep patterns in humans (McEwen, 1979). The
duration of rapid eye movement sleep is decreased in patients with Cushing's Syndrome
(Kreiger, 1972), and in normal subjects treated with exogenous glucocorticoids (Gallin et
al., 1972). Evidence for glucocorticoid-induced changes in mood also come largely from
clinical observations. Approximately 90% of patients with Cushing's Syndrome suffer
from psychological disturbances including depression (Cohen, 1980). In addition
patients with adrenal insufficiency may also suffer from psychological disturbances with
depression, apathy and lethargy being the most common. The mechanisms of action of
these behavioural effects of glucocorticoids are unknown.
1.1.6.6 Gastrointestinal Effects
Although the colon contains mineralocorticoid receptors which may mediate ion
transport in the colon, there is also evidence that glucocorticoids act through
glucocorticoid receptors to induce sodium transport. This has been shown through the
use of specific glucocorticoid receptor analogues to demonstrate a saturable effect on
sodium transport (Bastl, 1987). In addition, spironolactone which antagonises
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mineralocorticoid receptors has no effect on the sodium transport response to low dose
dexamethasone (a synthetic glucocorticoid, selective for glucocorticoid receptors)
treatment (Bastl, 1988).
1.1.6.7 Developmental Effects
Glucocorticoids have many and profound effects on development. For example,
glucocorticoids regulate organ development and maturation, and of particular clinical
importance are the effects of glucocorticoids in pre- and perinatal lung maturation.
Glucocorticoids stimulate surfactant production by type II pneumocytes, a normal
developmental process which can be accelerated by exogenous glucocorticoids (Ballard,
1987). Glucocorticoids also cause morphological changes in type II cells (Liley et al.,
1987), induce enzymes involved in phospholipid biosynthesis and regulate transcription
of the gene for the major surfactant protein (SP-A) (Odom et al., 1988; Boggaram &
Mendelson, 1988). Therefore threat of premature labour is sometimes treated with
dexamethasone to promote surfactant synthesis and release in the foetal lungs.
High glucocorticoid exposure during development may lead to retardation of foetal
growth (Reinisch et al., 1978) and may increase the risk of developing hypertension and
ischaemic heart disease mortality in later life (Barker et al., 1989a; 1989b; Whincup et
al., 1989; Barker et al., 1990). Foetal exposure to glucocorticoids may also affect
processes which involve cell death presumably due to direct inhibitory effects on bone
and connective tissue (section 1.1.6.3). High glucocorticoid exposure may therefore
result in incidences of cleft palate and polycystic kidney.
In the developing nervous system, glucocorticoids regulate the differentiation of
neural crest epithelium cells into chromaffin cells. Neural crest cells are precursors of
several differentiated cell types including autonomic ganglion cells and adrenomedullary
cells. It is under the influence of glucocorticoids that neural crest precursor cells, which
invade the embryonic adrenal gland, cease to express neurone-specific gene products
such as neurofilaments, and begin to achieve adrenal chromaffin cell morphology
(Fenderoff et al., 1988). The mechanisms by which glucocorticoids mediate this
differential process is not known.
1.1.7 Effects of Mineralocorticoids
Aldosterone is the most important and most potent endogenous mineralocorticoid
whose physiological role is to promote sodium reabsorption and potassium loss from
urine in kidney distal tubules and cortical collecting tubules, from gastrointestinal
contents in the colon, from saliva in the salivary glands, and from sweat (reviewed in
Morris, 1981). Probably the most important of these sodium retaining functions is that in
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kidney tubules, since electrolyte secretion and therefore extracellular volume and blood
pressure are generally controlled by this process. Aldosterone has almost the same
effects on sweat glands and salivary glands that it has on renal distal tubules. Both
glands contain a primary secretion that contains large quantities of sodium chloride, but
much of the sodium chloride is reabsorbed, while potassium and bicarbonate ions are
secreted. The effect on sweat glands is important to conserve body salt in hot
environments, and the effect on salivary glands is necessary to conserve salts when
excessive amounts of saliva are lost.
Aldosterone may also act on non-epithelial tissues. For example there is evidence for
aldosterone-selective actions in brain (McEwen et al., 1986a). Aldosterone infused
intracerebroventricularly (icv) at low concentrations has effects on salt seeking and
ingestion that are not mimicked or blocked by equal or higher amounts of corticosterone,
but are largely blocked by specific aldosterone antagonists (McEwen et al., 1986a). In
addition, there are recent reports of aldosterone actions on circulating mononuclear
leukocytes (Wehling et al., 1987). Nanomolar concentrations of aldosterone block the
ion flux that otherwise occurs during the process of cell preparation by Ficoll-Hyapaque
centrifugation. This effect is neither blocked nor mimicked by Cortisol. Thus as well as
the traditional epithelial actions of aldosterone in kidney distal tubules, sweat glands and
salivary glands, there may also be non-epithelial effects of aldosterone.
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1.2 Steroid Receptors
Steroid hormones classically elicit their effects by binding to steroid hormone
receptors to activate or transform the receptors, which act as nuclear transcription factors
that modulate cell function by either activating or repressing target genes or gene
networks (reviewed by Yamamoto, 1985). Activated receptors can then specifically bind
to DNA sequences called hormone response elements (HREs) which are usually found in
the 5' regulatory region of target genes. The steroid receptor-steroid HRE interaction
then acts to either induce or repress target gene transcription.
1.2.1 Steroid Hormone Receptor Superfamilv
The realisation that steroid hormone receptors belonged to a highly homologous
family became apparent when the various human and rat steroid receptors were cloned
(reviewed by Green & Chambon, 1988; Evans, 1988; Berg, 1989; Beato, 1989; O'Malley,
1990; King, 1992), and comparative analyses were performed. It is now known that the
steroid receptor superfamily includes glucocorticoid receptor (GR), mineralocorticoid
receptor (MR), progesterone receptor (PR), oestrogen receptor (ER) and androgen
receptor (AR). The existence of related nuclear receptors that respond to ligands other
than steroid hormones was demonstrated by the finding that the DNA binding domain of
GR was remarkably similar to the viral oncogene v-erbA and subsequent identification of
c-erbA as the thyroid hormone receptor (Weinberger et al., 1986). Molecular cloning
studies have since demonstrated three more thyroid receptors (ie now TRai, c-erbA<&,
TRgi, TRb2), three retinoic acid receptors (RARa, RARg, RARy), three retinoid X
receptors (RXRa, RXRg,RXRy) and vitamin D receptor (VDR) which are all
superfamily members. In addition, there appear to be several other superfamily members
for which no known activating ligand has been identified. For this reason, these
members are known as orphan receptors (reviewed by O'Malley, 1990; King, 1992).
Orphan receptors include at least two chicken ovalbumin upstream promoter transcription
factor (COUP-TF), two oestrogen receptor related proteins called ERR1 and ERR2,
peroxisome proliferator activated receptor (PPAR), the nerve growth factor-induced
NGFI-B protein, the hepatic nuclear factor HNF-4 and steroidogenic factor (SF1). It has
been predicted that the ligands for these orphan receptors may be indigenous to the cells
in which particular orphans are found (O'Malley, 1990). Alternatively, phosphorylation
may regulate the function of orphan receptors (O'Malley & Conneely, 1992). Finally, the
steroid hormone receptor superfamily also appears to incorporate a variety of steroid
hormone related proteins which regulate developmental pathways in invertebrates. The
14
invertebrate proteins include the ecdysone receptor, the seven up protein and Fushi-tarazu
(FTZ-F1) protein (Parker, 1993).
1.2.2 Functional Domains of Steroid Receptors
Analysis of steroid receptor structure is essential for understanding how steroid
receptors mediate transcriptional control of target genes. Before steroid receptors were
cloned, biochemical and immunological analysis of purified rat liver GR provided the
first evidence of a domain structure for steroid receptors. Thus it was shown that GR is
composed of three distinct domains, two of which function independently of each other
and contain information for DNA binding and steroid hormone binding, while the third
N-terminal domain contains a major epitope for immunoreactivity (Carlstedt-Duke et al.,
1982). The molecular cloning of GR and other receptors permitted functional and
structural comparisons of steroid receptors. It is now known that the ligand binding
domain is C-terminally located while the DNA binding domain is located towards the
middle of the receptor (Fig. 1.5) (reviewed by Evans, 1988; Green & Chambon, 1988;
Beato, 1989; O'Malley, 1990; King, 1992). Throughout all steroid receptors these two
domains, and in particular the DNA binding domain, share high degrees of homology. In
contrast, the N-terminal domain is not conserved.
1.2.2.1 The Ligand Binding Domain
The first step in the cascade of events leading to induction or repression of target gene
transcription by steroid hormones is binding of the hormone to the carboxy terminal
ligand binding domain of the receptor. Deletion of the steroid binding domain results in
constitutive activation of steroid receptors in the absence of hormone binding (Miesfeld
et al., 1987). Thus it appears that the hormone binding domain acts as a repressor of
steroid receptor activation in the absence of hormone and that this repression represents
an intrinsic property of the receptor. Repression of steroid activation appears to be
mediated by the association of steroid receptors with the 90kD heat shock protein (hsp90)
in the cytoplasm of target cells. Ligand binding leads to the dissociation of hsp90, thus
relieving repression of steroid receptor activation (reviewed for GR by Muller &
Renkawitz, 1991; Danielson, 1991).
The cellular localisation of unoccupied steroid receptors has been controversial for
many years, with some data suggesting predominance in the cytoplasm and others
indicating nuclear localisation (reviewed by Walters, 1985; Jenson, 1990). However
recent work has shown that GR and PR are shuttled between the nucleus and the
cytoplasm (DeFranco et al., 1991; Guiochon-Mantel et al., 1991) suggesting that
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Homologies between members of the steroid hormone receptor superfamily. The
numbers between E/F, the steroid binding domain and C, the DNA binding domain
indicate the percentage homology. Members of the family have been arranged within
groups with GR, TRa and RAR« arbitrarily assigned 100%. For comparison of DNA
binding domain between groups, if GR=100%, then TRa=44% and RARa=46%.
Adapted from King, 1991.
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measurements of cytoplasmic and nuclear receptor localisation are a reflection of an
equilibrium between the two locations.
Two domains of rat GR have been identified that are involved in translocation of
activated steroid receptors to the nucleus (Picard & Yamamoto, 1987). One sequence is
located in the ligand binding domain, and the other in the hinge region of the DNA and
ligand binding domains. Both sequences are necessary to direct the hormone-receptor
complex to the nucleus.
1.2.2.2 Receptor Dimerisation
Steroid receptors bind to target DNA as dimers, and this also appears to be a function
of the carboxy terminal steroid binding domain. The steroid hormone receptor
superfamily can be divided into subfamilies dependent on dimerisation properties. Thus
steroid hormone receptors such as MR and GR appear to function as homodimers. In
contrast, although receptors such as TR, RAR and VDR have been shown to bind to
DNA as homodimers, this binding was relatively weak. However it was shown that
binding could be enhanced by proteins in nuclear extracts of various types. The protein
responsible for enhanced binding has now been cloned, and was found to be another
member of the nuclear hormone receptor superfamily, RXR (Yu et al., 1991; Leid et al.,
1992). RXRa and RXRg have been shown to stimulate binding of TR, RAR, VDR,
COUP-TF and PPAR to their respective DNA binding sites suggesting that these
hormone receptors are most likely to function as heterodimers (Kliewer et al., 1992;
Zhang et al., 1992; Bugge et al., 1992). Finally, it is likely that superfamily members
such as NGFI-B and FTZ-F1 proteins will function as monomers (Parker, 1993).
1.2.2.3 Target Gene Recognition
The DNA binding domain is sufficient for specific binding of steroid receptors to
target genes in vivo and in vitro. However, high affinity binding to DNA requires
additional information encoded within the N and C-terminal domains of the receptor
(Danielson et al., 1987). The DNA binding domain is highly basic and contains a
number of highly conserved cysteine residues, eight of which are involved in the
formation of two zinc fingers (Evans & Hollenberg, 1988; Frankel & Pabo, 1988). In the
case of GR, the zinc finger consists of two pairs of cysteine residues co-ordinated with a
zinc atom (Hard et al., 1990). Two zinc finger motifs are present in the DNA binding
domain, and the zinc atom is essential for DNA-binding. The first (N-terminal) zinc
finger is involved in the distinction between glucocorticoid response element (GRE) and
ERE. Three residues at the C-terminus of the first finger and in the interfinger region are
sufficient for specific GRE recognition. Mutational analysis of the second zinc finger has
demonstrated that it is also required for stabilisation of the interaction (Mader et al.,
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1989; Danielson et al., 1989). It has recently been shown that the second zinc finger is
involved in distinction between GRE and ERE or TRE (thyroid response element).
Structural nuclear magnetic resonance data using the GR DNA binding domain expressed
in E. coli has confirmed the existence of zinc fingers, but the region contacting the DNA
was shown to be an a-helical structure located between the two zinc fingers (Hard et al.,
1990). The first chrystallographic data for the structure of GR DNA-binding domain
complexed with DNA has also recently been obtained (Luisi et al., 1991). The structure
revealed that amino acids in the two zinc fingers which are important for target gene
recognition, are found in a helical region which makes contact with the major groove of
DNA. It was also revealed that residues in the second zinc finger are involved in
dimerization of the DNA binding domain (Luisi et al., 1991).
One of the most remarkable features of steroid receptors is that they bind to DNA
response elements consisting of only two distinct sequence motifs related to either
AGAACA or AGGTCA. DNA binding specificity appears to be determined by the
orientation and relative spacing of these motifs. For example, AR, GR, MR and PR all
bind to a steroid response element known as the glucocorticoid response element (GRE)
which is an inverted repeat of AGAACA separated by three nucleotides (Table 1.1).
Other steroid receptors are capable of binding to varients of the AGGTCA sequence as
inverted or direct repeats, although direct repeats are most common in genes. COUP-TF
and RAR bind to direct repeats in a rather promiscuous manner (Table 1.1). Thus RAR
binds to direct repeats separated by 1, 2 or 5 nucleotides (Umesono et al., 1991; Durand
et al., 1992), while COUP-TF is able to bind to direct repeats with spacings of between 1
and 6 nucleotides (Cooney et al., 1992). Thus while the specificity of hormonal
responses is determined in part by a recognition code, additional factors must be involved
to confer specificity if cross-talk between hormonal responses is to be avoided.
The members of the steroid hormone superfamily which have been proposed to bind
to DNA in target genes as monomers (eg NGFI-B, FTZ-F1), appear to bind to a single
AGGTCA motif proceeded by three adenine nucleotides in the case of NGFI-B (Wilson
et al., 1991) or PyCA for FTZ-F1 (Ueda et al., 1992).
1.2.2.4 Transcriptional Regulation
The hormone binding domain and the amino-terminal domain of steroid receptors
appear to be important for efficient transcriptional activation. Several models have been
developed to explain the mechanism by which transcriptional activation is regulated.
The first was initially developed for prokaryotic promoters (Ptashne, 1986, 1988), and
suggests that interaction of the DNA bound hormone receptor complex with a
component(s) of the transcriptional machinery of the cell to form a transcription
activation complex may be involved in transcriptional regulation. Alternatively it has
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DNA binding sites Receptors
Steroid response elements
AGAACA nnn TGTTCT GRE AR, GR, MR, PR
AGGTCA nnn TGACCT ERE ER
Direct repeats
AGGTCA n AGGTCA DR-1 RXR-RXR, PPAR-RXR, RAR-RXR,
COUP-TF-RXR
AGGTCA nn AGGTCA DR-2 RAR-RXR
AGGTCA nnn AGGTCA DR-3 VDR-RXR
AGGTCA nnnn AGGTCA DR-4 TR-RXR
AGGTCA nnnnn AGGTCA DR-5 RAR-RXR
Table 1.1:
DNA-binding sites for nuclear receptors. GRE, glucocorticoid response element; ERE,
oestrogen response element; n, any nucleotide; DR-n, number of nucleotides between
direct repeats. Taken from Umesono et al., 1991.
been proposed that DNA bound hormone receptor complexes may realign nucleosomes
to allow transcription factor recognition of and binding to previously inaccessible regions
of the target gene promoter (Archer et al., 1991). It is also possible that a combination of
these two mechanisms may be used to regulate transcriptional activation.
In addition to their role as transcriptional activators, many nuclear receptors have
been shown to repress gene transcription. Several alternative mechanisms have been
suggested, including competition for common DNA-binding sites. Recently, a novel
mechanism has been proposed for the glucocorticoid repression of the POMC gene
(Drouin et al., 1993). The POMC gene contains a negative GRE (nGRE),
GGAAGGTCAGGTCCA) which has been shown to bind three GR molecules apparently
formed by binding of a GR homodimer followed by binding of a GR monomer on the
opposite side of the double helix. It is thought that GR inhibition of transcription may be
mediated by interference with the activity of other transcription factors or the
transcriptional machinery.
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1.2.2.5 Hormone Specificity and Crosstalk With Other Signalling Pathways
It is now known that members of the steroid hormone receptor superfamily can
interact with members of the AP-1 family of transcription factors to stimulate or repress
gene transcription (Miner & Yamamoto, 1991; 1992). It has been shown that the ability
of GR to stimulate proliferin gene transcription is enhanced by c-jun homodimers, but
repressed by c-jun : c-Fos heterodimers. The effects are mediated by an element related
to but distinct from, a GRE which binds GRE and AP-1, called a composite GRE. These
effects cannot be reproduced by replacing GR with MR or c-Fos with Fra-1. Thus one
mechanism for generating steroid-specific responses in cells expressing multiple types of
receptor involves interactions with AP-1 family members.
1.2.3 Corticosteroid Receptors: How Many Types?
It is evident that MR has very high affinity for both glucocorticoids and
mineralocorticoids in vitro (Krozowski & Funder, 1983). However in vivo, MR in
kidney selectively bind aldosterone, whereas the physiological ligand for MR in
hippocampus and heart is Cortisol or corticosterone. Cloning of human MR (hMR;
Arriza et al., 1987) and hGR (Hollenberg et al., 1985) cDNAs has demonstrated that the
receptors are highly homologous in both the DNA binding domains and the ligand
binding domains as discussed previously. Furthermore, the isolation of an MR cDNA
from a rat brain library indicated that MR in kidney and brain are identical (Arriza et al.,
1988; Patel et al., 1989). Thus tissue-specific differences in aldosterone and
glucocorticoid activation of MR cannot be explained by receptor differences.
The hormone binding specificity of recombinant expressed hMR and hGR has been
investigated by Arriza et al. (1988). A functional assay was developed where either hMR
or hGR were subcloned into expression vectors and transiently transfected into CV-1
cells which have no endogenous steroid receptors. This vector is known as the trans
vector. A reporter plasmid vector (the cis vector) in which a hormone-responsive
promoter is linked to a structural gene encoding an easily measurable enzyme activity
such as bacterial chloramphenicol acetyltransferase (CAT) or firefly luciferase, is co-
transfected with the receptor expression vector. Addition of hormone to the transfected
cell medium stimulates the receptor to activate transcription from the cis vector promoter.
Thus CAT or luciferase activity are convenient measures of receptor-regulated gene
transcription. In this case, the reporter plasmid was a chimaera of the mouse mammary
tumour virus long terminal repeat (MMTV-LTR) which is sensitive to glucocorticoids,
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Figure 1.6:
The co-transfection assay. Taken from Evans & Arriza, 1989.
Cortisol and corticosterone were found to be effective at activating both MR and GR,
but activated MR at 10-fold lower concentrations than GR (ie Kd for MR is 0.5nM, Kd
for GR is 5nM). Thus hMR appears to have little intrinsic ability to discriminate between
glucocorticoids and mineralocorticoids when recombinantly expressed in mammalian
cells. As a direct result of this, it has been speculated that glucocorticoid action is
determined by two receptor systems differing not only in their affinity for glucocorticoids
but also in their interactions with common sets of genes (Arriza et al., 1988). MR is
proposed to partially stimulate GR-responsive gene networks at low glucocorticoid
levels, but maximal activation is dependent on GR responding to higher glucocorticoid
levels such as those associated with the stress response for example. This proposal is
particularly relevant in cells where MR and GR are coexpressed such as hippocampal
neurones (Evans & Arriza, 1989).
Another question which arises however, is how do renal MR maintain aldosterone
selectivity in vivo, especially in the face of a 100 to 1000-fold excess of glucocorticoids?
Two studies have demonstrated that selective binding and activation of renal MR can be
determined, at least in part, by the intracellular enzyme 1 lB-hydroxysteroid
dehydrogenase (Edwards et al., 1988; Funder et al., 1988).
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1.3 llB-Hydroxysteroid Dehydrogenase
1.3.1 Background and History
1 lB-hydroxysteroid dehydrogenase (11B-OHSD) is a microsomal enzyme which
catalyses the reversible conversion of Cortisol to the inactive glucocorticoid, cortisone in
man, and corticosterone to the inactive 11-dehydrocorticosterone in rats (Fig. 1.7). The
two activities of the enzyme are separable, with the 1 lB-dehydrogenase activity oxidising
the hydroxyl group at Cll to an inactive 11-keto group, while the 1 lB-reductase
component catalyses the reverse reaction. In 1960 (Osinski et al., 1960) first reported
that 11B-OHSD activity was dependent on the presence of NADP for 1 lB-dehydrogenase
activity, and NADPH for llB-reductase activity.
Between 1960 and 1985, 11B-OHSD activity was demonstrated in various tissues in
vitro. Thus 11B-OHSD activity has been found in homogenates, subcellular fractions and
cultured cells of kidney (Murphy, 1981), liver (Hurlock & Talalay, 1959; Koerner &
Hellman, 1964; Bush et al., 1968), brain (Peterson et al., 1965; Grosser, 1966), lung
(Koerner, 1966; Murphy, 1981; Nicholas & Lugg, 1982; Abramowitz et al., 1982; 1984),













Principal reactions catalysed by 1 lB-hydroxysteroid dehydrogenase in man and rat. 11B-
DH, 1 lB-dehydrogenase and 11B-OR, 1 lB-reductase activities of 1 lB-hydroxysteroid
dehydrogenase (11B-OHSD).
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Initially, the presence of 11B-OHSD activity in liver led to the proposal that 11B-
OHSD may be a mechanism involved in the metabolism and clearance of Cortisol.
However, demonstrations of enzyme activity in other tissues, and the knowledge that the
1 lB-reductase component of 11B-OHSD is very active in liver (Hellman et al., 1971),
suggested that this was an oversimplification of the role of 11B-OHSD. It was not until
the late 1970's, that the importance of 11B-OHSD became apparent with the description
of congenital and acquired 11B-OHSD deficiencies in man.
1.3.2 11B-OHSD Deficiency
1.3.2.1 Congenital Deficiency of llfi-OHSD: The Syndrome of Apparent
Mineralocorticoid Excess
Congenital 11B-OHSD deficiency is a rare abnormality, but one which can lead to
severe and often fatal clinical hypertension. Indeed there have been only 21 reported
cases in children, and 1 adult (Shackleton & Stewart, 1990) to date. In 1974, Werder
described the first reported case of a 3 year old girl suffering from severe hypertension
and hypokalemia (Werder et al., 1974). Plasma renin activity was undetectable and
mineralocorticoid excess was suspected. However plasma aldosterone was low and no
other mineralocorticoids could be identified. A similar case of hypertension and
hypokalemia was reported a few years later (New et al., 1977; Ulick et al., 1977; 1979).
That Cortisol to cortisone metabolism was impaired in this syndrome was demonstrated
by raised urinary levels of Cortisol metabolites (tetrahydrocortisol [THF] and allo-THF)
with respect to those of cortisone (tetrahydrocortisone [THE]) (Fig. 1.8). However again,
there was apparently no increase in circulating mineralocorticoids and therefore the
syndrome became known as "apparent mineralocorticoid excess" or AME.
In 1983, Oberfield et al., reported sodium retention, potassium loss and hypertension
following ACTH and Cortisol infusion into a patient suffering from AME (Oberfield et
al., 1983). The hypertensive effects appeared to be mediated by MR since spironolactone
(an 'aldosterone'-MR antagonist) led to a reduction in blood pressure, natriuresis and
antikaliuresis. In addition dexamethasone treatment which binds selectively to GR
reversed the hypertensive syndrome in a similar way to spironolactone. It was therefore
suggested that Cortisol itself may be the hypertensive agent through one of two
mechanisms; (i) a defect in MR such that Cortisol had an abnormally high affinity for the
receptor. However this would mean that there would have to be a defect in MR as well
as impaired conversion of Cortisol to cortisone, which is unlikely, (ii) the normal
metabolism of Cortisol to cortisone may be impaired in MR containing tissues such that
Cortisol accumulated and then activated MR (Oberfield et al., 1983). In 1988, this
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Figure 1.8:
Pathways involved in the metabolism of Cortisol. SCC = side chain cleavage; 6B-
OHASE = 6B-hydroxylase; 20 HSD = 20-hydroxysteroid dehydrogenase; 11B-HSD =
1 lB-hydroxysteroid dehydrogenase; 21 OX = 21 oxidase. Taken from Orth et al., 1991.
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that intra-renal Cortisol levels would be increased and could spill over to occupy and












1 lB-hydroxysteroid dehydrogenase: enzyme mediated receptor protection, (illustration
by Brian Walker).
1.3.2.2 Acquired Deficiency of llfi-OHSD: Liquorice-Induced Hypertension
An important factor involved in testing the new hypothesis as to whether Cortisol
activates MR when 11B-OHSD is deficient, was to come from the parallels between
AME and the effects of liquorice addiction. Liquorice abuse has long been known to
result in hypertension and kalliuresis which can be reversed by spironolactone treatment
(Salassa et al., 1962). The effects of liquorice abuse were thought to be due to the active
component of liquorice - glyccyrhetinic acid (GE) - binding to MR (Ulmann et al., 1975;
Armanini et al., 1983). However since dexamethasone reversed the hypertensive
symptoms of liquorice ingestion (Hoefnagels & Kloppenborg, 1983), and sodium
retention was absent in patients without intact adrenal glands (Borst et al., 1953), this
suggested that the presence of Cortisol or another ACTH-dependent steroid was required.
Therefore a direct effect of GE on MR could not be responsible for the hypertensive
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effects of liquorice. However it was possible that GE may mediate its effects by
inhibiting the action of 11B-OHSD. This hypothesis was tested in volunteers taking
liquorice. The resulting hypertensive symptoms were indicative of inhibition of 11B-
OHSD (Stewart et al., 1987). Parallel studies in animals confirmed that GE and
glycyrrhizic acid (GI; which is converted to GE in vivo) inhibit renal 11B-OHSD both in
vitro and in vivo (Monder et al., 1989). Furthermore, carbenoxolone (the hemisuccinate
derivative of GE) has been shown to potentiate the mineralocorticoid effect of
corticosterone in intact rats (Souness & Morris, 1989) and in toad bladder mucosa (Brem
et al., 1989; Gaeggeler et al., 1989). However, carbenoxolone may also inhibit 5B-
reductase (Latif et al., 1990), and 15-hydroxyprostaglandin dehydrogenase (Peskar et al.,
1976), thus placing limitations on interpretation of the effects of carbenoxolone as being
solely related to glucocorticoid or indeed steroid metabolism (Monder, 1991a).
1.3.2.3 llfi-OHSD in Kidney: Tissue-Specific Protector ofRenal MR
Studies of congenital and acquired deficiency of 11B-OHSD indicated that Cortisol
has the ability to bind to and activate renal MR as well as GR. How therefore can renal
MR selectively bind aldosterone in vivo, when free circulating levels of Cortisol or
corticosterone are 100 to 1000-fold in excess of aldosterone? Cortisol/corticosterone
binding globulin was initially proposed as the specificity conferring mechanism
(Sheppard & Funder, 1987). However, MR selectivity is maintained in 10 day old rats
which express relatively low levels of the binding globulins (Sheppard & Funder, 1987).
An alternative suggestion that 11B-OHSD, by catalysing the conversion of active to
inactive glucocorticoids, could confer aldosterone selectivity on renal MR was originally
demonstrated experimentally by two studies which both led to the same conclusions
(Edwards et al., 1988; Funder et al., 1988).
The first step in both studies worked on the assumption that if 11B-OHSD confers
selective aldosterone binding to MR in mineralocorticoid tissues, then 11B-OHSD
activity should be found in these tissues, and not in other organs which contain MR.
Indeed, both groups demonstrated 11B-OHSD activity in kidney, parotid and colon, but
little activity was found in heart and hippocampus. Funder et al. (1988) then went on to
demonstrate that treatment of rats with carbenoxolone prior to measuring 11B-OHSD
activity in vitro resulted in inhibition of the conversion of Cortisol to cortisone. In
addition, it was surmised that if 11B-OHSD converted corticosterone to 11-
dehydrocorticosterone to protect MR from glucocorticoid exposure, then 11-
dehydrocorticosterone must have low affinity for MR. Indeed it was shown in cytosolic
preparations of MR and GR, that 11-dehydrocorticosterone was ineffective at competing
for receptor binding with aldosterone, corticosterone and dexamethasone (Funder et al.,
1988).
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Localisation of renal 116-OHSD using a polyclonal antibody raised against purified
rat liver 116-OHSD (Lakshmi & Monder, 1988), indicated that the enzyme was
predominantly located in proximal tubules leading to the suggestion that the enzyme was
a paracrine protector of renal MR which are principally located in distal tubules and
collecting tubules. No immunoreactive staining was detected in hippocampal or heart
tissue sections (Edwards et al., 1988).
Both groups then went on to demonstrate that corticosterone could bind to renal MR
when 116-OHSD was inhibited by carbenoxolone. This was achieved by injecting tracer
amounts of [3H] aldosterone or [3H] corticosterone in the presence or absence of
carbenoxelone into previously adrenalectomised rats. Funder et al., then measured
binding of the steroids to cytosolic receptors, while Edwards et al., localised steroid
binding in kidney tissue sections exposed to autoradiographic film. Essentially however,
both groups found that corticosterone exhibits no perceptible binding in kidney in an
intact system. However, prior treatment with carbenoxolone or glycyrrhizic acid permits
corticosterone binding in kidney, presumably to mineralocorticoid receptors, since
corticosterone binding is indistinguishable from that of aldosterone (Fig. 1.10).
Clearly, congenital and acquired deficiencies of 116-OHSD in addition to
experimental evidence have supported the proposal that the physiological role of 116-
OHSD in kidney is to convert active to inactive glucocorticoids thus regulating
glucocorticoid access to the otherwise non-selective renal mineralocorticoid receptors,
and therefore preventing symptoms of apparent mineralocorticoid excess.
1.3.3 Further Characterisation of 'Liver-Type' 116-OHSD
It was originally proposed that 116-OHSD may consist of two separate enzymes
encoding separate dehydrogenase and reductase activities. To determine if this was
indeed the case, and to further characterise the enzyme, 116-OHSD was purified from rat
liver microsomes, and found to possess only dehydrogenase activity thus supporting the
'two enzyme hypothesis'. However with the cloning of 116-OHSD from a rat liver cDNA
library, and expression in mammalian cells, it became apparent that both dehydrogenase
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Figure 1.10:
In vivo [3H] corticosterone binding to renal MR in the presence or absence of prior
carbenoxolone treatment, in comparison to [3H] aldosterone binding to renal MR. (a)
Taken from Edwards et al., 1988; (i) [3H] aldosterone binding, (ii) [3H] corticosterone
binding, (iii) [3H] corticosterone binding following carbenoxolone treatment, (iv) [3H]
corticosterone binding in the presence of excess unlabelled corticosterone. (b) Taken
from Funder et al., 1988; Aldo = aldosterone; B = corticosterone; CBX = carbenoxolone.
28
1.3.3.1 Purification of 11fi-OHSD
It was originally suggested that 1 lB-dehydrogenase and 11 B-reductase activities exist
as two separate enzymes at least in lung (Abramovitz et al., 1982) and liver (Lakshmi &
Monder, 1985). In an attempt to determine if this was the case, Lakshmi & Monder
(1988) purified 11B-OHSD from rat liver microsomes. Previous attempts at purifying
11B-OHSD were largely unsuccessful (Hurlock & Talalay, 1969; Bush et al., 1968) since
the enzyme was denatured when it was removed from its membrane-bound location.
However, it was found that if the native membrane environment was replaced by a
synthetic detergent (Lakshmi & Monder 1985), 11B-OHSD could be solubilised in an
active state. Since rat liver 11B-OHSD is NADP-dependent, purification of the enzyme
was achieved by single step NADP-agarose affinity chromatography (Lakshmi &
Monder, 1988). The purified enzyme was found to exclusively express 11B-
dehydrogenase activity in the absence of 11 B-reductase, supporting the suggestion that
the two activities of 11B-OHSD originate from separate structural entities. This was
supported by the finding that AME patients are deficient in llB-dehydrogenase activity
while llB-reductase activity is unaffected. Homogenous rat liver llB-dehydrogenase
was found to be a glycoprotein with a monomer molecular weight of 34kD (Lakshmi &
Monder, 1988) which exhibits a Km for Cortisol of approximately 17|iM and
corticosterone 2pM (Monder & Lakshmi, 1989; Monder et al., 1991).
1.3.3.2 Production ofAntisera Against Purified Rat Liver llfi-OHSD
Three polyclonal antibodies were generated (56-125, 56-126 and 56-127) by injection
of purified 11B-OHSD into three rabbits (Monder & Lakshmi, 1990). The antisera were
immunoprecipitins, but 1 lB-dehydrogenase activity was not completely inhibited by the
antibody suggesting that the epitopic regions did not correspond to the active site of the
enzyme. Two of the antibody preparations, 56-125 and 56-126, produced tissue-specific
staining patterns of 118-OHSD antigen by western blotting. With antiserum 56-125, a
single enzyme of 34kD (corresponding to the purified 11B-OHSD) was detected in liver,
kidney, testis and lung microsomes, while an additional 40kD band was detected in
kidney homogenates. Brain microsomes and homogenates showed additional cross-
reaction with a 26kD band, but in contrast, anti-serum 56-126 revealed no antigen. In
other tissues, antibody 56-126 showed a similar pattern of staining, although an
additional 68kD band in liver and kidney was detected, which may be due to
dimerisation of the 34kD species. Indeed the structurally related (Krook et al., 1990a,
1990b; section 1.3.4) bacterial 3a, 20B-hydroxysteroid dehydrogenase has been
crystallised, and shown to form multimeric complexes (Ghosh et al., 1991). However the
26kD species in brain, the 40kD species in kidney, and an additional 47kD cross-reacting
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species in testis remain unexplained, but are suggestive of more than one isoform of 116-
OHSD (Monder & Lakshmi, 1990).
In an independent study, a mouse anti-11B-OHSD monoclonal antibody was
generated (Castello et al., 1989) which detected a single antigenic species in kidney of
35kD. The mouse antibody bound both 116-dehydrogenase and 1 lB-reductase activities
as shown by binding of the antibody to solubilised kidney proteins followed by
incubation of the complexes with [3H] corticosterone or [3H]11-dehydrocorticosterone
and monitoring metabolite production by HPLC.
1.3.3.3 Cloning ofRat 'Liver-Type' llfi-OHSD
A rat liver cDNA library was screened using the rabbit anti-11B-OHSD serum
(Agarwal et al., 1989). One of three clones which bound the anti-serum was subcloned
into a plasmid vector for further analysis. The insert of this plasmid (pi 1-DH) was 1265
base pairs (bp) long, and when sequenced, revealed an 861 bp open reading frame
predicting a polypeptide of 287 residues with a molecular weight of 31,774 kD. The
difference between this and the predicted 34kD of the purified protein, may be due to
glycosylation; there are two putative N-linked (Asn-X-Ser) glycosylation sites on the
predicted sequence at residues 158-160, and 203-205.
The 11B-OHSD cDNA was cloned into an expression vector containing the SV40
promoter and transfected into Chinese hamster ovary (CHO) cells. llB-dehydrogenase
and llB-reductase activities were measured by the conversion of [^HJ-corticosterone to
[3H] 11-dehydrocorticosterone and vice versa in the cell medium over 20h. In contrast to
the purified native 11B-OHSD protein, recombinant 11B-OHSD was found to express
roughly equal 1 lB-dehydrogenase and 1 lB-reductase activities. Expression of 118-
OHSD in human osteosarcoma cells infected with vaccinia virus confirmed the finding of
equal dehydrogenase and reductase activities with a Km of 2.14|iM for corticosterone at
pH 8.5 (Agarwal et al., 1990). Although cloning of rat liver 11B-OHSD demonstrated
that this isoform of the enzyme is bi-directional, while purification studies suggested the
existence of separate enzymes responsible for 1 lB-dehydrogenase and 1 lB-reductase
activities, the two hypotheses are not mutually exclusive. The 1 lB-reductase component
of 118-OHSD has been shown to be labile, and thus under some conditions the 11B-
dehydrogenase activity can be studied in the absence of the reverse activity (Lakshmi &
Monder, 1985).
Recently a human 11B-OHSD cDNA has been cloned from a human testes cDNA
library using the rat liver cDNA as a probe (Tannin et al., 1991). The open reading frame
of this cDNA is 876bp which predicts a protein of 292 amino acids. The sequence is
11% identical to the rat liver isoform at the amino acid level. Using the human 11B-
OHSD cDNA as a probe, the 11B-OHSD gene was localised to chromosome 1, and was
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then isolated from a chromosome 1-specific human genomic library. The human gene
consists of 6 exons and is at least 9kb in length (Tannin et al., 1991). In addition, an
ovine 11B-OHSD cDNA has been isolated from a sheep liver cDNA library using the rat
liver 11B-OHSD cDNA as a probe. This 11B-OHSD cDNA has a 72% sequence
homology with the rat liver cDNA (Yang et al., 1992).
1.3.3.4 'Liver-Type' llfl-OHSD mRNA Expression
Northern analysis of rat liver 11B-OHSD revealed a single, 1700 nucleotide (nt)
mRNA species in liver, testis, ovary, lung, vascular tissue and various brain regions
(Agarwal et al., 1989; Moisan et al., 1990a). In contrast, rat kidney expresses at least
four mRNA species (Krozowski et al., 1990). In renal cortex and cortex/medulla,
1500nt, 1600nt and 1900nt species of 11B-OHSD exist, while in renal papilla a single
1700nt species (indistinguishable from the species expressed in liver) was detected.
Although deadenylation studies demonstrated that some may be due to variations in the
polyadenylation chain length, other transcripts could not be attributed to this mechanism,
and were proposed to represent products of a separate 11B-OHSD gene (Krozowski et al.,
1990).
The recent identification of a 5' truncated 11B-OHSD cDNA species from the kidney,
which lacks the region encoding the first 26 amino acids of the full length cDNA, and in
addition has a unique 5' untranslated region appeared to support the hypothesis of a
second 11B-OHSD gene (Mercer et al., 1991; Krozowski et al., 1992). However, cloning
of the rat 'liver-type' 11B-OHSD gene promoter demonstrated that the multiple species of
renal 11B-OHSD mRNA are a result of differential promoter usage of a single gene
(Moisan et al., 1992b). Using primer extension and RNase protection analyses, it was
shown that the major transcription start site in liver is 105bp upstream of the start site of
translation. This start site is also the predominant transcription initiation site in kidney.
Two additional transcription start sites are also utilised in kidney. The truncated cDNA
represents transcriptional initiation in the first intron, but this species may not be
translated (discussed in section 1.3.5.1). The second species has an extended 5'
untranslated region, but no in-phase open reading frame suggesting that this sequence
will produce the same translated protein as the full-length protein encoded from the major
transcription start site (Moisan et al., 1992b). The extended 5' untranslated region, in
common with the related 17B-hydroxysteroid dehydrogenase gene in placenta (The et al.,
1989), may alter stability and translatability of the mRNA by formation of secondary
structures such as stem loops within complementary regions of the RNA (Kozak, 1991).
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1.3.4 The Short Chain Alcohol Dehydrogenase Superfamilv
The deduced amino acid sequence of the rat liver, human and ovine 11B-OHSD
proteins is related to other members of a short-chain alcohol dehydrogenase gene family,
which includes prokaryotic and eukaryotic enzymes involved in nitrogen fixation, the
metabolism of sugars, steroids, aromatic hydrocarbons and prostaglandins as well as the
synthesis of antibiotics (Baker et al., 1990a; 1990b; Krook et al., 1990; Tannin et al.,
1991). The superfamily comprises enzymes which are approximately 300 amino acids in
length and function independently of metal co-factors. 11B-OHSD shares the most
significant sequence similarity with the bacterial enzyme 3a, 20B-hydroxysteroid
dehydrogenase from Streptomyces hydrogenans (Marekov et al., 1990), which is
involved in the reversible oxidation of 3a and 20B hydroxyl groups of androstane and
pregnane derivatives. Although human 17B-OHSD and human 3B-OHSD are also
members of the short chain alcohol dehydrogenase family, they are not closely related to
11B-OHSD.
Alignment of members of this family reveals 9 residues which are conserved in all
proteins. These residues are therefore likely to be structurally or functionally important.
3 of these residues are in an area near the amino terminus that is similar to known
nucleotide co-factor binding sites of other enzymes such as yeast alcohol dehydrogenase
(Jornvall et al., 1981). The three dimensional structure of 3a, 20B-hydroxysteroid
dehydrogenase is now known (Ghosh et al., 1991), and indeed the conserved region near
the amino terminus does form part of the nucleotide co-factor binding site. Two other
conserved residues have been shown to lie in close proximity with the co-factor binding
site, and have been proposed to participate in the catalytic functioning of the enzyme by
facilitating transfer of a hydride radical from the steroid to the co-factor (Ghosh et al.,
1991).
1.3.5 11B-OHSD-2?
Although cloning of the rat liver 11B-OHSD cDNA demonstrated that a single
enzyme was capable of encoding both 1 lB-dehydrogenase activity and 1 lB-reductase
activity (Agarwal et al., 1989), several lines of evidence are inconsistent with one
enzyme being responsible for all of the physiological actions of 11B-OHSD.
Use of polyclonal antibodies raised against purified rat liver 11B-OHSD have been
used to demonstrate the location of 11B-OHSD in kidney. Several of these studies
demonstrated 11B-OHSD staining in the proximal convoluted tubules (Edwards et al.,
1988; Rundle et al., 1989), whereas mineralocorticoid receptors are located in the distal
convoluted tubules and cortical collecting duct cells (Rundle et al., 1989; Farman et al.,
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1991). This led to the proposal that 11B-OHSD protected renal MR from exposure to
glucocorticoids by a paracrine mechanism (Edwards et al., 1988), although it has
subsequently been shown that 'liver-type' 11B-OHSD mRNA expression is present in
both proximal and distal tubules (Yau et al., 1991). In addition, 11B-OHSD activity has
been demonstrated in microdissected rabbit distal tubules as well as proximal tubules
(Bonvalet et al., 1990), and primary monolayer cultures of rabbit cortical collecting ducts
convert corticosterone to 11-dehydrocorticosterone very effectively (Naray Fejes-Toth et
al., 1991). Thus the aldosterone-sensitive regions of kidney tubules (cortical collecting
tubules) express high 11B-OHSD activity, but no apparent protein, while aldosterone-
insensitive regions (proximal tubules) appear to express substantial amounts of 11B-
OHSD mRNA and protein.
Kinetic studies on the liver-derived 11B-OHSD indicated that the Km of 11B-OHSD
for corticosterone was approximately 2pM, and that for Cortisol was 17|iM (Agarwal et
al., 1990). However, physiological glucocorticoids circulate 'free' at low nM
concentrations, and MR exhibit low nM (~0.5nM) affinity for glucocorticoids (Arriza et
al., 1987; Krozowski & Funder, 1983). Thus it seems unlikely that the 'liver-type' 11B-
OHSD would be an effective mechanism for conferring aldosterone selectivity on renal
MR.
Ontogenic studies of 11B-OHSD activity (Moisan et al., 1992a) and mRNA
expression (Krozowski et al., 1990; Moisan et al., 1992a) have shown that although 118-
OHSD activity in kidney is high at postnatal day 1, expression of the 'liver-type' 11B-
OHSD mRNA in kidney is low at postnatal day 1 and increases until reaching maximum
levels after postnatal day 15 (Moisan et al., 1992a). This in conjunction with studies
presented in chapter 5, suggest that in the face of low 'liver-type' 11B-OHSD mRNA
expression, another isoform of 11B-OHSD may be responsible for the high enzyme
activity observed in kidney during development.
Finally, patients suffering from apparent mineralocorticoid excess appear to exhibit a
selective deficiency in 118-dehydrogenase activity, while conversion of inactive to active
glucocorticoids remains unaffected. Indeed separate and distinct symptoms are presented
in patients suffering with an apparently isolated defect in 1 lB-reductase activity (Taylor
et al., 1984; Philipou & Higgins, 1985). In addition, recent genetic analysis of 4 patients
suffering from AME and the parents of one of these patients have indicated that there are
no gross deletions or rearrangements of the known 11B-OHSD gene (Nikkila et al.,
1993). Interestingly, there was also no obvious abnormalities of the gene in one patient
suffering from clinical reductase deficiency.
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1.3.5.1 llfi-OHSD-lB
Evidence for the existence of an alternative isoform of 11B-OHSD was presented in
1989, when it was demonstrated that a higher affinity 11B-OHSD species was present in
rat liver microsomes (Monder & Lakshmi, 1989). However this species only accounted
for approximately 10% of total 11B-OHSD activity, and has not been demonstrated in the
purified enzyme.
It has also recently been speculated that the truncated 11B-OHSD species found in
kidney (11B-OHSD IB) may be an important isoform of 11B-OHSD. Indeed, it has been
shown that 11B-OHSD IB mRNA is only expressed in kidney, predominantly in renal
medulla (Mercer et al., 1991; Krozowski et al., 1992). In addition, 11B-OHSD IB when
transfected into COS cells, is recognised by the polyclonal antibody 56-125. Unlike the
full length 11B-OHSD, the truncated species has an apparent molecular weight of 26kD
(the same size as the species expressed in brain). In contrast, kidney homogenates do not
express a 26kD 11B-OHSD species despite an abundance of 11B-OHSD IB mRNA,
suggesting that under normal physiological situations, 11B-OHSD IB may not be
translated. Furthermore, recombinant expressed 11B-OHSD IB does not metabolise [3H]
corticosterone and is therefore inactive (Krozowski et al., 1992, Obeid et al., 1993) at
least in the cell lines used. In addition this species of 11B-OHSD is not expressed in
other aldosterone-sensitive tissues such as colon and parotid and is therefore unlikely to
be a suitable protector of MR in mineralocorticoid-responsive tissues. The role of 11B-
OHSD IB is as yet unknown, but when aligned with other members of the short chain
alcohol dehydrogenase family, it was revealed that the truncated 11B-OHSD isoform still
contains the conserved residues which have been proposed to form the co-factor binding
site (Krozowski, 1992), suggesting that if translated, 118-OHSD IB may have some
functional significance. Since the first 26 hydrophobic residues are missing from 11B-
OHSD IB, it would be likely to have a different cellular location to the full length 11B-
OHSD, and may have a role as a binding protein.
Several reports now exist which support that the 11B-OHSD activity in
mineralocorticoid-target tissues is a distinctive enzyme with different co-factor
specificity, different molecular weight and different substrate affinities. This evidence is
reviewed below.
1.3.5.2 NAD-dependent isoform of 1 lfi-OHSD
Recently a novel activity staining technique has indicated the existence of an NAD-
dependent isoform of 11B-OHSD (Mercer & Krozowski, 1992). Generally, adenine
dinucleotide dependent enzymes favour either the use of NAD or NADP, but rarely
express no preference for one or the other. The NAD-dependent activity of 11B-OHSD
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was demonstrated in rat kidney distal tubules by looking at the production of diformazan
from tetrazolium blue using 1 lB-hydroxyandrostenedione as substrate in the presence of
NAD Mercer & Krozowski, 1992). NADP was not a functional co-factor in this assay.
NAD-dependence of 11B-OHSD using this assay has also been directly demonstrated in
pig kidney using Cortisol as a substrate (Provencher et al., 1992). Localisation of the
NAD-dependent isoform of 11B-OHSD is consistent with localisation of
mineralocorticoid receptors (Rundle et al., 1989; Farman et al., 1991). Similarly, another
study looking at the tissue-specific distribution of NAD-dependent 11B-OHSD activity
indicated that this isoform is more closely associated with aldosterone-selective
mineralocorticoid tissues such as colon and kidney. NAD-dependent 11B-OHSD activity
was also demonstrated in placenta, while other tissues such as liver, testes, hippocampus
and the vasculature exhibit little NAD-dependent 11B-OHSD activity (Walker et al.,
1992).
The placenta also expresses high levels of 11B-OHSD activity which is thought to
protect the foetus from the deleterious effects of high maternal glucocorticoids (Lopez-
Bernal et al., 1980; Murphy et al., 1974). Physicochemical and kinetic studies on
partially purified human placental 11B-OHSD suggest that it is likely to be a different
isoform from rat liver 11B-OHSD (Brown et al., 1993a). For example, the Km of human
placental 11B-OHSD for corticosterone is 14nM and for Cortisol is ~55nM, both of which
are 100-fold lower than 'liver-type' 11B-OHSD. In addition, human placental 11B-OHSD
is NAD-dependent, does not appear to labile and has different detergent solubility and pH
optimum than rat 'liver-type' 11B-OHSD (Brown et al., 1993a). These differences are not
a reflection of species specificity, since rat placental 11B-OHSD is also NAD-dependent
and has very similar characteristics to the human isoform. Over 1000-fold purification of
human placental 11B-OHSD was achieved by AMP-affinity chromatography using NAD
as the protein eluter. SDS-PAGE of the purified fractions indicate a protein of Mr 40kD
which consistently segregates with the NAD-dependent 11B-OHSD activity. Although a
40kD band was identified in kidney by western blotting using polyclonal antisera to the
purified rat liver 11B-OHSD, human placental 11B-OHSD did not cross-react with these
antisera (Brown et al., 1993a), nor did rat kidney 11B-OHSD which had been passed over
the column (Brown et al., 1993b). Similarly, it will be demonstrated in chapter 4 that an
additional isoform of 11B-OHSD found in kidney does not cross-react with the 'liver-
type' 11B-OHSD cDNA, suggesting that the two (or more) isoforms of 11B-OHSD are
substantially different from each other. This may be analogous to the substantial
differences between the two isoforms of 5a-reductase, which exhibit only ~50%
homology despite their similar functions (Andersson et al., 1991).
In light of the aforementioned studies demonstrating NAD-dependent 11B-OHSD
activity in kidney (Mercer & Krozowski, 1992; Walker et al., 1992), it may be speculated
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that the high affinity placental 11B-0HSD isoform would be a likely candidate for
protecting renal mineralocorticoid receptors from glucocorticoid exposure. Indeed, it has
been demonstrated recently that the NAD-dependent 11B-OHSD activity in microsomes
of renal collecting tubules has low nM Km for corticosterone and Cortisol, and expresses
very little reductase activity, similarly to placenta (Rusvai et al., 1993). However
definitive information as to whether the NAD-dependent isoform(s) of 11B-OHSD are the
same in placenta and renal collecting ducts will require complete purification of the
protein(s) and the cDNA(s) and the gene(s) which encode them.
1.3.6 Other Roles for 11B-OHSD
Although the physiological role of 11B-OHSD in kidney has been established as a
protective mechanism regulating glucocorticoid access to MR in distal convoluted
tubules and cortical collecting tubules, 11B-OHSD activity and 'liver-type' mRNA
expression have now been demonstrated in a number of other tissues. Thus as well as
being expressed in typical aldosterone-selective mineralocorticoid target tissues, 11B-
OHSD has also been demonstrated in tissues containing predominantly GR such as liver,
colon, skin and cerebellum (Fuller & Verity, 1990; Teelucksingh et al., 1990; Moisan et
al., 1990b; Whorwood et al., 1992), and in tissues such as hippocampus where MR are
present, but respond to glucocorticoids (Moisan et al., 1990a; Sakai et al., 1990; Lakshmi
et al., 1991). The physiological role of 11B-OHSD in these tissues is not clearly
understood.
1.3.6.1 Placenta
Epidemiological studies have implicated environmental factors acting during
intrauterine growth which may increase the risk of certain clinical disorders later in life.
For example, low birthweight is strongly correlated with the risk of ischaemic heart
disease mortality (Barker et al., 1989a) and high blood pressure at all ages (Barker et al.,
1989b; Whincup et al., 1989; Barker et al., 1990). The strongest predictor of adult
hypertension is a combination of low birthweight with a large placenta (Barker et al.,
1990); independent of other risk factors for hypertension such as obesity and smoking.
These features have been attributed to maternal malnutrition, but they have also been
found in rats with streptozotocin-induced diabetes mellitus (Robinson et al., 1988;
Canavan & Goldspink, 1988) which have high maternal glucocorticoid levels (Heller et
al., 1988). In addition, exogenous glucocorticoids retard foetal growth in humans and
animals (Reinisch et al., 1978). Placental 11B-OHSD protects the foetus from exposure
to maternal glucocorticoids (Beitins et al., 1973) by converting active Cortisol to inactive
cortisone with negligible reduction of cortisone to Cortisol. Foetal Cortisol concentrations
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are therefore much lower than maternal levels (Edwards et al., 1993). It has recently
been shown that placental 11B-OHSD activity positively correlates with birthweight and
negatively with placental weight (Benediktsson et al., 1993). Thus, small foetuses with a
large placentae (which have a higher risk of developing adult hypertension) have the
lowest 11B-OHSD activity, and presumably the highest exposure to glucocorticoids.
Placental 11B-OHSD has therefore been proposed as a crucial determinant of foetal
exposure to maternal glucocorticoids, and in turn a determinant of later hypertension and
ischaemic heart disease (Barkeret al., 1993; Edwards et al., 1993), though clearly this
may only be one of several mechanisms acting to regulate intrauterine events.
1.3.6.2 Liver
Very little is known about the functions of 11B-OHSD in liver. 11B-OHSD activity is
higher in liver than any other tissue, and liver was the source of the 'originally purified
11B-OHSD. In contrast to kidney, where 11B-OHSD converts active to inactive
glucocorticoids, high levels of Cortisol with respect to cortisone in the effluent of
perfused cat liver indicate that in cats, equilibrium in the liver favours the active steroid,
and therefore 1 lB-reductase predominates (Bush et al., 1969). In addition, recent
experiments suggest that 1 lB-reductase activity predominates in human liver. Following
oral administration of cortisone, peripheral plasma levels of Cortisol, but not cortisone,
rise (Stewart et al., 1990), thus indicating that substantial cortisone is activated by 11B-
reductase on first-pass through the liver. High levels of 11B-OHSD activity in liver in
conjunction with the enzyme being predominantly 1 lB-reductase suggest a very different
physiological role from that in kidney. However, considerable work is required to
determine the physiological actions of 11 B-OHSD in liver especially since in rats at least,
11B-OHSD activity in female liver is approximately 2-fold lower than that observed in
male rat liver (discussed in Chapter 4).
13.6.3 Testis
11 B-OHSD plays no direct role in the metabolism of testicular steroids since none are
11-hydroxylated. However, corticosteroids are known to directly suppress testosterone
secretion in rats (Saez et al., 1977) through GR-mediated actions (Bambino & Hseuh,
1981; Welsh et al., 1982). Testosterone levels are highest in foetal rats, fall at birth, and
rise again during the 4th and 5th weeks postnatally. Phillips et al. (1989) showed that
'liver-type' 11 B-OHSD immunoreactivity is not apparent in foetal testes or in the testes of
5-25 day old animals. However from age 31-33 days, intense 11B-OHSD
immunoreactivity is detected in leydig cells in the testes. It has therefore been
hypothesised that 11 B-OHSD activity in pubertal and adult testes inactivates
corticosterone so that testosterone secretion is no longer inhibited, and sexual maturation
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can proceed (Phillips et al., 1989). This theory is supported by the finding that
carbenoxolone treatment of leydig cell suspensions results in potentiation of
corticosterone inhibition of testosterone release (Monder, 1991b).
1.3.6.4 Ovary
11B-OHSD activity, 'liver-type' mRNA and immunoreactivity are found in the ovary
(Benediktsson et al., 1992) located in the oocyte and luteal bodies. 11B-OHSD activity
and mRNA have also been found in human ovaries (Murphy, 1981; Tannin et al., 1991).
GR are also present in the ovary (Schreiber et al., 1982), indicating a possible role of
11B-OHSD in modulating the glucocorticoid effects on ovarian function. Indeed it has
been recently shown that of 64 patients undergoing in vitro fertilisation and embryo
trnasfer, 32 had detectable 11B-OHSD activity in cultures of their granulosa-lutein cells,
and none of these 32 patients became pregnant although fertilisation was achieved in
each case (Michael et al., 1993). In contrast, 76% of the remaining '1 lB-OHSD-negative'
patients achieved pregnancy. Thus low ovarian 11B-OHSD activity and/or high
intrafollicular Cortisol may be necessary for a viable pregnancy to occur.
1.3.6.5 Mammary Gland
Glucocorticoids induce milk production from the mammary glands by a GR-mediated
process (Jahn et al., 1987; Quirk et al., 1988). High levels of 11B-OHSD activity have
been demonstrated in the adipose tissue of the mammary gland, but activity has been
shown to decrease following parturition (Quirk et al., 1990a). In addition 11B-OHSD
activity is three-fold higher in the adipose cells from pregnant rats than cells from
lactating rats (Quirk et al., 1990b). Therefore it has been suggested that high 11B-OHSD
activity during pregnancy may play a role in prevention of premature milk production in
response to glucocorticoids.
1.3.6.6 Skin
Cutaneous vasoconstriction by glucocorticoids is known to be a GR-mediated process
(Marks et al., 1982), suggesting a direct effect of corticosteroids in skin. The
effectiveness of topical corticosteroids on suppression of the inflammatory response is
partly determined by its persistence in the area of application. 11B-OHSD activity in the
oxidative direction would therefore attenuate the effectiveness of topical hydrocortisone,
and inhibition of 11B-OHSD should potentiate the local action of glucocorticoids. To test
this theory, a skin vasoconstrictor assay (which requires topical application of steroids to
the forearm under an occlusive dressing) was used to show that hydrocortisone alone has
minimal vasoconstrictive effects (Teelucksingh et al., 1990). However in the presence of
GE, there was a marked potentiation of the vasoconstrictor response. In addition
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immunohistochemistry and in vitro 11B-OHSD enzyme activity assays have
demonstrated the presence of 11B-OHSD in the epidermal layers of human and nude
mouse skin (Teelucksingh et al., 1990). Although this study has revealed a potential
therapeutic use of 11B-OHSD inhibition in maximising the effects of topical
hydrocortisone, the physiological role of 11B-OHSD in skin remains unclear. This is due
in part to a conflicting study which reported that 1 lB-reductase activity exceeds 11B-
dehydrogenase activity in cultured human skin fibroblasts (Hammami & Siiteri, 1991),
and therefore that the anti-inflammatory effects of topical application of GE on human
skin cannot be fully explained by the inhibition of 11B-OHSD.
1.3.6.7 Vasculature
Corticosteroids are believed to play important roles in blood pressure regulation by as
yet unknown mechanisms. However the presence of both MR and GR in vascular
smooth muscle cells (Meyer & Nichols, 1982; Kornel et al., 1982) and heart (Funder et
al., 1973; Arriza et al., 1987) indicates the possibility of a direct action of corticosteroids
on these tissues. High levels of glucocorticoids could, by binding to both MR and GR,
contribute to the pathogenesis of essential hypertension by stimulating vasoconstriction.
MR in the mesenteric vascular arcade is aldosterone specific in vivo (Funder et al., 1989),
leading to the proposal that 11B-OHSD may mediate aldosterone selectivity to MR in a
similar way to kidney. Glucocorticoids also have independent effects on vascular smooth
muscle cells in culture which are attenuated by RU38486 indicating glucocorticoid
dependence (Kornel, 1988; Nichols et al., 1985). 11B-OHSD activity has also been
reported in the vasculature (Kornel et al., 1982; Funder et al., 1989; Walker et al., 1991).
11B-OHSD is therefore appropriately located to modulate access of glucocorticoids to
vascular receptors, and could thereby influence vascular tone and blood pressure.
1.3.6.8 Colon
Corticosteroids increase colonic sodium absorption, probably in a manner similar to
the renal distal tubules (Bastl, 1987; 1988; Halvey et al., 1988). In the distal colon, Na.K
ATPase is the major sodium reabsorption mechanism (Marver, 1984). Induction of
expression of rat distal colonic Na.K ATPase al and B subunits has been recently shown
to be regulated by acute dexamethasone but not aldosterone administration suggesting a
GR-mediated effect (Fuller & Verity, 1990). Carbenoxolone treatment also induced
Na.K ATPase subunit expression in intact but not adrenalectomised rats, suggesting that
inhibition of 11B-OHSD by carbenoxolone increases glucocorticoid occupancy of GR. In
addition, GR and 11B-OHSD mRNAs, and 11B-OHSD activity have recently been
demonstrated in rat colon (Whorwood et al., 1992).
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1.3.6.9 Brain
As with other tissues, MR and GR mediate central corticosteroid effects. However
unlike kidney, MR displays equal preference for corticosterone and aldosterone in rat
brain. This suggests therefore in the presence of a 100- to 1000-fold circulating excess of
corticosterone, that central MR will be almost permanently occupied by corticosterone,
and thus insensitive to aldosterone. Based on these considerations, deKloet & Reul
(1987) proposed a "tonic" hypothesis of steroid action in the brain. They showed that
under physiological conditions, cerebral MR would be 80-90% occupied by
corticosterone, thus providing a basal expression (tonic influence) of brain function for
monitoring the external environment. Occupancy of GR is low at basal levels of
circulating corticosterone during the diurnal trough, but increases under stress, and to a
lesser extent during the diurnal peak, leading to occupancy of GR and generation of a
negative feedback mechanism. Thus there are reciprocal tonic-activating actions, and
feedback damping mechanisms. These mechanisms are viewed as continuous dependent
on the selective occupancy of MR and GR by corticosterone. Arriza et al. (1988) have
proposed that MR and GR act as a binary response system for corticosterone by both
receptors activating an overlapping set of genes, the size of the response being dependent
on circulating glucocorticoid levels. Van Den Berg et al. (1990) have suggested that
central MR and GR mediate opposing effects of glucocorticoids and mineralocorticoids
on blood pressure, consistent with other evidence that MR and GR in the brain mediate
reciprocal neurochemical, neuroendocrine and behavioural responses.
Nevertheless, the brain responds to aldosterone in specific ways which cannot be
mimicked by corticosterone. For example intracerebroventricular (icv) administration of
aldosterone leads to elevated blood pressure which cannot be produced either by
corticosterone or systemic steroid administration (Gomez-Sanchez, 1991). The
hypertension induced by icv aldosterone administration is dependent on corticosterone,
since adrenalectomy prevented the effect, and it was restored by exogenous
corticosterone. In addition, aldosterone implants placed in the paraventricular nucleus of
adrenalectomised rats has been shown to induce fat ingestion, while corticosterone
stimulated carbohydrate intake (Tempel & Liebowitz, 1989).
Thus the brain presents an unusual paradox: in some brain regions responses are
selectively evoked by aldosterone, whereas in others MR mediates corticosterone
selective effects. The regional selectivity of brain corticosteroid receptors for
mineralocorticoids and glucocorticoids has not yet been determined. For several years,
CBG was accepted as the specificity conferring mechanism, but in the same way as for
kidney, this proposal was withdrawn since selectivity was not altered in animals with
relatively little CBG (Funder, 1986; de Kloet & Reul, 1987). 11B-OHSD was then
proposed as a local selectivity mechanism by inactivating glucocorticoids to allow
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unimpeded access of aldosterone to MR. However, original studies did not detect any
11B-OHSD activity in whole brain homogenates (Edwards et al., 1988; Funder et al.,
1988). This may be due to low co-factor levels in brain tissue (Glock & McLean, 1955),
since addition of NADP to in vitro enzyme assays significantly increased the conversion
of corticosterone to 11-dehydrocorticosterone by 11B-OHSD in various regions of the
brain, with highest activity in hippocampus, cerebellum and cortex (Moisan et al., 1990a;
1990b; Lakshmi et al., 1991). Other regions have low but significant levels of 11B-
OHSD. This was substantiated by immunohistochemical localisation of brain regions
with antibodies raised against purified 11B-OHSD (Lakshmi et al., 1991), and by in situ
hybridisation using cRNA probes (Moisan et al., 1990a; 1990b) corresponding to the
'liver-type' 11B-OHSD cDNA (Agarwal et al., 1989).
Immunolocalisation of 11B-OHSD in the hippocampus in the CA1-4 regions and
dentate gyrus coincided with the distribution of MR (Sakai et al., 1992) supporting the
view that 11B-OHSD may regulate glucocorticoid access to corticosteroid receptors in
hippocampus. In addition, utilisation of the quantitative 2-deoxyglucose uptake method
in conscious rats, provided evidence of the in vivo relevance of 11B-OHSD in brain
(Seckl et al., 1991). It was shown that in vivo GE administration increases glucose
utilisation in hippocampus, particularly the CA3 field, and also several regions of the
hypothalamus (Seckl et al, 1991). In the hippocampus, as in other brain regions,
glucocorticoids and mineralocorticoids must both be present in some crucial relationship
for optimal function to occur. Neurones containing MR and GR must be able to
manipulate glucocorticoid and mineralocorticoid levels to allow activation of available
receptors. This may require that corticosterone concentrations are adjusted in such a way
as to maximise MR and/or GR occupation in line with the needs of the cell at a particular
time. Alternatively, glucocorticoid metabolism may proceed extensively to allow
aldosterone binding to MR. How 11B-OHSD activity is regulated to permit these
functions is unknown.
11B-OHSD is unlikely to simply provide selective access of aldosterone to MR in
brain. In some brain regions for example, 11B-OHSD may regulate glucocorticoid access
to GR. Cerebellum contains no measurable MR but has well defined GR (Sousa et al.,
1989). In addition, 11B-OHSD activity and mRNA expression are high in cerebellum
(Moisan et al., 1990b). Therefore 11B-OHSD may also regulate access of glucocorticoids
toGR.
1.3.7 Regulation of 11B-OHSD
The majority of the studies reviewed below describing the regulation of 11B-OHSD
by corticosteroids, sex steroids and thyroid hormone have been carried out by measuring
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changes in 11B-0HSD activity. However, measurements of enzyme activity alone do not
necessarily distinguish between the possible isoforms of 11B-OHSD. Thus opposite
effects in different tissues could be due to effects of the steroids or hormones on different
11B-OHSD isoforms. This is further discussed in Chapter 5.
1.3.7.1 Corticosteroids
It is entirely conceivable that glucocorticoids may modulate their own metabolism by
regulating 11B-OHSD activity. Indirect evidence supporting this concept comes from the
demonstration that stress in the form of cold exposure (2°C ambient temperature for 7
days) or starvation (withdrawal of food pellets for 3 days) leads to an increase in the
reductase component of 11B-OHSD in rat lung (Nicholas & Lugg, 1982). In addition,
adrenalectomy results in attenuation of cortisone to Cortisol conversion (Nicholas &
Lugg, 1982). Human foreskin fibroblast cell 11B-OHSD activity in both oxidative and
reductive directions is increased 3-fold following incubation with lOOnM dexamethasone
(Hammami & Siiteri, 1991). This effect is blocked by the glucocorticoid receptor
antagonists RU38486 and dexamethasone mesylate and by cycloheximide and
actinomycin D suggesting that protein synthesis and mRNA synthesis are involved in the
up-regulation of 11B-OHSD activity. However, glucocorticoid regulation of 11B-OHSD
appears to be tissue-specific since 11B-OHSD activity in kidney does not appear to be
affected by adrenalectomy or dexamethasone treatment (Moisan et al., 1990c; Smith &
Funder, 1991), while hippocampal 11B-OHSD activity is increased by dexamethasone
treatment and decreased by adrenalectomy compared to sham-operated controls (Moisan
etal., 1990c).
Glucocorticoids increase lung maturation in late gestation by increasing the amount
of pulmonary surfactant on the alveolar surface (Kotas & Avery, 1971). It is interesting
to note that in human foetal lung for example, 11B-OHSD activity in early pregnancy is
almost entirely in the dehydrogenase direction (ie inactivation of glucocorticoids), while
premature births appear to have little 11B-OHSD activity in either direction, and in early
childhood 11B-OHSD in lung shows slight conversion of cortisone to Cortisol (Muiphy,
1978). The alteration from inactivation of Cortisol to slight Cortisol production as a
function of gestational age has been proposed to be regulated by pituitary factors, since
foetal lung from anencephalics, although showing the same overall changes, did so to a
lesser extent. Furthermore, isolated late gestation perfused foetal rabbit lung has been
shown to produce active Cortisol in the near absence of the reverse reaction (Torday et al.,
1976), and the conversion of cortisone to Cortisol has been shown to increase with
gestational age, although this is not affected by direct administration of dexamethasone to
the foetus (Lugg & Nicholas, 1978). However in direct contradiction, Smith et al. (1973)
and Pasqualini et al. (1970), both demonstrated an net conversion of Cortisol to cortisone
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in human foetal lung cells, as with all other foetal tissues apart from liver and intestine
(Murphy, 1981). These results may not be mutually exclusive, since it has been
demonstrated that human foetal lung cells diverge during growth in cell culture into
populations of epithelial cells and fibroblast-like cells which can be separately cultured.
The epithelial cells preferentially oxidise Cortisol to cortisone, while the fibroblast-like
cells favour the reverse reaction (Abramowitz et al., 1982). Therefore it has been
suggested that alterations in the ratio of cell types in intact lung at particular stages of
development may influence the equilibrium of 11B-OHSD activity during gestation,
although this remains to be tested.
1.3.7.2 Androgens and Oestrogens
Sex differences in 11B-OHSD activity in males and females appear to develop after
puberty in normal rats (Ghraf et al., 1975a). Sexually dimorphic expression of 11B-
OHSD activity is apparent in several tissues including liver (Ghraf et al., 1975a; Lax et
al., 1978; 1979) and kidney (Ghraf et al., 1975a; 1975b; Smith & Funder 1991).
Consistent with the observation of sexual dimorphism is strong evidence that 11B-OHSD
activity is affected by the administration and withdrawal of sex steroids. Thus, 11B-
OHSD activity in rat liver typically exhibits sexual dimorphism, with higher levels of
activity found in male than female liver (Lax et al., 1978; 1979; Ghraf et al., 1975a) due
to oestradiol repression of hepatic 11B-OHSD activity in females (Lax et al., 1978).
Similarly, several studies have demonstrated sexual dimorphism of renal 11B-OHSD
activity, again with higher levels found in male kidney (Ghraf et al., 1975a; 1975b; Smith
& Funder, 1991). However, the role of sex steroids in the maintenance of this sex
difference is unclear. Ghraf et al (1975b) showed that ovariectomy of female rats
increased 11B-OHSD activity towards normal male levels, while oestradiol treatment of
intact males led to feminisation of renal 11B-OHSD activity. In addition, gonadectomy
of females had no effect on renal 11B-OHSD activity suggesting that oestradiol represses
11B-OHSD activity in normal female kidney (Ghraf et al., 1975b). In contrast, Smith &
Funder (1991) demonstrated that oestradiol treatment of intact males led to an increase in
renal 11B-OHSD activity, while gonadectomy and/or testosterone treatment of females
had no effect (Smith & Funder, 1991).
11B-OHSD in neonatal rat testis also responds to oestrogen administration.
Oestradiol decreased 11B-OHSD activity, while in contrast, testosterone treatment had no
effect (Ghraf et al., 1975c). It would therefore seem likely that 11B-OHSD activity may
also be regulated in other tissues which are responsive to sex steroids. Indeed, raised
oestrogen levels either naturally towards the end of pregnancy, or in response to
androstenedione administration led to increased 11B-OHSD activity in the oxidative
direction in baboon placenta (Baggia et al., 1990). This effect was reversed by
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foetectomy (Baggia et al., 1990) or administration of the anti-oestrogen MER-25 (Pepe &
Albrecht, 1987).
Finally, in perfused male rat lung, the reductase component of 11B-OHSD (measured
by conversion of cortisone to Cortisol) is decreased following castration (Nicholas &
Lugg, 1982). Thus, it appears that sex steroids affect 11B-OHSD activity in many
tissues, and indeed in a tissue-specific manner. However whether this is a direct effect of
sex steroids is not clear. In rats, hypophysectomy of females leads to an abolition of
sexual dimorphism, and the effects of sex steroids on hepatic 11B-OHSD activity (Lax et
al., 1978). This suggests the importance of one or more pituitary factors in the
maintenance of sexual dimorphism, but the effects of pituitary hormones on 11B-OHSD
have not been studied in any detail as yet.
1.3.7.3 Thyroid Hormone
Regulation of 11B-OHSD activity by thyroid hormone in addition to being tissue-
specific, also appears to be species-specific. Raised thyroid hormone levels either in
spontaneous hyperthyroidism, or following exogenous T3 administration have been
shown to increase 11B-OHSD activity (estimated by measuring THF/THE ratios in urine)
in humans (Hellman et al., 1961; Gordon & Southren, 1977). Increased conversion of
Cortisol to cortisone was also shown in an independent study by measuring the
production of 3H20 following administration of lla-[3H]-cortisol (Zumoff et al., 1983).
In contrast, in rats T3 administration has been reported to decrease 11B-OHSD activity in
liver (Koerner & Hellman, 1964; Lax et al., 1979) that is apparent after only 4d
continuous treatment. Hypothyroidism or thyroidectomy reverses these responses,
leading to a reduction in 11B-OHSD activity in humans (Hellman et al., 1961; Gordon &
Southren, 1977; Zumoff et al., 1983), and an increase in hepatic 11B-OHSD activity in
rats (Koerner & Hellman, 1964). In addition to the species specificity, Lax et al. (1979)
showed that hepatic 11B-OHSD activity responded in opposite ways depending on the
sex of the rat, such that 11B-OHSD activity was increased by thyroidectomy in female
rat, but in contrast was decreased in male rat liver.
The effects of thyroid hormone are tissue-specific. 11B-OHSD activity in rat kidney
is unaffected by thyroidectomy or T3 treatment for up to 17 days (Koerner & Hellman,
1964; Lax et al., 1979; Smith & Funder, 1991). In addition, thyroid hormones do not
affect 11B-OHSD activity in the reticuloendothelial system (Dougherty et al., 1960). It
has been proposed that thyroid hormones may act by controlling the levels of pyridine
nucleotides (Dougherty et ah, 1960). However in the presence of added co-factor, the
same regulatory patterns are maintained (Koerner & Hellman, 1964). Whether thyroid
hormones have a direct or indirect mechanism of action is not known.
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1.3.7.4 Other Hormones
In contrast to the increase in placental 116-OHSD activity by oestrogen (Baggia et al.,
1990), it has been shown that 116-OHSD is attenuated by pregnenolone and progesterone
when incubated with placental extract in vitro (Lopez Bernal et al., 1980; Murphy, 1981).
In addition, the Cortisol and cortisone content of amniotic fluid from diabetic and non-
diabetic pregnant women is identical, suggesting that insulin and glucagon do not
influence 116-OHSD activity, at least in placenta (Baird & Bush, 1960). However in
contrast, insulin has been shown to inhibit both dehydrogenase and reductase activities of
116-OHSD in cultured human genital skin fibroblasts (Hamammi & Siiteri, 1991).
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1.4 Growth Hormone Secretion in Rats
It has previously been shown that hypophysectomy of female rats abolishes sexually
dimorphic expression of 11B-OHSD and in addition abolishes the effects of sex steroids
on 11B-OHSD activity (Lax et al., 1978). This suggests the importance of one or more
pituitary factors in the maintenance of sexual dimorphism. If pituitary hormones regulate
11B-OHSD, then growth hormone (GH) is likely to be a good candidate as it has been
shown to mediate the sex differences of other enzymes in the liver (Gustafsson et al.,
1983) and is secreted in sex-specific patterns (Fig. 1.11).
Growth hormone (GH) secretion from the anterior pituitary is regulated by at least
two opposing hypothalamic peptides, somatostatin (SS) (Brazeau et al., 1973) which
inhibits GH release, and GH-releasing factor (GRF) (Guillemin et al., 1982; Rivier et al.,
1982) which promotes GH release. In addition, numerous other peripheral factors
including nutrients, thyroid hormones, and gonadal and adrenal steroids (Martial et al.,
1977; Tannenbaum et al., 1978; Evans et al., 1982; Wehrenberg et al., 1983; Jansson et
al., 1984a) all influence GH release. GH secretion is characterised by a pulsatile rhythm
in all mammalian species (Jansson et al., 1985a). In the rat, this pattern is age and sex-
specific. Whereas GH secretion is similar in both sexes up to the age of 22 days, it
differs by 30 days of age. Between 25 and 30 days of age, growth hormone (GH) levels
increase leading to similar mean plasma GH levels in male and female rats (Eden, 1979).
However in adult male rats, GH secretion is characterised by regularly occurring high
amplitude peaks of release every 3-4 hours, thus corresponding to approximately 7 surges
per day (Tannenbaum & Martin, 1976). In contrast, females typically exhibit a higher
frequency, lower amplitude pattern of secredon (1-2 pulses every 2 hours). Therefore the
trough period between GH pulses is longer in males than females and often falls below
the limits of detection in males (<lng/ml in males versus >5ng/ml in females) (Eden,
1979; Tannenbaum & Martin, 1976) (Fig. 1.11). The most obvious manifestation of the
different patterns of GH secretion, is the different growth rates in male and female rats
which, like GH release, are similar up to 22 days of age, but by 30 days of age, male rats
show a characteristic increase in weight gain (Jansson et al., 1982a; 1982b).
1.4.1 Hypothalamic Control of GH Secretion
The hypothalamus has both stimulatory and inhibitory effects on GH secretion from
the anterior pituitary (Kurlich et al., 1968). The hypothalamus predominantly stimulates
GH secretion through GRF release from the ventromedial nucleus and arcuate nucleus
into the median eminence (Frohman & Bernardis, 1968; Martin et al., 1974; Millard et
al., 1982). Electrolytic lesions of either the ventromedial nucleus or the arcuate nucleus
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Figure 1.11:
Plasma concentrations of GH in three (a) adult female and three (b) adult male rats over
24h. The period of darkness was from 2100-0100h (solid bar). The y-axis is different for
the two groups. Taken from Clark et al., 1986.
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leads to decreased pituitary GH levels and suppressed pulsatile GH secretion (Frohman &
Bernardis, 1968; Martin et al., 1974). In addition electrical stimulation of the two
hypothalamic areas results in induction of GH secretion (Martin et al., 1978; Frohman et
al., 1968). GH secretion is predominantly inhibited through SS release from the
periventricular preoptic/anterior hypothalamic area into the median eminence (Alpert et
al., 1976). Low plasma trough levels of GH are probably maintained by SS release. SS
antibodies increase basal GH levels in male rats (Ferland et al., 1976; Terry & Martin,
1981), and depletion of hypothalamic SS stores by electrical lesioning of the preoptic
area increase trough GH levels and cause more frequent pulses of GH release
(Willoughby & Martin, 1978). However, the effects of SS on the amplitude ofGH pulses
are not clear, with some investigators reporting increased pulse amplitude following
administration of SS antibodies (Ferland et al., 1976), while this effect is not reproduced
by others (Terry & Martin, 1981).
SS-induced inhibition of GH release from rat pituitaries in vitro is followed by
rebound release of GH after withdrawal of SS (Carlson et al., 1974; Stachura, 1976).
This effect is mimicked in vivo by administration of SS antibodies in rats (Tannenbaum
et al., 1978; Eden et al., 1981; Tannenbaum, 1981), suggesting that the pulsatility of GH
in vivo is due at least in part to the pulsatile removal of SS. However administration of
SS antibodies to rats with electrolytic lesions to GRF containing neurones in the
ventromedial hypothalamus and arcuate nucleus, although increasing baseline GH levels,
does not restore the pulsatility of GH secretion (Millard et al., 1982; Eiklebloom &
Tannenbaum, 1983). In contrast, exogenous GRF treatment of rats with the same
electrolytic lesions did induce GH pulsatility (Tannenbaum et al., 1983), and GRF
antibodies have been shown to abolish GH pulsatility in male rats (Wehrenberg et al.,
1982). Thus spontaneous GH pulsatility may be dependent on GRF release from the
hypothalamus.
1.4.2 Feedback Regulation of GH Secretion
GH itself has a role in regulating its own secretion through a short-loop feedback
mechanism. Exogenous GH administration leads to a reduction in hypophyseal GH
content and amplitude of endogenous plasma GH pulses in rats (Krulich & McCann,
1966; Willoughby et al., 1980; Abe et al., 1983). The concentration of GH in the
pituitary is reduced by implanting GH in the median eminence (Katz et al., 1969), and
endogenous GH pulse amplitude is decreased after administration of GH into the lateral
cerebral ventricle (Abe et al., 1983; Tannenbaum, 1980) suggesting that feedback
regulation of GH may involve the hypothalamus. GH autoregulation at the hypothalamic
level appears to involve SS. SS levels in the median eminence are reduced in
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hypophysectomised rats, but this can be restored to normal by GH replacement (Hoffman
& Baker, 1977; Patel, 1979). In addition GH administration to normal rats leads to
increased hypothalamic SS content (Patel, 1979).
1.4.3 Other Regulators of GH Secretion
Many other factors appear to be involved in the regulation of GH secretion from the
anterior pituitary including glucocorticoids, thyroid hormone, monoamines and various
neuropeptides. The regulatory actions of these factors are reviewed in detail in Jansson et
al. (1985a).
Monoamines are present in the hypothalamus in high concentrations, and appear to
induce GH release by stimulating GRF release from the hypothalamus via activation of
CX2 adrenergic receptors. In addition, endogenous opioids such as B-endorphin,
enkephalin and dynorphin induce GH release in vivo, but this does not appear to be a
direct effect on somatatrophs, and may reflect GRF release as a result of a-adrenergic
stimulation.
Thyroid hormones play an important role in the control of GH synthesis and
secretion, such that thyroidectomy leads to a decrease in pituitary GH content and
abolishes GH pulsatility in male rats, while thyroid replacement reverses these effects
(Solomon & Greep, 1959; Coiro et al., 1979; Suzuki et al., 1980). Thyroid hormones and
glucocorticoids have synergistic stimulatory actions on the activity and mRNA levels of
GH in cultured pituitary cells (Martial et al., 1977). In addition, glucocorticoids and
thyroid hormone stimulate GH gene expression leading to increased levels of GH mRNA
in cultured pituitary cells (Evans et al., 1982). Glucocorticoids appear to stimulate
transcription of the GH gene, resulting in increased accumulation of GH mRNA (Evans
et al., 1982). In addition, in vivo glucocorticoid manipulation may enhance the pituitary
GH response to GRF (Wehrenberg et al., 1983).
1.4.4 Sexual Dimorphism ofGH Secretion
There is a striking sex difference in the pattern of GH secretion in adult rats
(Saunders et al., 1976; Eden, 1979) as previously mentioned. Thus, in males, GH is
secreted as high amplitude pulses every 3-4h, interspersed with low or undetectable
levels between peaks, whereas female rats exhibit a more continuous pattern of secretion.
Gonadal steroids have been implicated in the production and maintenance of this sexual
dimorphism. For example, gonadectomy of male rats before puberty results in raised
basal GH levels, and this effect can be reversed by testosterone replacement (Jansson et
al., 1984a). In addition, oestrogens appear to elevate basal GH levels in male rats
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(Jansson et al., 1983). Gonadectomy of female rats results in partially decreased basal
GH levels, indicating the importance of androgens in the maintenance of low inter-pulse
GH levels in male rats (Jansson et al., 1984a). The role of androgens in maintenance of
the amplitude of GH release is less clear since gonadectomy pre-pubertally has no
apparent effect on GH pulse amplitude of male rats (Jansson et al., 1984b), and in
addition testosterone replacement at high supraphysiological levels does not affect the
pulse amplitude (Jansson et al., 1985a). However, neonatally ovariectomised female rats
treated with testosterone appear to exhibit high amplitude GH pulses in adult life
(Jansson et al., 1985b). In contrast, male rats gonadectomised neonatally show a
decrease in GH peak amplitude and increased GH trough levels compared to normal
males (Jansson et al., 1985b; Jansson & Frohman, 1987), and this effect can be reversed
by testosterone replacement (Jansson & Frohman, 1987). However neonatal testosterone
replacement although restoring the high amplitude of GH pulses, led to increased
frequency, and shortened duration of these pulses (Jansson & Frohman, 1987). If
however neonatal testosterone replacement is continued into adulthood, the GH secretory
pattern was found to be indistinguishable from normal males. This therefore suggests
that adult androgen secretion plays both a corrective and a maintenance role in the sexual
dimorphism of GH release. During puberty, oestradiol administration to male rats
appears to decrease GH peak amplitude, while ovariectomy of the females leads to
increased peak amplitudes (Jansson et al, 1984a). No such effects of ovariectomy or
oestradiol replacement have been observed in postpubertal rats (Jansson et al., 1984a).
Autoradiographic studies by Herbert & Sheridan (1983) have demonstrated that
hypophyseal somatatrophs have oestrogen binding sites suggesting the possibility of a
direct mechanism of action of oestrogens on somatatrophs. In addition, treatment of
ovariectomised female rats with [3H] oestradiol for lh, showed that oestradiol was
loclised in the nuclei of 80-90% of GH-secreting cells (Shirazu et al., 1990). The effects
of oestrogens on GH release from pituitary cells in vitro are conflicting. Thus it has been
shown that oestrogens increase (Komolov et al., 1980), decrease (Birge et al., 1967) or
have no effect (Webb et al., 1983) on GH secretion. In contrast there are few reports of
testosterone effects on GH release in vitro. It has however been recently shown that the
effect of gonadal steroids on anterior pituitary cells isolated from rats gonadectomised
before puberty, depends on the sex of the source. Thus the GH response to GRF and SS
was increased by testosterone only in male pituitary cells, and was decreased by
oestrogen only in female pituitary cells (Hertz et al., 1989), suggesting that the sex
differences present before puberty were maintained in vitro for the period of the study.
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1.4.5 Gonadal Steroids and GRF and SS Secretion
To date, there is no direct evidence demonstrating differences in GRF release
between male and female rats. However indirect evidence from monosodium glutamate-
treated rats (Maiter et al., 1991a), and passively immunised rats (Wehrenberg et al., 1982;
Ono et al., 1991; Painson & Tannenbaum, 1991) suggests that baseline GRF secretion is
slightly elevated with low amplitude GRF pulses in female rats, and that baseline GRF
values are lower with higher amplitude pulses in male animals. In addition, GRF mRNA
levels are 2-3 times higher in adult male than female rat hypothalami (Maiter et al.,
1991b; Mizobuchi et al., 1991). The effects of gonadal steroids in the maintenance of
this putative sexual dimorphism are not clear. It has been shown that GRF mRNA levels
are not affected by gonadectomy or sex steroid replacement in adult male or female rats
(Maiter et al., 1991b; de Gennaro et al., 1989). However it has also been reported that
male hypothalamic GRF mRNA content is decreased following castration, and this effect
can be reversed by testosterone replacement (Zeitler et al., 1990). In addition, lh after
injection of ovariectomised feamle Sprague-Dawley rats with [3H] oestradiol, the tracer
was found in 35% of GRF-producing cells (Shirasu et al., 1990).
Similarly to GRF, there is no direct evidence demonstrating a sexually dimorphic
pattern of SS release. However, conscious freely moving female rats consistently
respond to GRF administration, whereas male rats only respond intermitently, suggesting
that hypothalamic release of SS is different between male and female rats (Clark &
Robinson, 1985). Several other studies have also suggested differences in SS release
between male and female rats (Wehrenberg et al., 1982; Ono, et al., 1991; Painson &
Tannenbaum, 1991). Gonadectomised male rats have been shown to express lower levels
of SS mRNA in the periventricular nucleus compared to controls (Werner et al., 1988;
Zorrilla et al., 1990). This effect was reversed by testosterone replacement, while
oestradiol treatment had no effect in male animals (Argente et al., 1990). Similarly in
female rats, ovariectomy has been shown to decrease SS mRNA levels in the
periventricular nucleus while oestradiol reverses this effect (Werner et al., 1988; Zorrilla
et al., 1990). These results suggest that sex steroids exert their effects on SS at the level
of transcription, and that a reduction in the sex steroid environment leads to similar
effects on SS in male and female rats. Whether gonadal steroids have direct or indirect
effects on SS is not known, but since it has recently been demonstrated that there is no
oestrogen response element on the SS gene (Goodman et al., 1990), a direct action of sex
steroids is unlikely.
1.4.6 Physiological Significance of Sexually Dimorphic Patterns of GH
The most obvious manifestation of the differences in GH secretion is seen in the
different growth rates of male and female rats which diverge at puberty leading to faster
growth rates in the male animal (Wehrenberg & Giustina, 1992). In addition,
hypophysectomised rats treated with GH showed increased growth rates when treated
with pulsatile GH compared to continuous GH (Jansson et al., 1982a; Clark et al., 1985).
However when administration frequency is increased, growth rates decrease indicating
that high amplitude and low baseline levels of GH (ie male GH patterns) induce higher
rates of somatic growth than low peak/high trough plasma levels of GH (ie female GH
patterns).
Rat liver expresses several drug and steroid metabolising enzymes which are
expressed in a sexually dimorphic manner (Gustafsson et al., 1983). For example two
cytochrome P450 enzymes, 16a-hydroxylase and androstanediol disulphate 15B-
hydroxylase, exhibit sexually differentiated expression in rat liver (Morgan &
Gustafsson, 1987). However, it has been demonstrated that this is not due to a direct
effect of sex steroids since gonadal steroids have no effect on hepatic steroid metabolism
in the absence of the pituitary (Kamatak et al., 1985). In contrast, GH administration to
hypophysectomised rats can cause feminisation or masculinisation of liver steroid
metabolism depending on its mode of administration which can be manipulated to mimic
physiological male or female patterns of GH (Gustafsson et al., 1983). This suggests
therefore that normal GH patterns mediate the sexually differentiated expression of
hepatic steroid metabolising enzymes. GH patterns are also important for several other
sexually differentiated functions such as body growth (Eden et al., 1987), serum levels of
apolipoprotein E and cholesterol (Oscarsson et al., 1989), CBG (Eden et al., 1987), and
major urinary proteins in mice (Knopf et al., 1983; Norstedt & Palmiter, 1984).
3B-hydroxysteroid dehydrogenase, which is a member of the short chain alcohol
dehydrogenase superfamily (section 1.3.4), is expressed at higher levels in male rat liver
due to testosterone induction of the enzyme in male animals which can be reversed by
high constant (female pattern) GH administration (Naville et al., 1991). Sexual
dimorphism of 11B-OHSD in liver has been previously reported (Lax et al., 1978), but
the role of GH in the maintenance of this dimorphism is unknown.
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1.5 Aims of The Thesis
The aim of the thesis was firstly to investigate the tissue specific regulation of 116-
OHSD. Liver, kidney and hippocampus were chosen as representative tissues. Firstly,
kidney is a classical mineralocorticoid responsive tissue where the physiological actions
of 116-OHSD are well understood. In contrast, the role of 11B-OHSD in liver is not
clear, but since UB-OHSD activity is particularly high in liver, and this was the original
source of the purified enzyme, it is likely that 11B-OHSD has some importance in this
glucocorticoid receptor-rich tissue. Finally hippocampus was chosen since it contains
mineralocorticoid receptors and 11B-OHSD, but in contrast to kidney, responds to
physiological glucocorticoids in vivo.
Adrenal steroids have a wide range of actions in many tissues including liver, kidney
and hippocampus. It is quite conceivable that 11B-OHSD which regulates glucocorticoid
levels in vivo could itself be regulated by both pharmacological glucocorticoid
manipulations as well as chronically raised physiological glucocorticoids for example
during chronic stress. These studies are discussed in Chapter 3.
That 11B-OHSD activity in liver is expressed at higher levels in male than female
animals is well established. In Chapter 4, gonadal steroid manipulations demonstrate that
this sex difference is due to oestrogen repression of 11B-OHSD in female liver. In
addition, the role of sex-specific patterns of growth hormone secretion in the maintenance
of this sexual dimorphism is considered in Chapter 5.
In light of recent literature suggesting the presence of a second gene encoding an
isoform of 11B-OHSD which is more likely to be responsible for the regulation of access
of glucocorticoids to mineralocorticoid receptors in renal distal tubules and cortical
collecting tubules, the final studies in this thesis were undertaken to determine whether
the 'liver-type' 11B-OHSD was capable of altering glucocorticoid access to GR when




In general, all basic protocols used in these studies can be found in Sambrook et
al. (1989).
2.1 DNA Analysis Techniques
2.1.1 Restriction Endonuclease Digestion and Electrophoresis of DNA
DNA was digested using 1 unit of restriction enzyme per |ig of DNA in lx
restriction buffer which was supplied with the enzymes (as a lOx solution) and
distilled H2O (dH20) to the required volume. Digestion of plasmid DNA was
routinely carried out at 37°C for l-2h. The enzyme reaction was stopped by heating
digests to 60°C for 10 min and digested DNA was visualised after electrophoresis
through agarose gels. 1% agarose gels (w/v) were routinely used to separate DNA
fragments of 400bp-7kb and were prepared by dissolving agarose in lx TBE (lOx
TBE = 108g Tris, 55g boric acid, 4.7g EDTA made up to 1 litre with dH20) in a
microwave oven. The agarose solution was allowed to cool slightly before adding 1-
5jal of ethidium bromide (10 mg/ml) and pouring the solution into a gel mould with a
comb in place - the tooth size of the comb dependent on the size of DNA sample -
and allowed to set. The gel was placed in a horizontal gel apparatus containing
sufficient lx TBE to cover the surface of the gel. 2pl of agarose loading buffer
(0.25% (w/v) bromophenol blue, 0.25% xylene cyanol (w/v), 30% glycerol) was
added to DNA samples before loading onto the gel. Gels were usually run at 50-
80mA with a lkb DNA ladder (Gibco BRL) containing DNA fragments of 75bp-
12kb as a size marker, for as long as required to see sufficient separation of DNA
fragments.
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2.1.2 Subcloning of DNA Fragments
2.1.2.1 Plasmid Vectors
pllDH: This is a 4.2kb plasmid which was constructed using a 1.2kb EcoRl
fragment of the 11B-OHSD cDNA (Agarwal et al., 1989) subcloned into pBluescript.
pBluescript has the capability to maintain a high copy number and also contains the
ampicillin resistance gene B lactamase and an artificial polylinker inserted into the lac
Z operon. pBluescript also contains the phage T3 and T7 RNA polymerase promoter
sequences flanking the polylinker thus enabling in vitro synthesis of specific single
stranded sense (T7) and antisense (T3) RNA transcripts.
prMR: The rat mineralocorticoid receptor plasmid was constructed by
subcloning a 513bp EcoRl fragment of the receptor cDNA into pGEM4 (Arriza et al.,
1988). pGEM4 contains the B-lactamase gene and an artificial polylinker inserted
into the lac Z operon. It also contains the phage SP6 and T7 RNA polymerase
transcription initiation sites flanking the polylinker. This therefore allows in vitro
synthesis of specific single stranded sense (T7) and antisense (SP6) RNA transcripts.
prGR: The rat glucocorticoid receptor plasmid was constructed from a 674bp
Pstl/EcoRl fragment of the receptor subcloned into pGEM3 (Miesfeld et al., 1984).
pGEM3 like pGEM4, contains the B-lactamase gene and an artificial polylinker
inserted into the lac Z operon. However in pGEM3, the polycloning site is in the
opposite orientation to pGEM4 so that in vitro synthesis of a single stranded sense
RNA transcript is obtained using the SP6 RNA polymerase, while an antisense
transcript can be obtained from the T7 RNA polymerase transcription initiation site.
p7S: A plasmid vector containing the the ampicillin resistance gene and entire
coding region of the 7S cDNA subcloned into pAT 153 (Balmain et al., 1982). 7S is
a ribosomal RNA which is found in relative abundance in numerous cells (Balmain et
al., 1982) and can therefore be used to control for RNA loading on northern analysis.
PJ3: A 3 ,5kb vector containing the ampicillin resistance gene and the SV40
(Simian Virus 40) origin and early promoter (Morgenstern & Land, 1990). This
plasmid was used in transfection studies as a control for pSLl activity.
pSLl: This plasmid was constructed by myself by subcloning a 1.2kb
EcoRl/Sstl fragment of pllDH into pJ3 (Morgenstern & Land, 1990) so that the
entire coding region of 11B-OHSD was under control of the SV40 promoter (section
2.1.2.3). This plasmid was used in transfection studies to encode the 11B-OHSD
protein.
pKC275: This plasmid was used in transfection studies as an internal control for
transfection efficiency since it encodes the B-galactosidase gene. pKC275 was
constructed by Karen Chapman by subcloning the HindlH/Bam HI fragment of B-
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galactosidase into pRSVCAT (Gorman et al., 1982) thus producing a B-galactosidase
gene under control of the Rous sarcoma virus promoter.
pRShGR: The entire coding sequence of human GR (hGR) is contained within
this expression plasmid under control of the SV40 promoter (Giguere et al., 1986).
The coding sequence of hGR was subcloned into pRSVCAT (Gorman et al., 1982)
which had the CAT coding sequence removed, and the SV40 origin added. The
resulting expression plasmid also contains the B-lactamase gene encoding ampicillin
resistance.
MMTV-LTR luciferase: This plasmid contains the ampicillin resistance gene
and the entire coding sequence of firefly luciferase under control of the mouse
mammary tumour virus long terminal repeat promoter (Lefebvre et al., 1991). The
expression plasmid was constructed by subcloning the coding sequence of firefly
luciferase into pMLuc which contains the MMTV-LTR promoter (Nordeen, 1988).
RSV-luciferase: contains the entire coding region of firefly luciferase under
control of the Rous sarcoma virus promoter (de Wet et al., 1987). This expression
plasmid was also subcloned into pMLuc (Nordeen, 1988) and in addition contains the
B-lactamase gene.
2.1.2.2 Bacterial Media
LB (Luria-Bertoni) broth per litre: lOg bactotryptone (Difco); 5g bacto yeast
extract (Difco) and lOg NaCl. For LB agar, 15g agar was added per litre to LB broth.
M9 Minimal Medium per litre: lx M9; 0.3% casamino acids; 0.5% glucose;
O.lmM CaCl2; 0.00002% vitamin Bj and 4mM MgSC>4.
Media Additives: Ampicillin (Sigma) at a concentration of 100pg/ml was used to
select for plasmids containing ampicillin resistance.
All media were sterilised by autoclaving and media additives sterilised by filter
sterilisation. Bacteria were grown at 37°C in a shaking incubator to provide
aeriation.
2.1.2.3 Construction of the pSLl Subclone
pllDH was digested EcoRl and SStl and run on 1% low melting point agarose
gels as described (section 2.1.1). A gel slice containing the 1.2kb fragment of pi 1DH
was cut from the gel using a sterile scalpel, weighed, put in a 1.5ml eppendorf tube
and dissolved in dH20 (2|il/mg) at 70°C for 5-10 min. The DNA was cleaned by
adding 100|il Tris-saturated phenol, vortexing and centrifuging for 10 min. in a bench
top eppendorf centrifuge. The upper aqueous phase containing the DNA was
removed into a fresh eppendorf tube and was extracted twice; once with 100ql Tris-
saturated phenol and lOOpl chloroforrmisoamylalcohol (24:1, v/v) and once with
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100|il chloroform:isoamylalcohol. The DNA fragment was then ethanol precipitated
with 0.15 volumes of 5M NaCl or 0.05 volumes of 8M ammonium acetate, and 2.5
volumes of ethanol, put on dry ice for 5-10 min. and then centrifuged for 10 min.
The supernatant was discarded and the DNA pellet dried briefly at room temperature
before resuspension in an appropriate volume of TE (lOmM Tris-HCl (pH 8), 0.1M
EDTA). Recovery of precipitated DNA was checked by electrophoresis of an aliquot
(l-2|il) of the total recovered DNA, through an agarose gel.
10qg of pJ3 was linearised with EcoRl/Sstl (10 units) in a 20jil reaction
containing 2(il of lOx restriction buffer, at 37°C for l-2h. An aliquot of the
restriction digest was run on an agarose gel to check the concentration of linearised
vector. The reaction was diluted 2-fold to reduce the salt concentration; then the
digested pJ3 was treated with calf intestinal phosphatase (C1P) (lU/ql) at 37°C for lh
to prevent religation of the vector with itself.
The pi 1DH restriction fragment was inserted into pJ3 in a lOql ligation reaction
containing l|il of lOx ligation buffer (50mM Tris-HCl pH 7.5, lOmM MgCl2, ImM
DTT), ImM ATP (pH 7.0), 0.5 units T4 DNA ligase and a 1:3 molar ratio of
linearised pJ3:pl 1DH fragment. Ligation reactions were incubated at 37°C for l-2h.
2.1.2.4 Bacterial Transformation
Escherichia coli strain HB101 were made competent for DNA uptake by the
CaCl2 method (Sambrook et al., 1989). Cells were grown in 100ml LB to mid log
phase (A600 = 0.3-0.6) then harvested at 3000rpm in a Beckman J20 rotor for 10 min.
at 4°C. The pellet was resuspended in 10ml ice-cold 0.1M CaCl2 and stored on ice
for 10 min. Cells were then repelleted, and resuspended in 2ml 0.1M CaCl2 and
could then be stored at 4°C for up to 4d before transformation. 150JJ.1 of competent
cells were mixed with up to 50ng DNA in a volume of lOql TE and stored on ice for
10 min. Cells were heat shocked at 42°C for exactly 90 sec and then transferred back
onto ice. The entire transformation mix was spread onto LB agar plates containing
lOOjig/ml ampicillin using a glass spreader. Plates were incubated at 37°C overnight.
Control plates for transformations included HB101 alone (which do not have the
ampicillin resistance gene) and plasmids which transform well e.g. pGEM3. Cells
which grew on the selective media represented cells which had successfully been
transformed by the recombinant DNA bearing the ampicillin resistance marker.
Plates with transformed colonies were stored at 4°C for up to 3 months.
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2.1.3 DNA Preparation
2.1.3.1 Plasmid DNA Minipreparation
A single transformed bacterial colony was transferred into 3ml LB containing
100|ig/ml ampicillin and incubated overnight in a loosely capped tube at 37°C. 1.5
ml of the overnight culture was recovered by centrifugation at 14,000 rpm in a bench
top eppendorf centrifuge for 1 min (the rest of the culture was stored at 4°C). The
pellet was resuspended in 100(il ice cold GTE (50mM glucose, 25mM Tris-HCl (pH
8.0), lOmM EDTA) then mixed gently with 200fil of freshly prepared alkaline-SDS
solution (0.2M NaOH, 1% SDS) and stored on ice for 5-10min. Ice cold potassium
acetate, 150jil (3M with respect to potassium, 5M with respect to acetate) was added
and mixed by inverting the tube several times before storing on ice for 5-10 min.
Denatured chromosomal DNA and cellular proteins were removed by centrifugation
for 5 min. The supernatant was transferred to a fresh eppendorf tube and extracted
with an equal volume of phenoLchloroform/isoamyl alcohol. After mixing and
centrifuging for 2 min, the supernatant was transferred to a fresh eppendorf tube, and
the DNA precipitated with 2 volumes of ethanol at room temperature for 5 min.
After centrifuging for 5 min, the supernatant was aspirated and the DNA pellet rinsed
with 70% ethanol. The pellet was then dried briefly at room temperature and
resuspended in 50|il TE containing DNase-free RNase (20|ig/ml) and stored at -20°C.
2.1.3.2 Large Scale PlasmidDNA Preparation
A single bacterial colony was transferred asceptically into 3ml LB containing
100(tg/ml ampicillin and incubated overnight in a loosely capped tube at 37°C. The
overnight culture was diluted in 500ml LB or M9 minimal medium containing
100pg/ml ampicillin, and grown in a 2 litre flask at 37°C overnight, then centrifuged
at 6000rpm for 5 min at 4°C in a Beckman J2-MC centrifuge. The bacterial pellet
was resuspended in 12ml of ice-cold GTE solution (50mM glucose, 25mM Tris-HCl
(pH 8.0), lOmM EDTA) and mixed immediately with 24ml of freshly prepared
alkaline-SDS solution (0.2M NaOH, 1% SDS), then stored on ice for 5 min. 16ml of
ice-cold potassium acetate (3M with respect to potassium, 5M with respect to acetate)
was added, mixed well, and stored on ice for a further 10 min. before centrifuging at
6000rpm for 10 min. at 4°C. The supernatant was strained through 4 layers of sterile
gauze into 250ml centrifuge pots, and precipitated at room temperature for 20-30
min. by the addition of 32ml isopropanol. Plasmid DNA was recovered by
centrifuging at 10,000rpm for 5min. at 4°C. The DNA pellet was dried at room
temperature before being resuspended in 1.5ml TE buffer. Following resuspension,
lg of CsCl per ml of DNA solution was added and dissolved in the DNA by gentle
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warming at 30°C. Then 50|J.l of ethidium bromide (lOmg/ml) was added, and the
resulting DNA/CsCl solution transferred into a 3ml Beckman Quick Seal
ultracentrifuge tube with enough CsCl solution (prepared by adding lOOg CsCl to
100ml TE) to fill the tubes, and centrifuged at 70,000rpm for 17h at 20°C in a
Beckman Optima LTX 120,000rpm Ultracentrifuge. Plasmid DNA bands were
collected through the tube wall using a syringe and a 21 gauge needle. For the
purposes of transfections, plasmid DNA was transferred to fresh heat seal tubes with
enough CsCl solution to fill the tubes, and centrifuged again for 4h at 100,000rpm or
17h at 70,000rpm at 20°C. For all other purposes, a single centrifugation was
sufficient to purify the DNA. After collecting the DNA band through the wall of the
tube, ethidium bromide was removed from the plasmid DNA by extracting several
times with equal volumes of water saturated butanol (until both aqueous and organic
phases were no longer pink). The plasmid DNA was precipitated in 2 volumes of
70% ethanol for 10 min. at room temperature, and recovered by centrifugation at
14,000rpm in a bench top eppendorf centrifuge. The DNA pellet was then dried
briefly at room temperature and resuspended in an appropriate volume of TE.
The concentration and purity of recovered plasmid was determined
spectrophotometrically by measuring absorbance at 260nm and 280nm in a Shimadzu
UV-160A spectrophotometer. Plasmid DNA was routinely stored at -20°C.
Occasionally, if the plasmid to be prepared did not have a high copy number, or if
it was required in larger amounts than are normally obtained from large scale DNA
preparations, chloramphenicol amplification of the plasmid was employed. After
diluting the 3ml overnight culture into 500ml in a 2 litre flask, the preparation was
allowed to grow until the absorbance of the culture at 600nm was 0.6-0.8. At this
point, 2.5ml of 34mg/ml chloramphenicol in ethanol was added to each culture.
Chloramphenicol is an antibiotic which inhibits bacterial replication but not DNA
amplification. Therefore more of the DNA produced from this kind of preparation is
the DNA of interest and less is the bacterial DNA.
2.2 Preparation Of Nucleic Acid Probes
2.2.1 Random Priming of DNA
This method of random priming of DNA was developed by Feinberg and
Vogelstein (1983) and is based on the hybridisation of a mixture of all possible
hexanucleotides to the DNA to be labelled. The complementary strand is then
hybridised from the 3' OH termini of the hexanucleotide primers using Klenow
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enzyme in the presence of radiolabelled nucleotides using a Random Primed DNA
labelling Kit (Boehringer Mannheim).
pllDH plasmid DNA was digested with EcoRl (section 2.1.1) and the resulting
1.2 kb 11B-OHSD fragment isolated on a 1% low melting point agarose gel (section
2.1.2.4) and the recovery checked on a 1% agarose gel. The DNA was then
denatured at 95°C for 10 min and subsequently cooled on ice. The reaction mix
(made up on ice) consisted of up to 25ng denatured DNA; 3|il dATP, dGTP, dTTP
mixture (prepared by making a 1 + 1 + 1 mixture of the nucleotides); 2pl
hexanucleotide primer mixture; 5pl [a32P] dCTP (3000 Ci/mmol; Amersham
International, UK) made up to 19pl with dH20 and lpl Klenow enzyme. The
reaction was incubated at 37°C for lh, then terminated by adding 2pl 250mM EDTA
(pH 8.0). The DNA probe was precipitated by adding lpl 5M NaCl, lpl glycogen
and 65pl ice-cold ethanol and storing on dry ice for 5 min. The pellet was recovered
by centrifuging at 14,000rpm for 10 min in a bench top eppendorf centrifuge, the
supernatant discarded and the pellet dried and resuspended in 50pl of dH20.
7S plasmid DNA was also linearised with EcoRl but was not routinely isolated
from agarose gels. It was however, labelled in exactly the same way as the 11B-
OHSD fragment.
2.2.2 Synthesis of Radioactive RNA Probes
RNA probes were synthesised in vitro using phage T3, T7 or SP6 RNA
polymerase systems for in situ hybridisation experiments.
Rat MR, GR and 11B-OHSD plasmids were linearised with restriction enzymes
distal to the insert (Table 2.1) to produce both sense and antisense DNA templates as
necessary. 0.5-1.0pg of linear DNA template in a DEPC-treated eppendorf was
incubated with 2pl of 5x transcription buffer (5x TB= 200mM Tris-HCl (pH 7.5),
30mM MgCl2, lOmM spermidine, 50mM NaCl); 1.5pl of a lOmM ATP, lOmM CTP,
lOmM GTP mix; 0.5pl of 200mM dithiothreitol (DTT); <0.3pl of RNase Inhibitor
(Promega); 1.2pl of 175pM UTP; lpl of 35S UTP (40mCi/ml, Amersham
International; UK) and lpl of the appropriate RNA polymerase in a total volume of
lOpl with DEPC-treated H2O at 37°C (40°C for SP6) for lh. The volume of the
reaction was then increased by adding 2pl 5x transcription buffer and 8pl DEPC-
treated H2O, and the DNA template degraded using lpl RNase-free DNase at 37°C
for 10 min. The probe was purified by phenol:chloroform extraction (lOpl each of
phenol and chloroforrmisoamyl; 24:1), and after centrifugation in a bench top
centrifuge, the upper aqueous layer was removed into a fresh DEPC-treated
eppendorf, and the probe precipitated with lpl glycogen, lpl of 10M ammonium
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acetate and 50|il of ethanol on dry ice for 5 min. The pellet was recovered by
centrifugation for 15 min, dried briefly at room temperature and resuspended in 50|il
of DEPC-treated H2O. Routinely, lfil of the resuspended probe was counted in 5ml
Cocktail T (BDH) to check the incorporation of 35s UTP into the probe, and lfil run
on a vertical 4% polyacrylamide gel to check the integrity of the probe. The probe
was then added to 500p.l of 2x hybridisation buffer (1.2M NaCl, 20mM Tris-HCl (pH
7.5), 0.04% ficoll, 0.04% polyvinylpyrrolidone, 0.2% BSA, 2mM EDTA, 0.2mg/ml
denatured salmon sperm DNA, 0.4g/ml dextran sulphate and O.lmg/ml total yeast
RNA made up in DEPC-treated H2O) and stored at -20°C for no more than 3-4d
since degradation of the probe appears to occur quite rapidly.
To check the incorporation of radionucleotide into the cRNA probes, lpl of each
probe was run on a 4% polyacrylamide 15cmx 17cmx 1.5mm gel. For a gel of this
size, 10.5g of urea was dissolved in 3.3ml of 30% acrylamide and 2.5ml of lOx TBE,
then made up to a total volume of 25ml. After dissolving, 250(il 10% ammonium
persulphate and 25ql of TEMED were then added and the solution immediately
poured into a 15cmx 17cmx 1.5mm glass sandwich which had been previously sealed
with 1% (w/v) agarose (in dH20). A 20 tooth comb was placed in the top of the gel
between the glass plates. After polymerisation, the gel plates were attached to
vertical glass electrophoresis apparatus containing lx TBE buffer. After adding 2jil
loading buffer to the sample of probe, the probe was loaded onto the gel which was
then electrophoresed at 40-80mA until the first dye front (bromophenol blue which
runs at approximately 300bp) reached the bottom of the glass plates. One of the glass
plates was then carefully removed leaving the gel on the other plate. The gel was
covered with clingfilm and exposed to autoradiographic film (Hyperfim B-max)
overnight at room temperature before being developed in D19 developer for 2min.
and fixed in a 1:5 dilution of Amfix, washed in tap water in the light and allowed to
dry.
2.2.3 Synthesis of Non-Isotopic RNA Probes
Non-isotopic RNA probes were synthesised in a similar way to isotopic probes
but instead of incorporating 35S-labelled UTP, biotin-ll-UTP (biotin linked to UTP
through an 11 nucleotide arm) was used as the label. Again 0.5-1.0|ig linearised
DNA was incubated in lx transcription buffer, with 3|il of a nucleotide mix
consisting of lOmM ATP, lOmM CTP and lOmM GTP; lpl of 200mM DTT; 0.3pl
of RNase Inhibitor; 2(il of 25|lM UTP; 2|il of lOmM biotin-11-UTP and ljll of the
appropriate RNA polymerase in a total volume of 20|il with DEPC-treated H2O at




pll-DH Template for antisense ISH probes Sty I
Template for sense ISH probes Hind IB
Template for antisense northern probes EcoRI
p7S Template for antisense northern probes EcoRI
prGR Template for antisense ISH probes Aval
Template for sense ISH probes EcoRI
prMR Template for antisense ISH probes Hind III
Template for sense ISH probes EcoRI
Table 2.1:
Restriction enzymes routinely used in linearising and isolating fragments of DNA
from plasmids.
precipitated in the same way as the isotopic RNA probes (section 2.2.2). Biotinylated
cRNA probes were routinely stored in DEPC-treated H2O at -20°C where they
appeared to be more stable than isotopic probes and were used up to months after
preparation. To check the integrity and incorporation of biotin label into the probes, a
lfil aliquot was run on a 1% denaturing agarose gel and blotted onto nitrocellulose or
nylon membrane (section 2.3.1.3). Once dried, the blot was stained for the presence
of biotin label using a BluGENE Nonradioactive Nucleic Acid Detection System
(Gibco BRL). The membrane was rehydrated in buffer 1 (0.1M Tris-HCl (pH 7.5),
0.15M NaCl) at room temperature and then incubated in buffer 2 (3% bovine serum
albumin (w/v) in buffer 1) for lh at 65°C. The membrane was then incubated in a
streptavidin-alkaline phosphatase conjugate for 10 min at room temperature with
gentle agitation before washing twice in buffer 1 for 15 min. each. Following a wash
in buffer 3 (0.1M Tris-HCl (pH 9.5), 0.1M NaCl, 50mM MgCl2), the filter was
incubated in a dye solution consisting of NBT (nitroblue tetrazolium) and BCIP (5-
bromo-4-chloro-3-indolyl phosphate) for 30 min to 3h in a sealed hybridisation bag in
the dark. When the colour reaction was sufficient, filters were washed in a 'stop
buffer' (20mM Tris-HCl (pH 7.5), 0.5mM Na2EDTA) to terminate the colour
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development. Filters were baked in the oven at 80°C for 2h and stored protected
from the light.
2.3 RNA Analysis Techniques
2.3.1 Northern Analysis
2.3.1.1 Tissue Dissection
Rats were killed by decapitation and the organs of interest were rapidly removed,
dissected on ice and immediately frozen down on dry ice. Hippocampus was
dissected as follows: the brain was removed from the skull and the cerebellum
severed from the cerebrum. The remainder of the brain was split into two halves
down the midsaggital plane, the fornix detached and the hippocampus rolled away
from the wall of the lateral ventricle. All tissues were frozen immediately on dry ice
and stored at -70°C until required.
2.3.1.2 Extraction ofRNA From Rat Tissues
Total RNA was extracted from hippocampus, liver and kidney by the
guanidinium thiocyanate method as described by Chomczynski and Sacchi (1987).
Tissues were homogenised in 4M guanidinium thiocyanate, 0.025M sodium citrate,
0.5% sarcosyl and 0.1M B-mercaptoethanol using sterilised Dounce tissue grinders.
Routinely, half of the hippocampus was homogenised in 500pl of this denaturing
solution, while liver and kidney were homogenised in 5-10ml of solution per g of
tissue. Homogenised tissue was split into 500|il aliquots in DEPC-treated
eppendorfs. DNA was precipitated by addition of 50|il 0.2M sodium acetate (pH 4)
and protein was removed by 500(il water-saturated or citrate-saturated phenol and
lOOpl chloroformiisoamyl alcohol (49:1) extraction. The homogenates were vortexed
vigorously and stored on ice for 15 min before centrifugation at 14,000 rpm in a
bench top centrifuge for 20 min. The upper aqueous phase containing RNA was
removed into fresh DEPC-treated eppendorfs, mixed with 200|il isopropanol to
precipitate the RNA, and stored at -20°C for at least lh. The RNA was centrifuged
again at 14,000 rpm for 20min, and the RNA resuspended in 60|il guanidinium
thiocyanate denaturing solution and 60|il isopropanol. The RNA was reprecipitated
at -20°C for at least lh, the pellet recovered by centrifugation for 10 min, washed in
100|il 70% ethanol, dried and resuspended in an appropriate volume of DEPC-treated
H2O. This was generally 20|il for hippocampal RNA and 50-100(il for liver and
kidney RNA depending on the size of the RNA pellet. RNA concentration and purity
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were estimated spectrophotometrically by measuring the absorbance at 260nm and
280nm, and aliquots stored at -70°C prior to use.
2.3.1.3 RNA Electrophoresis and Capillary Transfer
Aliquots of total RNA from hippocampus (15|lg), liver (lOpig) and kidney (10|ig)
were fractionated on 20x 25cm 1.2% agarose-2.2M formaldehyde denaturing gels.
For 250ml gel mix, 3g of agarose was melted in 220ml DEPC-treated dH20 and after
cooling slightly, 5ml formaldehyde and 25ml lOx MOPS buffer (lOx MOPS= 0.2M
MOPS (pH 7.0), 50mM NaAc, 5mM EDTA) were added and poured into the gel
mould with a comb whose tooth size was appropriate to the amount of RNA to be
loaded onto the gel. After setting, the gel was aged in the gel tank with lx MOPS
buffer. RNA samples were mixed with 50% deionised formamide, 12.5%
formaldehyde and 12.5% lOx MOPS in a total volume of 20|J.l and denatured at 65°C
for 15 min. lpl of lOmg/ml ethidium bromide was added to 40[il of 2.5x loading
buffer and 2(il of this mixture was added to each RNA sample. Samples were loaded
onto the gel which was run either for 8h at 100V or for 16h at 50V. The gel was
soaked in 20x SSC, then blotted onto nitrocellulose (Hybond C extra, Amersham
International) or nylon (Hybond N, Amersham International) membrane by capillary
transfer overnight. This was achieved by laying the gel on a transfer apparatus
consisting of a wick of Whatman 3MM filter paper over an upturned gel mould
running into a reservoir of 20x SSC. The nylon or nitrocellulose membrane, cut to
exactly the same size as the gel was placed in direct contact with the gel. Two sheets
ofWhatman 3MM paper were placed over the membrane followed by paper towels to
a depth of approximately 5cm. An even weight balanced on a glass plate was then
placed on the apparatus and transfer allowed to take place. After checking the
efficiency of transfer under UV, the membrane was baked between two sheets of
Whatman 3MM paper at 80°C for 2h.
2.3.1.4 Northern Hybridisation
Northern hybridisation was routinely carried out by one of two methods:
(a) Nitrocellulose and nylon membranes were rehydrated in sterile 20x SSC and
separated by layers of nylon mesh of the same size as the filter so that when the filters
were rolled up, no part of the filters would be in direct contact. Filters and mesh were
then rolled up together and inserted into a Hybaid Mini Hybridisation Oven bottle.
Filters were prehybridised and hybridised in 20 ml of 50% formamide, 5x SSPE (20x
SSPE= 6M NaCl, 0.18M NaH2P04, 20mM EDTA; pH 7.4), 5x Denhardt's solution
(0.1% BSA, 0.1% ficoll, 0.1% polyvinylpyrrolidone), 200pg/ml denatured herring
testes DNA, 0.1% SDS and ImM EDTA for at least 2h at 42°C while rotating in a
Note: aging the gel consists of soaking it in buffer in the gel tank.
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Hybaid Mini Hybridisation Oven. Both prehybridisation and hybridisation buffer
were made up fresh for each hybridisation. After prehybridisation, the random-
primed 32P-labelled cDNA probe (section 2.2.1) was carefully added to the
hybridisation bottle and the filters hybridised overnight at 42°C.
(b) Alternatively, membranes were prehybridised (for at least 2h) and hybridised
(overnight) at 65°C in 10-20ml of 0.2M NaH2P04, 0.6M Na2HP04, 5mM EDTA,
6% SDS and 100|ig/ml of denatured salmon sperm DNA. Hybridisation was carried
out at 65°C overnight in the same way as above.
The next morning, the probe was carefully disposed of, and filters washed in the
hybridisation bottle with approximately 50ml of 2x SSC (or lx SSPE) and 0.1% SDS
for 15-30 min at room temperature. For the following higher stringency washes, the
filters were removed from the hybridisation bottles and placed in plastic containers of
at least the same size as the filters containing 500ml of 0.2x SSC (or 0.1 x SSPE) and
0.1% SDS. These containers were then sealed and incubated at 60°C for 30-60 min.
on a rocking table to agitate the washing buffer. This wash was repeated once more,
or until the radioactive signal reached background levels. Filters were then wrapped
in clingfilm and exposed to Kodak XAR-5 film at -70°C at least overnight. Films
were developed in Kodak D19 developing solution (Ilford) for 2 min, and fixed in a 1
in 5 dilution of Amfix fixative (Champion) for 2 min. All filters were stripped by
submerging in boiling water which was then allowed to cool to room temperature.
Stripping was checked by exposing filters to Kodak XAR-5 film overnight. Filters
were then rehybridised with 7S in exactly the same way as above, to control for RNA
loading. Both 7S and 11B-OHSD were quantified by computer densitometry
(Seescan, Cambridge, UK) and expressed as a ratio of the optical densities of 11B-
OHSD:7S.
2.3.2 In Situ Hybridisation Analysis
2.3.2.1 Tissue Preparation
Rats were killed by decapitation and the brain rapidly removed, the cerebellum
severed and the cerebrum frozen on dry ice. Tissue was stored at -70°C prior to
sectioning in a cryostat at -20°C. 10pm coronal brain sections were cut and thaw-
mounted onto slides which had been treated with gelatine and were poly-L-lysine
coated. Sections were then stored at -70°C until required.
2.3.2.2 Isotopic In situ hybridisation
Tissue sections were fixed in 4% paraformaldehyde/0.1M phosphate buffer
(20mM NaH2P04, 80mM Na2HPC>4) for 10 min followed by three washes in 2x SSC
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made up in DEPC-treated H2O for 5 min each. Both the fixation and washing
treatments were carried out in sterilised glassware.
Sufficient hybridisation mix was made up to apply 200|il to each slide. The
hybridisation mix consisted of 50% formamide, lOx 106 counts/ml of radioactive
cRNA probe, made up to a final volume with 2x hybridisation buffer. This
hybridisation mix was denatured at 70°C for 10 min, cooled on ice and 10|il/ml of
1M DTT added. Tissue sections were dried around the edges with lens tissue before
adding 200|il hybridisation mix to each slide and ensuring each tissue section was
covered. The slides were placed flat in plastic boxes containing 3MM Whatman
paper soaked with 'box buffer' (4x SSC, 50% formamide in DEPC-treated H2O).
These boxes were then sealed with autoclave tape and incubated at 50°C overnight.
Following hybridisation, slides were rinsed twice in 2x SSC (made up in dH20) for
10 min at room temperature prior to RNase digestion with 200|il of RNase A
(30|ig/ml in 0.5M NaCl, lOmM Tris-HCl (pH 7.5), ImM EDTA) at 37°C for 45-60
min. Slides were then washed in 2x SSC at room temperature for lh followed by a
more stringent wash of O.lx SSC at 60°C for lh. After dehydration in 50%, 70% and
90% ethanol in 0.3M ammonium acetate for 2 min each, slides were left to air dry
overnight in a fume hood before being exposed to autoradiographic film (Hyperfilm
B-max, Amersham International, UK) for lOd or being dipped in photographic
emulsion (K5, Ilford, UK) and stored at 4°C for 21-28d. Films were developed in
D19 developer for 2 min and fixed in a 1:5 dilution of Amfix fixative for 2 min.
Slides were developed for 3 min, rinsed in dFUO, fixed for 3 min and washed 5x in
dH20 for 5 min each in the light. In order to visualise silver grains clearly, slides
were also counterstained with haematoxylin and eosin and coverslipped using DPX
as a mountant.
Hybridisation with sense cRNA probes under the same conditions as above were
performed as controls for isotopic in situ hybridisation.
2.3.2.3 Non-lsotopic In Situ Hybridisation
Non-isotopic RNA probes were added to the hybridisation mix at a concentration
of 30|ig/ml (determined spectrophotometrically). In all other aspects, non-isotopic in
situ hybridisation was identical to the isotopic method.
Development of the non-isotopic in situ hybridisation was carried out with an
ABC kit (Vector). The principle of this kit depends on the complexing of each biotin
molecule with 4 avidin molecules. A complex of avidin-biotin-horseradish
peroxidase (hence ABC) is therefore made and applied to the sections. Since MR,
GR and 11B-OHSD mRNA species are relatively rare, the system was amplified by
incubating slides with a biotinylated anti-avidin antibody followed by another
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incubation with the avidin-biotin-horseradish peroxidase complex. A substrate which
turns brown (DAB) or red (AEC) in the presence of horseradish peroxidase is then
added to indicate the presence of the original biotinylated probe.
After the stringent wash of 0.1 x SSC at 60°C for lh, sections were rinsed in lx
phosphate buffered saline (PBS) (lx PBS= 137mM NaCl, 2.7mM KC1, 4.3mM
Na2HPC>4, 1.47mM KH2PO4) and incubated in the ABC complex for 30 min at room
temperature. This was rinsed off briefly with lx PBS, before addition of the
biotinylated anti-avidin antibody (1:250 dilution) for lh. Again slides were washed
in lx PBS and incubated with the ABC complex for 30 min. After a final wash in lx
PBS, sections were incubated in either 0.5mg/ml DAB (3,3'-diaminobenzidine) and
0.1% H2O2 in lx PBS, or AEC (3-amino-9-ethylcarbazole; Vector kit) for 10 min.
Slides were then rinsed in tap water, dehydrated (DAB), treated with methyl green as
a counterstain and coverslipped using DPX as a fixative, or air dried (AEC; AEC is
alcohol soluble) and coverslipped using an aqueous mountant.
Controls for non-isotopic in situ hybridisation included hybridisation of tissue
sections with hybridisation mix minus biotinylated probes, and competition studies
with 100-fold excess unlabelled homologous or heterologous probes added to the
hybridisation mix.
2.3.2.4 Double In Situ Hybridisation
Tissue sections were incubated in a hybridisation mix containing lOx 10^
counts/ml of the isotopic RNA probe and 30|ig/ml of the biotinylated RNA probe at
50°C overnight, treated with 30|ig/ml RNase A and washed to a maximum stringency
of O.lx SSC at 60°C (section 2.3.2.1). The biotin in situ hybridisation was then
developed (section 2.3.2.2), the slides air-dried overnight and exposed to
autoradiographic film or dipped in emulsion (section 2.3.2.1).
2.4 In Vitro Assays
2.4.1 11B-OHSD Enzyme Assay
Rats were decapitated, liver, kidney and hippocampus removed and dissected on
ice. Tissues were homogenised in Krebs-Ringer bicarbonate buffer (118mM NaCl,
3.8mM KC1, 1.19mM KH2P04, 2.54mM CaCl2.2H20, 1.19mM MgS04.7H20,
25mM NaHC03 and 0.2% glucose, pH 7.4, gassed with 95% 02/5% CO2 for lh) in
Dounce tissue homogenisers. Routinely, half a hippocampus was homogenised in
500p.l Krebs-Ringer, while liver and kidney were homogenised in 5-10ml/g tissue.
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After estimating the total protein concentration of each sample colorimetrically
(Bio-Rad protein assay kit), duplicate aliquots of homogenate were incubated with
200|J.M NADP and 12nM 1,2,6,7 [3H]-corticosterone ([3H]-B) (specific activity
approx. 84Ci/mmol, Amersham International) in a total volume of 250fil with Krebs-
Ringer buffer (+ 0.2% BSA) at 37°C. Preliminary studies were carried out to
optimise conditions for the enzyme assay and the protein concentration for each
tissue was chosen such that (i) additional protein led to an approximately linear
increase in percentage conversion of [3H]-B to [3H] 11-dehydrocorticosterone ([3H]-
A) in the presence of 200|iM NADP and (ii) the percentage conversion was within
the range of 20-50% conversion in a 10 min assay. This was found to be 50|ig/ml
liver, 25|ig/ml kidney and 500|ig/ml hippocampus (Fig. 2.1). After incubation, at
least 2 volumes of ethyl acetate was added to each sample and mixed to extract the
steroids from the homogenate. The upper aqueous layer was removed into fresh
tubes and dried at 50°C under air. Steroids were resuspended in lOOjil ethanol
containing 2.5mg/ml each of unlabelled corticosterone and 11-dehydrocorticosterone
and stored at 4°C overnight. 10|il samples of the steroids were pipetted onto silica
gel coated aluminium thin layer chromatography plates (TLC, Merck Ltd), the plates
allowed to dry, and another 10|il of the sample plated. This was repeated 4 times so
that a total of 40pl of each steroid sample had been plated. TLC plates were divided
into lanes of 2.5cm width to allow application of 8 steroid samples on each plate.
Corticosterone and 11-dehydrocorticosterone were then separated by running the
TLC plates in sealed tanks containing a mixture of chloroform: 95% ethanol (92:8).
The steroid bands were visualised under ultra-violet light and scraped into
scintillation vials containing 5ml liquid scintillant (Cocktail T, BDH). Radioactivity
was quantitated on a B-counter and the conversion of [3H]-B to [3H]-A was estimated
from the radioactivity of each fraction.
2.4.2 Corticosterone Binding Globulin Assay
Trunk blood was collected from decapitated rats for both plasma corticosterone
and corticosterone binding globulin (CBG) assays. Blood was collected into
heparinised tubes, chilled immediately on ice, and centrifuged at 3000rpm for 10 min
at 4°C. CBG levels were measured using the method of Martin et al. (1977).
Endogenous steroids were removed from plasma by running the samples through
sephadex LH-20 columns of 10 x 1cm. Plasma samples were then diluted 50:1 with
TEGMD (30mM Tris, ImM EDTA, 10% glycerol, lOmM sodium molybdate and
ImM dithiothreitol, pH 7.4). Aliquots of plasma were incubated overnight at 4°C
with 200nM 1,2,6,7 [3H]-corticosterone in TEGMD (total binding) or with 200nM
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Figure 2.1:
11B-0HSD activity with various protein concentrations of male rat liver, kidney and
hippocampus. 11B-OHSD activity is expressed as % conversion B->A in the
presence of 200|iM NADP at 37°C for 10 min. This is a representative experiment
which was repeated three times. Each data point is the mean of duplicate
measurements.
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1,2,6,7 [3H]-corticosterone and 0.1mM unlabelled corticosterone (non-specific
binding). Separation of bound from free corticosterone was achieved by running
samples through sephadex LH-20 columns as described above. The elutant from
these columns was collected into scintillation vials containing 5ml Picoflour and
counted on a B-counter. CBG levels were expressed as pmol [^H] corticosterone
bound/mg protein.
2.4.3 Corticosterone Radioimmunoassay
Plasma corticosterone assays were performed on unextracted plasma samples as
described previously (MacPhee et al., 1989). All plasma samples were diluted 1:25
(as well as 1:50 if the plasma was from potentially stressed rats) in 0.135M sodium
borate buffer (0.133M boric acid, 67.5mM NaOH, 0.35% HC1 (pH 7.4),
supplemented with 0.5% BSA, 1.0% methanol and 0.1% ethylene glycol) and
incubated at 75-80°C for 30 min, before being assayed in duplicate. Into 10x75mm
borosilicate glass tubes, 50|il of diluted plasma sample was mixed with 100(il of a
specific antibody against corticosterone raised in rabbits and 50pl [3H] B. The
antibody was diluted 1:5000, while the tracer was diluted 1:4500 (producing
approximately 10,000cpm per tube), both in 0.135M sodium borate buffer. A
standard curve of corticosterone was created by adding 1025|il 0.135M sodium borate
buffer to 100pl stock corticosterone solution of lpg/ml. This solution
(12.8pmol/50(J.l) was then double diluted down to 0.00625pmol/50|il and assayed in
duplicate in the same way as plasma samples. Standards and plasma samples were
incubated overnight at 4°C before adding 500pl dextran-coated charcoal suspension
(0.5% activated charcoal, 0.05% Dextran T70, 0.05% BSA in 65mM sodium borate
buffer), vortexing and centrifuging at 3000xg for 30 min at 4°C to separate the
antibody bound and unbound fractions. The bound fraction (supernatant) was
counted in a B-counter in 5ml picofluor (Picofluor 40, Packard).
2.5 In Vivo Studies
2.5.1 Animal Maintenance
Han Wistar, dwarf (dw/dw) and the parent strain of the dwarf (AS) male and
female rats were routinely used for the in vivo studies. All three strains were
maintained under conditions of controlled lighting (lights on from 05.00 to 19.00h)
and temperature (22°C) and water and food ad libitum. Following surgery all
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animals were monitored closely, and any rat which appeared to be suffering or in ill
health was killed.
2.5.2 Adrenal Steroid Manipulation Studies
2.5.2.1 Adrenalectomy ±Adrenal Steroid Replacement
Male Han Wistar rats (200-250g; n=6/group) were anaesthetised with 4%
halothane and bilaterally adrenalectomised through dorsal incisions. Control animals
were sham-operated by making bilateral dorsal subcutaneous incisions under
halothane anaesthesia. Adrenalectomised animals were injected subcutaneously with
high dose dexamethasone (0.2mg/kg/day), a selective glucocorticoid which is poorly
metabolised by 11B-OHSD, aldosterone (20pg/kg/day), which is a selective MR
agonist, or vehicle (5% ethanol saline). Sham-operated controls also received
vehicle. Adrenalectomised rats were maintained on physiological saline to maintain
electrolyte balance in these animals.
2.5.2.2 Arthritis Stress
The model used to imitate chronic stress was achieved by inducing arthritis in
male Han Wistar rats (200-250g; n=10/group) under 4% halothane anaesthesia.
Animals were injected subdermally with Freund's Complete Adjuvant containing
250pg attenuated Mycobacterium tuberculosis (MAFF, UK) suspended in a total
volume of 0.05ml paraffin oil, at two sites around the left tarsal joint (adjuvant
injection was performed by Lucy Donaldson). Control animals were left completely
untreated. Groups of animals were also adrenalectomised three days prior to
induction of arthritis or treated with the glucocorticoid antagonist RU38486
(lOmg/kg/day) by gavage or subcutaneous injection, while two further groups of rats
were treated with vehicle (50% ethanol-saline by gavage or 10% DMSO by
subcutaneous injection). Rats were killed 14 days after induction of arthritis or after
14d treatment with RU38486. During the development of arthritis all animals were
monitored closely, but showed little or no apparent signs of discomfort and locomotor
activity was nearly normal, with only occasional guarding of the affected limbs.
Trunk blood samples were collected first thing in the morning to determine
corticosteroid binding globulin and corticosterone levels in these animals. Thymus
and adrenal weights were also measured as additional indicators of chronically raised
corticosteroid levels.
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2.5.3 Sex Steroid Manipulation Studies
2.5.3.1 llfi-OHSD and the Oestrus Cycle
Vaginal smears were taken from female Han Wistar rats (150-200g) every day,
and the cycling stage of each rat determined microscopically. Pro-oestrus is
characterised by epithelial and cornified cells which tend to clump together. During
oestrus only cornified cells are apparent, while the final stage, met-oestrus again
exhibits cornified and epithelial cells, but in contrast to pro-oestrus the cornified cell
walls begin to break down in this stage of the cycle. The animals were divided into
groups of pro-oestrus, oestrus and met-oestrus (n=5/group), and were killed.
2.5.3.2 Gonadectomy ±Sex Steroid Replacement
Groups of male Han Wistar rats (200-250g; n=5-6/group) and age-matched
female Han Wistar rats (n=6/group) were gonadectomised or sham-operated under
4% halothane anaesthesia. Male animals were gonadectomised by a ventral incision
through the scrotum followed by tying off the vas deferens. The testicles were then
removed by cutting below the sutures. Female animals were ovariectomised by
bilateral dorsal incisions and removal of both ovaries.
While still anaesthetised, gonadectomised animals were implanted
subcutaneously with silastic capsules (1.98mm internal diameter, 12mm in length)
containing testosterone propionate or 176-oestradiol. Sham-operated controls and a
group of gonadectomised animals received blank capsules. Capsules were made by
sealing one end of a length of medical grade silastic tubing with silastic sealant (both
from Dow corning, Midland, Michigan). The sealant was allowed to set overnight
before completely filling the capsules with the appropriate hormone and sealing the
other end of the capsule. Before using, capsules were equilibrated for at least 4h in
0.9% NaCl. Rats were killed 48h or lOd after surgery.
2.5.3.3 llfi-OHSD and Pregnancy
As a model for high physiological oestrogen levels, a group of female Han Wistar
rats were impregnated, and on day 19 of pregnancy this group and a group of non¬
pregnant controls (n=6/group) were killed. Full term pregnancy in Han Wistar rats is
21-22 days.
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2.5.4 Growth Hormone Manipulation Studies
2.5.4.1 Female Versus Male GH Patterns
The normal male and female rats used in this study are from a colony inbred at
the NIMR at Mill Hill in London called NIMR/AS. The dwarf male and female rats
were originally derived from a spontaneous mutation in Lewis rats resulting in a
growth hormone (GH) deficiency. However due to breeding problems in Lewis rats,
the mutation was transferred to the NIMR/AS strain, and homozygous dwarfs mated
with heterozygous partners until a pure colony of homozygous dwarf (dw/dw) rats
was established. These dwarf rats appear to produce insufficient GH from the
pituitary, while other hormone levels are unaffected (Charlton et al., 1988). Groups
(n = 6-16/group) of male and female dwarf rats were age-matched with parent strain
animals (AS). A group of dwarf male animals were implanted subcutaneously with
osmotic mini-pumps (Charles River) containing human GH (200|ig/day; Lilly) to
mimic the normal female pattern of GH secretion. A group of dwarf female animals
received 3 min intravenous pulses of human GH (25|ig/3 min pulse) every 3h via an
automatic injection system anchored to the skull plate to mimic the normal male
pattern of GH secretion (Clark et al., 1985; carried out by T. Wells, NIMR, Mill Hill,
London). Controls received vehicle. Rats were killed after 6d treatment.
2.5.4.2 Hypophysectomy ± Growth Hormone ±Oestradiol
Groups (n=5/group) of male and female Wistar rats were hypophysectomised, and
a group of male Wistar rats sham-operated under halothane anaesthesia (Charles
River) and allowed to recover for 14d after surgery. A group of the
hypophysectomised male animals was implanted subdermally with silastic capsules
containing 176-oestradiol (1.98mm internal diameter, 12mm long), while a second
group was implanted subcutaneously with osmotic mini-pumps containing human
GH (200|ig/day) and a third group received both treatments. Rats were killed after 6d
treatment.
2.6 Tissue Culture Studies
2.6.1 Maintenance of Cells in Culture
CV-1 cells are originally derived from African Green Monkey kidney and now
contain no steroid receptors (Giguere et al., 1986; Arriza et al., 1987) or 11B-OHSD
activity or mRNA (Low et al., unpublished observations). COS-7 cells are derived
from CV-1 cells, but contain t-antigen (Gluzman, 1981).
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These cells were maintained in culture in Dulbecco's Modification of Eagle's
Medium (DMEM) supplemented with 100 units/ml penicillin, lOOpg/ml streptomycin
and 200mM L-glutamine (all from Northumbria Biologicals Ltd or Gibco BRL) as
well as 10% foetal bovine serum (CV-1), or 10% newborn bovine serum (COS-7).
Cells were grown in vented 75cm2 flasks (Costar UK Ltd) at 37°C in 5% CO2.
Confluent cells were split with lx trypsin/EDTA solution (Northumbria
Biologicals Ltd) as follows: The medium in which the cells were growing was
aspirated off and discarded into Chloros. Cells were then rinsed in 2ml
trypsin/EDTA to remove residual serum which inactivates the trypsin/EDTA, the
wash aspirated and discarded again into Chloros. Another 2ml of trypsin/EDTA was
added to each flask, and the cells incubated either at room temperature or at 37°C for
approximately 5 min or until cells detached under gentle agitation from the surface of
the flask. Then cells were split back 1 in 4, and either added to a fresh 75cm2 flask or
discarded into Chloros if cells were only to be maintained. 18ml of fresh culture
medium (described above) was added to each flask and the cells once again incubated
at 37°C in 5% CO2 until confluent. If required, the medium on the cells was replaced
by fresh medium between cell splitting. Generally for transfections, four 75cm2
flasks of CV-1 or COS cells were maintained and required for each experiment.
2.6.2 1113-OHSD Activity in Intact Cells Versus Cell Homogenates
In these experiments, the ability of 0.1-10(ig pSLl to act as a dehydrogenase or
reductase in intact cells was examined over a 24h period. Then the dehydrogenase
activity of 11B-OHSD in homogenates of the same cells was measured as an
indication of potential activity of the plasmid.
CV-1 cells were initially transfected using several methods, including
electroporation, lipofection, DEAE dextran and calcium phosphate, but were found to
transfect most efficiently with the calcium phosphate method of transfection (Low et
al., unpublished observations). In contrast, COS-7 cells were routinely transfected by
the DEAE dextran method.
Cells were harvested in 2ml trypsin/EDTA per 75cm2 flask (section 2.6.1) and
put in a 50ml falcon centrifuge tube (Costar UK) with some medium to inactivate the
trypsin/EDTA solution. The cells were recovered by centrifugation at 3000rpm for 2
min in a Fisons MSE Chilspin centrifuge. The medium was aspirated off into
Chloros, and the cell pellet resuspended in 10ml transfection medium. Cells were
then counted using a haemocytometer, and 5x 105 cells plated onto 100mm cell
culture dishes in 10ml transfection medium which consists of DMEM containing 100
units/ml penicillin, 100(ig/ml streptomycin and 200mM glutamine as well as 10%
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charcoal stripped foetal calf serum (CV-1) or either 10% Nu serum or 10% foetal calf
serum (COS-7). Charcoal stripping (section 2.6.2.4) was used to remove endogenous
glucocorticoids from the serum. Nu-serum is a synthetic serum consisting of 25%
foetal calf serum with various growth factors and steroids. The advantage of Nu-
serum in the DEAE dextran method of transfection is that protein levels are very low,
and high protein concentrations reduce the efficiency of transfection by this method.
Unfortunately, Nu-serum contains 28|iM Cortisol (information provided Universal
Biologicals, London, UK) which is probably not completely removed by charcoal
stripping (charcoal stripping procedure removes 99.8% of added [3H] corticosterone
[section 2.6.2.4], Thus of 28|iM Cortisol, approximately 56nM may still be left in the
serum). These transfections were therefore also repeated in 10% foetal calf serum.
Cells were plated on 100mm cell culture dishes (Costar UK) since insufficient protein
was produced from smaller plates to allow the 118-OHSD assay to be performed at
an appropriate protein concentration.
2.6.2.1 DEAE Dextran Transfection ofCOS-7 Cells
24h after plating, 0.1-10|ig of SL1 or pJ3 in addition to l-5|ig pCHllO or pKC
275 (to control for transfection efficiency) was made up to 15|ig with pGEM3 and
mixed with DEAE dextran (final concentration= 250|ig/ml) and chloroquine (final
concentration=80|iM) (Table 2.2). This DNA mixture was then added to the culture
dishes dropwise while swirling.
It was found that DMSO shocking the cells 4-8h after adding the DNA to the cells
increased the efficiency of transfection. The medium containing the DNA/DEAE
dextran was aspirated off into Chloros, and replaced by 2ml 10% DMSO in lx PBS
for 2 min exactly. The DMSO was then aspirated off and replaced as quickly as
possible by two volumes of serum free DMEM to wash the cells. This was repeated
once more before the cells were returned to regular transfection medium and replaced
in the incubator at 37°C and 5% CO2.
To measure 118-dehydrogenase and 116-reductase activities in the intact cells,
24h after transfection, the medium was aspirated off the cells and replaced by 12ml of
fresh growth medium containing 25nM corticosterone (23nM unlabelled B and
0.16(il [3H]-B; specific activity 84Ci/mmol) or 25nM 11-dehydrocorticosterone
(23nM unlabelled A and 0.16|il [3H]-A; synthesised as described in section 2.6.2.5).
Aliquots of 750ql medium were then removed from the culture dishes at various time
points and steroids extracted with 1ml ethyl acetate, dried down, and resuspended in
lOOpl ethanol containing 2.5mg/ml each of unlabelled B and A, and the conversion of
[3H]-B to [3H]-A or [3H]-A to [3H]-B determined by thin layer chromatography in






Volume of medium per 4ml 10ml
plate
No. of cells plated/dish 3x 105 5x 105
Total amount of DNA lOqg 15pg
lOmg/ml DEAE dextran 150)11 250ql
8mM Chloroquine 40pl 100JJ.1
10% DMSO 1ml 2ml
Harvesting buffer 500|ll TM triton 1ml lx PBS
Table 2.2:
Requirements for DEAE Dextran Transfections
48h after transfection, the medium was aspirated from the plates into Decon, and the
cells washed in 3ml lxPBS. This was also aspirated off, and replaced with 1ml of lx
PBS. Cells were scraped into eppendorf tubes, and spun down at 14,000xg in a bench
top eppendorf centrifuge for 2 min. The lx PBS solution was aspirated off, and
replaced by 100|il of TM triton (TM triton=0.1% triton X100 in 20mM Tris-HCl (pH
7.5), 2mM MgCl2). From this suspension of cells, B-galactosidase assays (section
2.6.5), protein assays, and 11B-OHSD activity assays (section 2.6.2.3) were routinely
performed.
2.6.2.2 Calcium Phosphate Transfection ofCV-1 Cells
CV-1 cells were plated the day before the transfection experiment in the same
way as COS-7 cells. For each transfection, 500jil of 2x HEPES buffered saline
(HBS; 2x HBS= 50mM HEPES (pH 7.1), 280mM NaCl, 1.5mM Na2HP04) was
pipetted into sterile eppendorf tubes. In separate tubes, the DNA required for the
transfection (O.l-lOqg pSLl/pJ3, l-5(ig pCHllO/pKC 275) made up to 15pg with
pGEM3 was mixed with 62|il of 2M CaCl2 and filter sterilised mH20 (millipore
H20) to a volume of 500|il. While vortexing the 2x HBS, the prepared DNA solution
was added dropwise so that the resulting solution appeared slightly opaque due to the
formation of a fine co-precipitate of DNA with calcium phosphate. It was found that
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transfections were most efficient if the 2x HBS and CaCl2/DNA solutions were
mixed at 20-21°C. The DNA/CaPC>4 solution was incubated at room temperature for
30 min, then vortexed again just prior to adding it to the cells. The DNA was added
dropwise to the plates while swirling to evenly distribute the precipitate, and to avoid
local acidification of the cells. The plates were then returned to the incubator at 37°C
and 5% CO2. 4-8h later, cells were shocked for exactly 2 min with 15% glycerol
(30% glycerol diluted down to 15% with 2x HBS prior to shocking), but were
otherwise treated in the same way as COS-7 cells.
2.6.2.3 In Vitro llfi-OHSD Enzyme Assay in Cell Extracts
48 hours after transfection the cells were harvested in lx PBS, the cells spun
down, and the pellet resuspended in TM triton. After estimating the total protein
concentration of each cell suspension colorimetrically (Bio-Rad protein assay kit),
500(ig/ml aliquots of cell homogenates were incubated with ImM NADP and 60nM
1,2,6,7 [3H] B in a total volume of 20jil with Krebs Ringer buffer supplemented with
0.2% glucose and 0.2% BSA, for 10 min at 37°C. Steroids were extracted with at
least 2 volumes ethyl acetate and the conversion of [3H]-B to [3H]-A was estimated
by thin layer chromatography in the same way as for intact cells.
2.6.2.4 Charcoal Stripping ofSerum
0.25% charcoal and 0.0025% dextran T70 were incubated overnight at 4°C in
0.25M sucrose, 1.5mM MgCl2 and lOmM Hepes (pH 7.4) on a clock stirrer so the
suspension was completely mixed. 50ml of the charcoal suspension was then
centrifuged at 3000rpm for 10 min. to pellet the charcoal. The supernatant was
discarded and replaced with an equivalent volume of the serum to be stripped. This
mixture was vortexed thoroughly, and incubated at 4°C overnight on the clock stirrer
again, before being filtered through a 0.22pm bottle filter (Costar, UK) into a 500ml
bottle of DMEM. To check the efficiency of the stripping procedure, lpl [3H]-B was
added to an aliquot of serum to be stripped. The amount of radioactivity present in
the serum was then checked before and after the stripping procedure on a B-counter.
The stripping procedure removed >99.8% [3H]-B.
2.6.2.5 Synthesis of [3H] 11 -Dehydrocorticosterone
[3H] 11-dehydrocorticosterone was made using human placental tissue extract in
a modification of the method reported by Lakshmi and Monder (1988). Human
placenta is a pure source of 1 lB-dehydrogenase activity (Brown et al., 1993a) and
was therefore found to be the best tissue producing the least contamination with
corticosterone.
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Routinely, placental extract was incubated with ImM NAD in 0.1M Tris-HCl (pH
7.5) buffer containing 12nM [2H]-B in a total volume of 5ml, at 37°C for at least 2h.
The steroids were then extracted with 2 volumes of ethyl acetate twice, and dried
down under air. A sample of the steroids was dried down and then resuspended in
600pl of 50:50 methanol: HPLC H2O and run through an HPLC to check the purity
of the [2H]-A. Using this method, purity was at least 98% [3H]-A. The [3H]-A was
resuspended in an appropriate volume of ethanol to give approximately the same
specific activity as the [3H]-B used in the transfection experiments. [3H]-A was
stored at -20°C for up to months, but was checked again on the HPLC before using
because it has a tendency to reform [3H]-B.
2.6.3 Effect of 11B-OHSD on MMTV-LTR Luciferase Activity
For this assay, COS-7 cells were plated on 60mm dishes in 4ml growth medium
containing the same additives as previously described (section 2.6.2.2). This assay
was carried out to determine the ability of human glucocorticoid receptor (hGR) to
activate a glucocorticoid responsive reporter gene (MMTV-LTR luciferase) in the
presence or absence of various concentrations of unlabelled B or A. In each
transfection assay, there was 1 gig pKC275 as an internal control, ljig hGR, 5(ig
MMTV-LTR luciferase or RSV-luciferase, and 10|ig of pSLl or pJ3.
Transfection was carried out in exactly the same way as described in section
2.6.2.1, except in smaller quantities (Table 2.2). After DMSO shocking the cells,
fresh transfection medium was supplemented with O.lnM-lpM unlabelled B or A or
lOnM dexamethasone or no steroid supplement at all. 48h after transfection, cells
were washed in 1ml of lx PBS and harvested into eppendorf tubes with 500(il lysis
buffer in which luciferase assays and B-galactosidase assays could be performed. The
lysis buffer consisted of 25mM Tris-phosphate (pH 7.8), 8mM MgCl2, ImM DTT,
ImM EDTA, 1% triton X100, 1% BSA and 15% glycerol. This buffer was made up
fresh on the day of harvesting.
2.6.4 Efficiency of Transfection
COS-7 cells were plated in 100mm2 cell culture dishes and transfected with 15|ig
pCHl 10 or pKC 275 as described in section 2.6.2.2. 48h following transfection, cells
were fixed in 0.5% glutaraldehyde in lx PBS for 15 min at room temperature. After
washing in lx PBS, the cells were incubated in 3.3mM Fe4K(CN)6.3H20, 3.3mM
Fe3K(CN)6, ImM MgCl2, and 150mM NaCl in lOmM sodium phosphate buffer
(pH7.0) containing 0.1% X-Gal (5-bromo-4-chloro-indolyl-b-D-galactosidase) for 2h
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at 37°C. The reaction was stopped by replacing the X-Gal solution with 70%
glycerol. The percentage of transfected cells was determined microscopically. As a
control, COS-7 cells were transfected with pGEM3 and incubated in 0.1% X-Gal in
exactly the same way.
2.6.5 B-Galactosidase Assay
Plasmids encoding B-galactosidase were routinely incorporated into transfection
experiments to determine the transfection efficiency.
For each sample to be assayed, 50|il of cell extract was mixed with 181 pil 0.1M
sodium phosphate; pH 7.5 (41ml 0.2M Na2HP04.2H20, 9ml 0.2M NaH2P04.2H20,
50ml dH20), 66pl lx ONPG (o-nitrophenyl-B-D-galactopyranoside; lx ONPG=
4mg/ml ONPG in 0.1M sodium phosphate) and 3(J.l lOOx Mg solution (0.1M MgCl2,
4.5M B-mercaptoethanol). This reaction was incubated at 37°C until a yellow colour
developed. The reaction was stopped by adding 500|il 1M Na2C03 t0 each reaction.
The optical density of the reactions was measured at a wavelength of 420nm. From
these absorbance readings, each transfection result could be corrected depending on
the transfection efficiency.
2.6.6 Luciferase Assay
The firefly enzyme luciferase catalyses the ATP-dependent oxidation of luciferin.
For every mole of luciferin oxidised, one photon is released which can then be
detected on a scintillation counter, or in this case, the more accurate luminometer.
The reaction mix for luciferase assays was made up in 500|il eppendorf tubes.
The reaction mix consisted of 50(il cell extract, 200|il lysis buffer (25mM Tri¬
phosphate (pH 7.8), 8mM MgCl2, ImM DTT, ImM EDTA, 1% triton x-100, 15%
glycerol and 1% BSA) and 4(il 20mM ATP, and placed in the counting chamber of a
Berthold luminometer. 100(il of 0.25 mM luciferin was injected into the counting
chamber and an instantaneous measurement of light produced was recorded.
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2.7 Statistics
Adrenal steroid, sex steroid and growth hormone manipulation studies were
analysed by Analysis of Variance followed by Duncan's Multiple Range Test.
Significance was set at p<0.05. Values are expressed as means±SEM. Transfection
studies were not statistically analysed.
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CHAPTER 3
GLUCOCORTICOID REGULATION OF 11B-OHSD
3.1 Introduction
The liver is a major target organ for the actions of glucocorticoids. For example,
glucocorticoids maintain glycogen reserves in the liver by activating glycogen
synthase and inactivating glycogen phosphorylase. Glucocorticoids may also have
effects on fatty acid metabolism and insulin control. In addition, liver is the organ
which expresses the highest levels of 11B-OHSD activity (Monder & Shackleton,
1984). However, it is widely believed that the predominant direction of 11B-OHSD
in liver is reductase (Bush, 1969) and therefore hepatic 11B-OHSD will presumably
have a very different role to the proposed actions in aldosterone-sensitive tissues.
Glucocorticoids also have multiple effects on the brain in the regulation of mood and
behaviour as demonstrated by the raised frequency of psychological disturbances (eg
depression) being found in clinical syndromes of glucocorticoid excess, such as
Cushing's syndrome (Cohen, 1980). The hippocampus in particular is extremely
vulnerable to glucocorticoids, such that chronic glucocorticoid exposure during stress
or ageing for example, especially in combination with other chronic insults such as
ischaemia, can result in the specific degeneration of hippocampal neurones in the
CA1 and CA3 fields (Sapolsky et al., 1985; Sapolsky & Pulsinelli, 1985; Sapolsky et
al., 1986). Glucocorticoid deficiency also results in specific hippocampal
degeneration (Sloviter et al., 1989). Therefore a mechanism must exist to regulate
glucocorticoid levels in hippocampal neurones, and presumably other regions of the
brain. 11B-OHSD activity (Lakshmi et al., 1991), mRNA expression (Moisan et al.,
1990a) and immunohistochemistry (Sakai et al., 1992) have been demonstrated in
various regions of the brain, with high levels expressed in hippocampus. It has
therefore been suggested that 11B-OHSD may be the selection mechanism
responsible for regulating glucocorticoid access to hippocampal neurones in vivo. In
support of this, 11B-OHSD activity in hippocampus during development falls from
postnatal day 1 to a nadir at postnatal day 10, only to rise again in adult rats, thus
following glucocorticoid levels during development (Moisan et al., 1992a). In
addition, sequencing of the 'liver-type' 11B-OHSD gene promoter revealed potential
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glucocorticoid response elements indicating a possible direct interaction between
glucocorticoids and the 11B-OHSD gene (Moisan et al., 1992b). 11B-OHSD may
also be appropriately regulated by long term exposure to chronically raised
glucocorticoid levels found for example in long term stress. Indeed, regulation of
11B-OHSD activity by glucocorticoids has been demonstrated in cultured normal
human foreskin fibroblasts, where 11B-OHSD activity was increased by the addition
of dexamethasone, Cortisol and corticosterone to the cell culture medium (Hammami
& Siiteri, 1991). In contrast, in vivo glucocorticoid manipulations had no effect on
rat kidney 11B-OHSD activity (Smith & Funder, 1991). I have begun to address the
possibility of 11B-OHSD regulating glucocorticoid access to hippocampal neurones
by firstly demonstrating the co-localisation of 'liver-type' 11B-OHSD mRNA with
both MR and GR mRNAs, and furthermore investigating whether 11B-OHSD is
regulated by adrenal steroid manipulations. I have also considered regulation of 11B-
OHSD using a model of chronic stress, the arthritic rat, to mimic physiologically
raised levels of glucocorticoids.
3.2 Results
3.2.1 Co-Localisation of 11B-OHSD with MR and GR in Hippocampus
For 11B-OHSD to be involved in regulating access of glucocorticoids to
mineralocorticoid and glucocorticoid receptors, it is likely that the enzyme would be
co-localised in cells containing these receptors. Therefore in situ hybridisation was
used to investigate whether 11B-OHSD mRNA is co-localised with MR and GR
mRNAs in hippocampus.
Firstly, non-isotopic in situ hybridisation in hippocampus was developed using
biotin-labelled MR, GR and 11B-OHSD cRNA probes. These probes were
hybridised to lOpm coronal hippocampal tissue sections and developed using an
avidin-biotin-horseradish peroxidase complex with 3, 3'-diaminobenzidine (DAB) as
substrate for the enzyme. Figure 3.1 shows DAB stained 11B-OHSD mRNA in
hippocampus in comparison to tissue sections hybridised under the same conditions
in the absence of probe. As previously described for 35S-labelled 11B-OHSD cRNA
probes (Moisan et al., 1990a), biotin-labelled 11B-OHSD cRNA probes demonstrated
the presence of 11B-OHSD mRNA in all regions of the hippocampus and dentate
gyrus with highest expression found in the CA3 subfield. In the same way, optimal
conditions for hybridisation of biotin-labelled GR cRNA probes were determined.
GR mRNA was highly expressed in dentate gyrus, CA1 and CA2 but showed lower
expression in CA3 and CA4 subfields (data not shown) as previously described for
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Figure 3.1:
In situ hybridisation of 11B-OHSD mRNA in rat hippocampus using (a) a biotin-
labelled 11B-OHSD cRNA probe, and (b) no probe. Biotin staining was visualised
using an avidin-biotin-horseradish peroxidase complex with 3,3-diaminobenzidine as
substrate.
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35S-labelled GR probes (Arriza et al., 1988; Van Eekelen et al., 1989; Sousa et al.,
1989). For both of these probes, competition studies were also performed to
determine the specificity of hybridisation. Hybridisation of biotin-labelled 116-
OHSD was attenuated by competition with 100-fold excess unlabelled 11B-OHSD
cRNA probe, but not by excess unlabelled GR probe. In the same way, hybridisation
of biotin-labelled GR probes was decreased by homologous but not heterologous
probe (data not shown). Unlike biotin-labelled 11B-OHSD and GR probes, optimal
conditions for specific hybridisation of biotin-labelled MR probes could not be
determined.
Double in situ hybridisation was performed by simultaneously hybridising 35S-
labelled MR or GR cRNA probes with a biotin-labelled 116-OHSD cRNA probe.
Following hybridisation and stringent washing, biotin-labelled 11B-OHSD was again
detected using DAB as substrate for the horseradish peroxidase detection system.
Slides were then put against autoradiographic film and/or dipped in emulsion to
localise the 35S-labelled MR and GR mRNAs. 116-OHSD was again found in all
regions of the hippocampus (Fig. 3.2a). Similarly, autoradiographs of MR in
hippocampus showed characteristic binding in all regions of the hippocampus
indicating probable co-localisation with 11B-OHSD (Fig. 3.2b). However following
exposure to nuclear emulsion, it was found that DAB is silver enhanced, and
therefore is not a useful substrate for co-localisation studies for in situ hybridisation.
Co-localisation of 11B-OHSD with both MR and GR was confirmed using AEC
(which is not silver enhanced) as substrate for the horseradish peroxidase detection
system. At a microscopic level, 11B-OHSD mRNA was found in the pyramidal and
granule cell neuronal layers of the hippocampus with highest expression in the CA3
subfield in agreement with previous findings (Moisan et al., 1990a). MR (Fig. 3.3a)
and GR (Fig. 3.3b) mRNAs as indicated by the presence of silver grains, are both
found in regions of the hippocampus containing 11B-OHSD mRNA, thus
demonstrating for the first time that 11B-OHSD and corticosteroid receptors are
colocalised in rat hippocampus.
3.2.2 Effects of lOd Adrenal Manipulations on 11B-QHSD
To examine the effects of adrenal steroids, groups of rats were adrenalectomised
and then replaced either with high dose dexamethasone (200pg/kg/day), a selective
GR agonist which is poorly metabolised by 11B-OHSD, or aldosterone
(20fig/kg/day), which is a selective MR agonist. After lOd treatment, 11B-OHSD





Co-localisation of 116-OHSD mRNA with MR mRNA. Hippocampal tissue sections
were hybridised simultaneously with a biotin-labelled 116-OHSD cRNA probe and a
35S-labelled MR cRNA probe, (a) 116-OHSD mRNA visualised with 3,3-
diaminobenzidine. The same hippocampal sections were then exposed to
autoradiographic film to determine the hippocampal localisation of (b) MR mRNA.
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Figure 3.3:
Co-localisation of 11G-OHSD mRNA with MR and GR mRNAs. Hippocampal
tissue sections were hybridised simultaneously with biotin-labelled 11G-OHSD cRNA
probes and 35S-labelled MR or GR cRNA probes. Biotin label was detected using 3-
amino-9-ethylcarbazole as the substrate. The same hippocampal tissue sections were
then dipped in nuclear emulsion for 28d. (a) Co-localisation of 11B-OHSD mRNA
with MR mRNA and (b) GR mRNA in the CA1 subfield of the hippocampus.
Co-localisation is demonstrated by the presence of silver grains over cells stained for
the presence of the biotin label. Photographs were taken at 40x magnification.
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Adrenalectomy led to a decrease in 11B-OHSD activity in liver, but in contrast
had no effect on hippocampal 11B-OHSD activity (Fig. 3.4a). Dexamethasone, but
not aldosterone, treatment reversed the decrease in hepatic 11B-OHSD activity to
control levels, and significantly increased hippocampal 11B-OHSD activity (23% rise
compared to adrenalectomy) (Fig. 3.4a). None of the adrenal steroid manipulations
had any effect on 11B-OHSD activity in kidney (Fig. 3.4a). It is interesting to note
that 11B-OHSD activity in sham-operated controls was low in hippocampus (similar
to levels expressed in adrenalectomised animals) while 11B-OHSD activity was high
(similar to chronic dexamethasone treatment) in liver (Fig. 3.4a).
To determine whether changes in 11B-OHSD activity in hippocampus and liver
occurred at the level of transcription, the effects of adrenalectomy alone or in
combination with dexamethasone replacement were also examined by northern
analysis. In hippocampus, adrenalectomy led to a decrease in 'liver-type' 11B-OHSD
mRNA expression (32% decrease compared to sham-operated controls), while
dexamethasone treatment increased 11B-OHSD mRNA expression by 69% when
compared to adrenalectomy alone (Figs. 3.4b, 3.5). In a similar way, lOd
dexamethasone treatment resulted in a non-significant rise in hepatic 11B-OHSD
mRNA expression (48% increase), while mRNA levels in sham-operated controls
were similar to those found in glucocorticoid treated animals (Fig. 3.4b, 3.5).
Adrenalectomy alone or followed by dexamethasone replacement had no effect on
any of the transcripts of 'liver-type' 11B-OHSD which hybridise to the known 11B-
OHSD cDNA in kidney (Fig. 3.4b, 3.5).
3.2.3 Arthritic Stress and 11B-OHSD
In order to determine whether a physiological stress has similar regulatory effects
on 11B-OHSD as dexamethasone, a model of adjuvant-induced arthritis was used.
Similar models of arthritis in rats have been shown to chronically activate the
hypothalamic-pituitary-adrenal axis (Sarlis et al., 1992). Corticosterone and CBG
were measured in arthritic animals to assess the effects of long term stress, as were
adrenal weight and thymus weight. 14d after injection of 250|ig attenuated
Mycobacterium tuberculosis around the left tarsal joint, chronic arthritis was apparent
(monitored by Lucy Donaldson). At this time, adrenal weight was significantly
raised and thymus weight significantly decreased compared to untreated controls. In
addition, morning plasma corticosterone levels were raised and CBG levels were
reduced compared to controls, although these changes did not reach statistical
significance (Table 3.1). These differences are indicative of chronic glucocorticoid

















The effect of adrenalectomy alone (Adx) or followed by dexamethasone treatment
(Adx+Dex) or aldosterone treatment (Adx+Aldo) for lOd on (a) 11B-OHSD activity
or (b) 'liver-type' 11B-OHSD mRNA levels in male rat liver, kidney and
hippocampus. 11B-OHSD activity is expressed as percentage conversion of [3H]-B
to [3H]-A. 'Liver-type' 11B-OHSD mRNA levels are expressed as a percentage of
sham-operated controls. *p<0.05 compared to sham-operated controls (Duncan's




Northern blot analysis of 11B-OHSD mRNA hybridised with 32P-labelled 'liver-type'
11B-OHSD cDNA showing the effects of adrenalectomy (Adx) alone or followed by
dexamethasone treatment (Adx+Dex) compared to sham-operated controls (Sham) in
male rat liver, kidney and hippocampus. Each lane represents RNA extracted from a
single individual. 11B-OHSD mRNA expression was quantified by computer
densitometry and expressed as a ratio of the optical densities of 11B-0HSD:7S. The
11B-OHSD mRNA species in liver and hippocampus is 1.7 kb, while in kidney there
are multiple mRNA species of 1.5,1.6,1.7 and 1.9 kb.
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Corticosterone CBG Thymus Adrenal
(nmol/1) (pmol/mg) weight weight
(g) (g)
Controls 337±35 13.2±1.9 0.66±0.08 0.07±0.01
Arthritis 490+91 7.5±2.1 0.46±0.04* 0.10±0.01*
Adx-(-Arthritis ND 24.6±7.9 0.69±0.08
Table 3.1:
Plasma corticosterone and CBG levels and thymus and adrenal weights in completely
untreated controls, arthritic rats 14 days after mycobacterium tuberculosis injection
around the left tarsal joint, and similarly arthritic rats which had been
adrenalectomised 3 days prior to the induction of arthritis. n=5/group. ND= below
the limits of assay detection. *p<0.05 compared to control values (Duncan's Multiple
Range tests).
stress. The effects of arthritis on hippocampal 11B-OHSD were in agreement with
the effects of dexamethasone treatment; hippocampal 11B-OHSD activity was
significantly increased in arthritic animals when compared to controls (20% increase)
(Fig. 3.6a). Adrenalectomy 3d prior to induction of arthritis prevented the increase in
hippocampal 11B-OHSD activity, although the degree of arthritis (estimated by
measuring joint circumference) was similar in both groups (measurements made by
Lucy Donaldson). In contrast, adrenalectomy led to a non-significant decrease in
hippocampal 11B-OHSD mRNA expression (41% decrease), while induction of
arthritis had no effect compared to untreated controls (Fig. 3.6a). Similarly in liver,
induction of arthritis had no effect on 11B-OHSD mRNA expression, whereas prior
adrenalectomy led to a decrease in 11B-OHSD mRNA expression of 56% (Fig. 3.6b).
However, hepatic 11B-OHSD activity was not affected in this model of stress (Fig.
3.6a).
3.2.4 Effects of RU38486 on 11B-OHSD
The experiments described in section 3.2.3 suggested that in arthritic rats the





























Effect of 14d arthritis (stress) and arthritis with prior adrenalectomy (Adx+stress)
compared to untreated control rat liver and hippocampus, (a) 11B-OHSD activity
expressed as percentage conversion of [3H]-B to [3H]-A and (b) 'liver-type' 11B-
OHSD mRNA levels expressed as a percentage of untreated controls. *p<0.05
compared to untreated controls (Duncan's Multiple Range test). n=10/group.
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substantiate this suggestion, 118-OHSD activity was also measured in intact arthritic
rats treated for 14d with the glucocorticoid antagonist RU38486 (lOmg/kg/day) either
in 10% DMSO by subcutaneous injection, or in 50% ethanol by gavage in two
separate experiments. RU38486 was predicted to prevent the arthritis-induced rise in
118-OHSD activity. However on post-mortem examination it was found that the
RU38486 had precipitated either around the site of subcutaneous injection or in the
stomach when administered by gavage. 11B-OHSD activity was nevertheless
measured to determine whether a sufficient amount of RU38486 had remained in
solution and had any effect on enzyme activity. Compared to untreated arthritic
animals, 118-OHSD activity in liver was unexpectedly increased by administration of
RU38486 in 10% DMSO (Fig. 3.7b). However, 10% DMSO alone also increased
118-OHSD activity, and this was not significantly different to the rise in activity
observed following RU38486 administration (Fig. 3.7b). Neither 10% DMSO or
RU38486 had any effect on hippocampal 118-OHSD activity (Fig. 3.7b).
Hippocampal and hepatic 118-OHSD activity were unaffected by 50% ethanol and
RU38486 in ethanol compared to untreated arthritic controls (Fig. 3.7a).
Interestingly, RU38486 treatment led to a significant reduction in hepatic 118-
OHSD activity when compared to ethanol treatment alone (Fig. 3.7a).
3.4 Discussion
Within the hippocampus, 118-OHSD mRNA is co-localised with both MR and
GR mRNAs, supporting the view that 118-OHSD may regulate glucocorticoid access
to corticosteroid receptors. In this chapter I have shown that glucocorticoids but not
mineralocorticoids regulate 11B-OHSD in hippocampus and liver. In addition none
of the adrenal steroid manipulations had any effect on 11B-OHSD in kidney in
agreement with previous work (Smith et al., 1991).
In liver, 118-OHSD activity was induced by dexamethasone treatment, but in
contrast was not affected by the arthritic model of stress. In contrast 118-OHSD
activity in hippocampus was significantly increased by both glucocorticoid
manipulations. A possible explanation for this discrepancy becomes apparent in the
comparison of levels of activity in sham-operated controls. In liver, sham-operated
control animals expressed similar levels of 11B-OHSD activity to those seen
following chronic dexamethasone treatment. Adrenalectomy led to a decrease in
118-OHSD in liver. In hippocampus, the opposite was found. Control animals
expressed similar levels of 11B-OHSD activity to adrenalectomised animals, while
dexamethasone treatment led to a significant increase in hippocampal 118-OHSD


















Effect of 14d RU38486 treatment in (a) 50% ethanol by gavage and (b) 10% DMSO
by subcutaneous injection on 11B-OHSD activity in male rat liver and hippocampus.
11B-OHSD activity is expressed as percentage conversion of [3H]-B to [3H]-A.
*p<0.05 compared to untreated controls. n=6/group.
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hippocampus and liver are exposed to glucocorticoids under basal conditions, and
that normally, 11B-OHSD is fully induced in rat liver (possibly due to high
intrahepatic glucocorticoid levels), and it is therefore not surprising that the stress
model used did not alter liver enzyme activity. The difference between hepatic and
hippocampal exposure to glucocorticoids may be due to the predominant direction of
11B-OHSD activity in the two tissues. It is believed that 11B-OHSD in liver acts as a
reductase (Bush et al., 1969) such that the liver would be exposed to high levels of
active glucocorticoids under basal conditions. In contrast, the direction of 11B-
OHSD activity in hippocampus is not known although a role for 11BOHSD as a
dehydrogenase has been proposed (Moisan et al., 1990a). If this were the case, 116-
OHSD would be expected to protect the hippocampus from high glucocorticoid
levels. In addition, hepatic and hippocampal 11B-OHSD may be influenced by the
presence of tissue-specific transcription factors which may regulate expression of
11B-OHSD in a tissue-specific manner (Williams et al., 1993). However the
mechanism(s) of these differences between hepatic and hippocampal 11B-OHSD have
yet to be determined.
Adrenalectomy led to an attenuation of 'liver-type 11B-OHSD mRNA expression
in hippocampus which is presumably due to a depletion of glucocorticoids since
dexamethasone reversed this effect. The fact that hippocampal 11B-OHSD activity
was not attenuated, unlike mRNA expression may reflect differences in the half-lives
or stability of 11B-OHSD protein and mRNA. In support of this, sex steroid (Chapter
4) and growth hormone (Chapter 5) manipulations both show similar discrepancies
between 11B-OHSD activity and mRNA expression with mRNA changes preceding
or being greater than changes in 11B-OHSD activity. Nevertheless, northern analysis
demonstrates that the glucocorticoid effects on hippocampal 11B-OHSD activity may
occur, at least in part, at the level of 11B-OHSD gene transcription. Furthermore,
sequences resembling glucocorticoid response elements have been reported in both
human (Tannin et al., 1991) and rat (Moisan et al., 1992b) 11B-OHSD genes.
Dexamethasone is a synthetic glucocorticoid which is poorly metabolised by 11B-
OHSD, and was administered in supraphysiological doses in this study. The increase
in hippocampal 11B-OHSD activity could also be caused by naturally occurring
stress. Induction of arthritis was used as a model of chronically raised glucocorticoid
levels, since similar rat arthritic models have been shown to chronically activate the
hypothalamic-pituitary-adrenal axis (Sarlis et al., 1992). However when endogenous
glucocorticoid levels were chronically, if modestly, raised following induction of
arthritis (Table 3.1), 11B-OHSD activity was significantly raised in hippocampus.
This effect was prevented by prior adrenalectomy suggesting that raised
glucocorticoid levels were indeed responsible for the raised hippocampal 11B-OHSD
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activity. In addition, the effects of dexamethasone and stress on hippocampal 116-
OHSD were similar, thus indicating that the effects are likely to be directly mediated
and not due to indirect actions of ACTH, since ACTH is suppressed by
dexamethasone, but induced by stress. This has been further corroborated by a recent
study which showed that administration of ACTH to rats had no effect on 11B-OHSD
activity in hippocampus, kidney or the vasculature (Walker et al., 1994).
Although indicative, corticosterone levels and CBG levels in the arthritic animals
used in this study were not significantly different between controls and 'stress'. This
may be due to one of two possibilities (i) our model of arthritis is a less severe
stressor than previous arthritic models. This is supported by the lack of other adverse
effects on the immune system (Donaldson et al., 1993) which may become apparent
in other models (Pearson & Wood, 1959), although still leading to chronic arthritis
after 14 days, (ii) It is also possible that control animals are stressed and therefore are
not significantly different from the proposed 'stressed' group. Basal morning levels of
corticosterone in rats are approximately lOOnM or less. In this study, both control
and stress groups have higher than basal corticosterone levels (337nM and 490nM
respectively); it is therefore possible that control animals were stressed, although this
may be related to events immediately preceding killing. Thus although the changes
in hippocampal 116-OHSD activity with mild chronic stress were not paralleled by
altered 116-OHSD mRNA expression, a weak trend was observed, and perhaps
alternative stressors may have greater or lesser effects on 116-OHSD in
hippocampus, but this remains to be determined.
RU38486 is a glucocorticoid antagonist which was used in these studies to
determine whether the effects observed could be glucocorticoid mediated. However
maintaining the antagonist in solution proved to be a problem which was not
overcome. Previous studies using RU38486 often do not report how the drug was
dissolved or administered (Gaillard et al., 1985), and the method of dissolving and
administration of RU38486 reported in a similar study from this group (Moisan et al.,
1990c) could not be reproduced here. However this study does indicate the
importance of incorporating vehicle treated groups in experiments since 50% ethanol
and 10% DMSO appeared to affect 11B-OHSD activity in liver. It also indicates the
difficulty faced in choosing an appropriate vehicle for compounds such as RU38486,
since other similar solvents such as gossypol which is a polyphenolic compound of
cotton seed oil, has recently been reported to inhibit 11B-OHSD (Song et al., 1991).
Mineralocorticoid receptors in hippocampus are apparently non-selective, and
have been shown to bind corticosterone in vivo (McEwen et al., 1986b). However the
hippocampus may also contain aldosterone-selective mineralocorticoid receptors,
suggested by the inability of corticosterone to displace all hippocampal aldosterone
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binding (McEwen et al., 1986b). The selectivity mechanism in the face of excess
circulating glucocorticoids has not yet been determined. In the same way as for the
kidney (de Kloet & Reul, 1987; Funder, 1986), CBG was proposed as an appropriate
mechanism, but since neural MR can selectively bind aldosterone in animals with
little or no circulating CBG this hypothesis was rejected (Sheppard & Funder, 1987).
Recently 11B-OHSD activity has been detected in brain, with highest activities found
in hippocampus and cortex (Moisan et al., 1990a; Lakshmi et al., 1991) suggesting
that there may be a subpopulation of MR or GR in hippocampus which are protected,
at least in part, from corticosterone by 11B-OHSD. There is as yet, no direct
experimental evidence to corroborate this mechanism in hippocampus. However co-
localisation of 11B-OHSD and MR immunoreactivities (Sakai et al., 1992) and
mRNAs (this chapter) have been demonstrated providing further evidence for the
involvement of 11B-OHSD in regulating glucocorticoid access to MR and perhaps
GR in hippocampus. This may prove important since either chronic excess or
deficiency of glucocorticoids exert deleterious effects on the brain, including
neuronal loss particularly in the hippocampus (Sloviter et al., 1989; Sapolsky et al.,
1985; Sapolsky et al., 1986). Glucocorticoid-mediated regulation of 11B-OHSD
activity may function to protect sensitive neurones from long-term elevation or
depression of glucocorticoid levels, such as might occur in chronic stress, affective
disorders or neurodegeneration (Seckl et al., 1993). Thus corticosteroid regulation of
brain 11B-OHSD may ensure optimal exposure of neurones to glucocorticoids and
preserve essential 'tonic' neurochemical functions (de Kloet & Reul, 1987; McEwen
et al., 1986b), whilst not attenuating the effects of the diurnal variation, or acute
stress. Although only in vitro 1 lB-dehydrogenase activity was measured in this
study, it is possible that the proposed presence of reductase activity may complicate
the interpretation of these findings. Further study as to the importance of 11B-
reductase activity in brain is therefore essential to the understanding of the role of
11B-OHSD in hippocampus, especially in light of the finding here that
glucocorticoids up-regulate hippocampal 11B-OHSD. Thus if 1 lB-reductase activity
predominates in hippocampus, this would lead to increased glucocorticoid exposure
and the implication that 11B-OHSD is actually a neuronal 'suicide' enzyme and not a
protective mechanism as proposed.
The absence of glucocorticoid regulation in kidney may be due to high efficiency
11B-OHSD, capable of handling even very high levels of glucocorticoids seen in
stress. This would tend to indicate the need for renal 11B-OHSD to protect MR in the
distal convoluted tubules and cortical collecting ducts from prevailing glucocorticoids
independent of circulating glucocorticoid concentrations (Naray-Fejes-Toth et al.,
1991), thus ensuring selective access of aldosterone to renal MR even when
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glucocorticoid levels are raised through chronic stress or in states of excess
endogenous or exogenous glucocorticoids. Similarly, adrenalectomy would not be
expected to have an effect, since the kidney would not normally be exposed to
glucocorticoids due to the activity of 11B-OHSD. A recent report has shown that
11B-OHSD in kidney is capable of effectively metabolising dexamethasone (Siebe et
al., 1993). Although metabolism of dexamethasone by hippocampal 11B-OHSD was
not looked at in this study, liver and testes, both of which express only the 'liver-type'
11B-OHSD do not metabolise dexamethasone indicating that hippocampal 116-
OHSD is unlikely to utilise dexamethasone as a substrate, and in addition that the
distinct high activity renal 11B-OHSD isoform may be responsible for metabolism in
tissues such as kidney. Therefore the absence of regulation of 11B-OHSD in rat
kidney by dexamethasone could alternatively be explained by 11B-OHSD
metabolising dexamethasone which would then be ineffective in regulating 116-
OHSD activity or mRNA expression. However induction of arthritis did not have
any effect on renal 11B-OHSD activity compared to controls suggesting that the
inability of dexamethasone to regulate renal 11B-OHSD cannot solely be due to its
metabolism by 11B-OHSD.
In conclusion, chronic changes in glucocorticoid, but not mineralocorticoid levels
regulate 11B-OHSD mRNA expression and enzyme activity in hippocampus and
liver, but not kidney. Similarly, physiological changes in glucocorticoid levels
regulate hippocampal and hepatic 11B-OHSD activity and mRNA expression.
Hippocampal 11B-OHSD may represent a tissue-specific mechanism to ensure
optimal long-term exposure of sensitive neurones to glucocorticoids.
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CHAPTER 4
SEX STEROID REGULATION OF 11G-OHSD
4.1 Introduction
11B-OHSD activity in rats has been shown previously to exhibit a sexually
dimorphic pattern of expression in both liver (Lax et al., 1978; Ghraf et al., 1975a)
and kidney (Ghraf et al., 1975a; 1975b; Smith and Funder, 1991) with approximately
two-fold higher activity being expressed in the male animal. This dimorphism may
be due to sex steroids themselves, since studies have been performed which
demonstrate that 11B-OHSD activity is affected by the administration or withdrawal
of sex steroids. For example, hepatic 11B-OHSD activity in male rats has been
shown to decrease following gonadectomy, an effect which was reversed by
testosterone replacement (Lax et al., 1978). In contrast, ovariectomy appeared to
have no effect on 11B-OHSD activity in female animals, while testosterone treatment
increased 11B-OHSD activity towards the levels found in control male liver. This
suggested that the normal higher level of 11B-OHSD activity in male liver is
maintained by the presence of androgens, and that the activity observed in control or
ovariectomised females represents the constitutive level. This same study also
showed that in contrast to, and unlike other androgen regulated enzyme activities,
11B-OHSD activity in male and female rats was almost completely repressed by
oestradiol treatment, suggesting that hepatic 11B-OHSD activity may be oestrogen, as
well as androgen regulated. Paradoxically, there was no reported change in hepatic
11B-OHSD activity following ovariectomy, in contrast to the increase in activity
which would be predicted from the removal of endogenous oestrogen.
In rat kidney the effects of sex steroids on 11B-OHSD activity are also
contradictory. In one study (Ghraf et al., 1975b), it was reported that female rats
responded to ovariectomy by developing higher renal 11B-OHSD activity similar to
levels found in normal males, while castration of male animals had no effect on 11B-
OHSD activity. In addition, treatment of intact males with oestradiol resulted in a
decrease in renal enzyme activity towards normal female levels, leading the authors
to conclude that 11B-OHSD activity in rat kidney was oestrogen-repressed. In a
different study in contrast, the opposite was found (Smith and Funder, 1991).
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Gonadectomy had no effect on 11B-OHSD activity in male or female rat kidney, and
oestradiol treatment of intact males resulted in a marked and significant increase in
renal 11B-OHSD activity.
These studies in rat liver and kidney suggest that the effects of sex steroids on
11B-OHSD activity are tissue-specific and diverse. However the results are
confusing and sometimes contradictory due to the fact that the 11B-OHSD activity
measured in these studies may result from any one of a number of isoforms of the
enzyme, and the relative contributions of these isoforms to total enzyme activity was
not determined. The work presented in this chapter was carried out in order to
determine the effects of sex steroids on total 11B-OHSD activity and mRNA
encoding the 'liver-type' 11B-OHSD isoform in order to investigate the relative
contribution of 'liver-type' 11B-OHSD to total 11B-OHSD activity in liver, kidney,
and also hippocampus, and to determine whether this isoform specifically is regulated
by sex steroid treatments. As a natural model of high physiological levels of sex
steroids, the effect of pregnancy on total 11B-OHSD activity and 'liver-type' 11B-
OHSD mRNA expression was also investigated.
4.2 Results
4.2.1 Effect of lOd Sex Steroid Manipulations
Liver
11B-OHSD activity exhibits sexual dimorphism in rat liver with approximately 2-
fold higher enzyme activity expressed in male than female liver. Ovariectomy of
female rats resulted in a marked increase in 11B-OHSD activity (120±37% increase)
which was not affected by testosterone treatment (108±24% increase compared to
controls) but was reversed by oestradiol replacement (Fig. 4.1a). lOd ovariectomy
resulted in a slight, but non-significant increase in 11B-OHSD mRNA expression
which was unaffected by testosterone treatment, while oestradiol replacement
resulted in a significant decrease in mRNA levels (82±10% decrease compared to
control levels) (Fig. 4.1b).
In male rats, gonadectomy alone or gonadectomy followed by testosterone
replacement did not affect hepatic 11B-OHSD activity (Fig. 4.2a). However,
oestradiol treatment for lOd produced a large decrease in enzyme activity of 69±8%
in male liver (Fig. 4.2a). In parallel, lOd oestradiol administration led to a dramatic
decrease in 11B-OHSD mRNA expression of 97±1% (Fig. 4.2b, 4.3). As with
enzyme activity, no other sex steroid treatment had any effect on 11B-OHSD mRNA












Effect of lOd sex steroid manipulations on (a) 11B-OHSD activity (expressed as
percentage conversion of [3H]-B to [3H]-A) and (b) 'liver-type' 11B-OHSD mRNA
expression (expressed as a percentage of mRNA levels in sham-operated control
animals) in female rat liver, kidney and hippocampus. Ovx = ovariectomy; Ovx+T=
ovariectomy followed by testosterone treatment; Ovx+E=ovariectomy followed by
oestradiol replacement. p<0.05 compared with sham-operated control females








Effect of lOd sex steroid manipulations on (a) 116-OHSD activity (expressed as
percentage conversion of [3H]-B to [3H]-A) and (b) 'liver-type' 118-OHSD mRNA
expression (expressed as a percentage of sham-operated controls) in male rat liver,
kidney and hippocampus. Gdx = gonadectomy; Gdx+T = gonadectomy followed by
testosterone treatment; Gdx+E = gonadectomy followed by oestradiol treatment.







Northern blot autoradiograph of 116-OHSD mRNA hybridised with 32P-labelled
'liver-type' 116-OHSD cDNA probes, showing the effects of sham-operation (C);
gonadectomy (G); gonadectomy followed by testosterone replacement (T); and
gonadectomy followed by oestradiol treatment (E) for lOd on 116-OHSD mRNA
expression in male rat liver, kidney and hippocampus. Each lane represents RNA
from an individual animal. 116-OHSD mRNA expression was quantified by
computer densitometry and expressed as a ratio of the optical densities of 116-
OHSD:7S. The 116-OHSD mRNA species in liver and hippocampus is 1.7 kb,
while in kidney there are multiple mRNA species of 1.5, 1.6, 1.7 and 1.9 kb.
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Kidney
11B-0HSD activity in kidney does not exhibit sexual dimorphism. However, sex
steroid manipulations for lOd were associated with marked changes in both 11B-
OHSD activity and mRNA expression in kidney. In female kidney, 11B-OHSD
activity was increased by lOd oestradiol replacement (91±15% rise) but not by
ovariectomy either alone or following testosterone treatment (Fig. 4.1a). Similarly to
liver, oestradiol treatment resulted in a dramatic decrease in 11B-OHSD mRNA levels
in female kidney (89±6% decrease) despite the induction of 11B-OHSD activity (Fig.
4.1b).
Gonadectomy of male rats resulted in a rise in enzyme activity of 72±5% (Fig.
4.2a). Testosterone replacement prevented the gonadectomy-induced increase in 11B-
OHSD activity by lOd (Fig. 4.2a). Oestradiol treatment of gonadectomised male rats
led to a large increase in 11B-OHSD activity (103±4% rise) (Fig. 4.2a). In marked
contrast, 11B-OHSD mRNA expression was virtually undetectable after lOd (Figs.
4.2b, 4.3). It is interesting to note that all transcripts of 'liver-type' 11B-OHSD in
kidney which hybridise to the known cDNA, were suppressed by lOd oestradiol
treatment (Fig. 4.3).
Hippocampus
None of the sex steroid manipulations had any effect on hippocampal 11B-OHSD
activity (Fig. 4.1a, 4.2a) or mRNA expression (Figs. 4.1b, 4.2b, 4.3) in male or
female rats at lOd.
4.2.2 In Situ Hybridisation
Ten days after gonadectomy 11B-OHSD mRNA was highly expressed in the male
kidney, showing the same localisation predominantly in the inner cortex and outer
medulla as has been previously shown in control male kidney (Yau et al., 1991). lOd
oestradiol treatment of gonadectomised male rats markedly attenuated 11B-OHSD
mRNA expression in all kidney regions (Fig. 4.4).
4.2.3 Effect of 48h Sex Steroid Manipulations
The oestrus cycle in the rat extends over approximately four to five days.
Therefore as an exaggerated model of the oestrus cycle, and as a time course of the
effects of sex steroids on 11B-OHSD activity and 'liver-type' mRNA expression, both
were measured in male rats following sex steroid manipulations for 48h.
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Figure 4.4:
Autoradiograph of longitudinal sections of male Han Wistar rat kidney hybridised
with 35S-labelled cRNA probes showing 'liver-type' 11B-OHSD mRNA expression
following (a) gonadectomy and (b) gonadectomy + oestradiol treatment for lOd.
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Liver
48h gonadectomy alone, and gonadectomy with testosterone replacement or
oestradiol treatment, had no effect on 11B-OHSD activity in male liver (Fig. 4.5a).
Similarly, 48h gonadectomy alone or with testosterone replacement had no effect on
hepatic 11B-OHSD mRNA expression in males. However, 48h gonadectomy with
oestradiol treatment led to a significant reduction of 11B-OHSD mRNA expression
by 77±7% (Fig. 4.5b) despite having no effect on enzyme activity at this time point.
Kidnev
Sex steroid manipulations were associated with marked changes in both 11B-
OHSD enzyme activity and mRNA expression at 48h in male kidney. Gonadectomy
resulted in a small, non-significant rise (21±7%) in enzyme activity at 48h (Fig. 4.5a),
which was unaffected by testosterone replacement (46±7% rise compared to controls;
Fig 4.5a). Gonadectomy led to a parallel increase in kidney 11B-OHSD mRNA
levels at 48h (72±5% rise; Fig. 4.5b), which again was not reversed by 48h
testosterone replacement (Fig. 4.5b).
Oestradiol treatment of gonadectomised male rats resulted in a large increase in
11B-OHSD activity (82+1% rise) at 48h (Fig. 4.5a). In striking contrast, 11B-OHSD
mRNA expression was markedly attenuated by 48h oestradiol treatment (decrease of
84±4%; Fig. 4.5b). In the same way as lOd oestradiol treatment in kidney, all
transcripts of the 'liver-type' 11B-OHSD which hybridise to the known cDNA were
suppressed by 48h oestradiol treatment (data not shown).
Hippocampus
None of the sex steroid manipulations had any effect on hippocampal 11B-OHSD
activity (Figs. 4.5a) or mRNA expression (Fig. 4.5b) at 48h in male rats.
4.2.4 11B-OHSD Activity During the Oestrus Cycle
Normal female adult Han Wistar rats were smeared daily, and cervical cells
examined microscopically to determine whether each animal was in pro-oestrus,
oestrus or met-oestrus. Rats were then divided into three groups based on the three
stages of the oestrus cycle. 11B-OHSD activity was measured in liver, kidney and
hippocampus of these groups of animals, and was found to be unaffected by the
























Effect of 48h sex steroid manipulations on (a) 11B-OHSD activity (expressed as
percentage conversion [3H]-B to [3H]-A, and (b) 'liver-type' 11B-OHSD mRNA
expression (expressed as a percentage of levels in sham-operated controls) in male rat
liver, kidney and hippocampus. Gdx = gonadectomy; Gdx+T = gonadectomy
followed by testosterone replacement; Gdx+E = gonadectomy followed by oestradiol












118-OHSD activity during the oestrus, met oestrus and di-oestrus stages of the
oestrus cycle in female rat liver, kidney and hippocampus. Data are expressed as
percentage conversion of [^H]-B to [^H]-A. *p<0.05 (Duncan's Multiple Range test).
n=5/group.
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4.2.5 11B-0HSD in Pregnancy
On day 19 of pregnancy, when oestrogen levels in the rat are raised (Albert et al.,
1992), 11B-OHSD activity in liver is significantly higher (46±2% higher) than the
activity measured in non-pregnant control female rats (Fig. 4.7a) in contrast to the
repression of 11B-OHSD activity observed after lOd oestradiol treatment of male and
female animals (Figs. 4.3a, 4.5a). Similarly, 11B-OHSD mRNA expression was also
significantly raised in pregnancy (277±87% increase) compared to non-pregnant
controls (Fig. 4.7b).
Renal 11B-OHSD activity was significantly decreased by day 19 of pregnancy
(43±7% decrease), again in contrast to the marked induction in 11B-OHSD activity
observed following gonadectomy with oestradiol treatment of male or female rats
(Fig. 4.7a). However, despite the repression of renal 11B-OHSD activity during
pregnancy, 'liver-type' 11B-OHSD mRNA levels in kidney were unaffected by
pregnancy (Fig. 4.7b).
4.3 Discussion
In agreement with previous studies, I have demonstrated that 11B-OHSD exhibits
a sexually dimorphic pattern of expression in rat liver (Lax et al., 1978; Ghraf et al.,
1975a), and that 11B-OHSD activity is regulated in liver and kidney in a tissue-
specific manner by chronic sex steroid treatments (Lax et al., 1978; Smith et al.,
1991). I have also demonstrated that the mRNA encoding the 'liver-type' 11B-OHSD
mRNA is regulated by the sex steroid manipulations employed and have provided
further evidence for the existence of a second 11B-OHSD isoform which is
differentially regulated by oestradiol treatment in rat kidney. Finally, using
pregnancy as a natural model of high oestrogen levels, I have shown that total 11B-
OHSD activity and 'liver-type' 11B-OHSD mRNA expression are regulated during
pregnancy in a tissue-specific manner, but interestingly, not in the manner predicted
by the results of the chronic oestradiol manipulation studies.
11B-OHSD activity in liver in female rats is approximately 50% of the levels of
activity exhibited in male rat liver (Fig. 4.1a). However lOd ovariectomy resulted in
a two-fold increase in 11B-OHSD activity which was reversed by oestradiol
replacement but not testosterone treatment Similarly in male rat liver, lOd
gonadectomy either alone or with testosterone replacement had no effect on 11B-
OHSD activity while oestradiol treatment for lOd following gonadectomy repressed
male hepatic 11B-OHSD activity to levels similar to those expressed in control female
























(a) 11B-OHSD activity (expressed as percentage conversion of [3H]-B to [3H]-A) and
(b) 'liver-type' 116-OHSD mRNA expression (expressed as a percentage of non¬
pregnant controls) during pregnancy in female rat liver and kidney. *p<0.05
compared with non-pregnant controls (Duncan's Multiple Range test). n=7/group.
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expressed in normal female liver are due to oestrogen repression of the enzyme.
'Liver-type' 11B-OHSD mRNA levels in liver show the same trend as total 11B-
OHSD activity although the changes in female animals do not reach significance.
Remarkably, although 11B-OHSD activity is only repressed to control female levels
by the oestradiol manipulations, 'liver-type' 11B-OHSD mRNA expression is
drastically decreased by this treatment in both male and female rats. Perhaps the 11B-
OHSD activity would also decrease further in parallel to mRNA levels, but the
treatment period was not extended to determine if this was indeed the case. However
at 48h, gonadectomised male animals treated with oestradiol, exhibited significantly
decreased levels of 'liver-type' 11B-OHSD mRNA whereas total activity was not
effected suggesting that 11B-OHSD mRNA and protein may have different half-lives.
Alternatively, there is the possibility of a different isoform of 11B-OHSD being
responsible for the activity measured, or it may be simply that the enzyme assay is
not as sensitive in detecting perturbations in 11B-OHSD activity as northern analysis
is at revealing changes in mRNA levels, or that mRNA levels although undetectable,
are not truly zero. Irrespective of the reasons for the different degrees of effect on
11B-OHSD activity and mRNA expression, it is apparent from the marked repression
of 'liver-type' 11B-OHSD mRNA levels that although published data suggested that
the dose of oestradiol administered in these experiments would result in plasma
oestrogen levels not significantly different from those of normal female rats (Painson
et al., 1992), this is not the case here. It is likely that the oestrogen levels produced in
these animals are higher than levels found in control females, which led to repression
of 'liver-type' 11B-OHSD mRNA below levels expressed in control females. In these
experiments the levels of plasma oestrogen were not measured, but obviously this
would provide useful information in any future studies.
In both male and female rat kidney, oestradiol treatment at 48h and lOd had
strikingly different effects on total 11B-OHSD activity and 'liver-type' 11B-OHSD
mRNA expression. While oestradiol treatment markedly induced 11B-OHSD
activity, the same treatment almost completely repressed 'liver-type' 11B-OHSD
mRNA expression in both male and female kidney. There are several possible
explanations for the discrepancies between 11B-OHSD activity and mRNA
expression in kidney, (i) This might represent differences in turnover/half-life of
mRNA and protein. However given the extent of the suppression of 'liver-type' 116-
OHSD mRNA, it is very unlikely that increased enzyme activity represents increased
translation of any remaining mRNA. In addition, the hepatic 11B-OHSD data in
which enzyme activity decreased broadly in parallel to 'liver-type' mRNA expression
by lOd suggest that gross differences between mRNA and protein half-life seem
unlikely explanations for the opposite changes in mRNA levels and enzyme activity
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seen in the kidney, (ii) Previous studies using 11B-OHSD cDNA probes encoding the
'liver-type' 11B-OHSD have shown multiple RNA species in the kidney (Krozowski
et al., 1990), one of which encodes a truncated protein which contains the putative
active sites of the enzyme. However it appears unlikely that any one of these mRNA
species is responsible for the high enzyme activity in the kidney since all result from
differential promoter usage of the same gene (Moisan et al., 1992b) and all were
repressed following oestradiol treatment, (iii) Alternatively, a second gene product
might be responsible for the oestradiol-induced renal 11B-OHSD enzyme activity.
The second gene product would presumably produce mRNA which hybridises very
weakly or not at all on northern analysis with the cloned 'liver-type' 11B-OHSD
cDNA. This would be consistent with a growing body of evidence suggesting the
presence of at least one other distinct 11B-OHSD isoform (described in section 1.3.5).
Gonadectomy of male rats caused a transient increase in renal 11B-OHSD activity
and mRNA expression at 48h, although the increase in activity did not reach
significance. Testosterone replacement for 48h reversed the increase in 11B-OHSD
mRNA levels, but did not affect enzyme activity. However at lOd, the increase in
11B-OHSD activity as a result of gonadectomy persisted, and testosterone
replacement reversed the effect of gonadectomy on 11B-OHSD activity. These
results again indicate a possible difference in half-life of 11B-OHSD protein and
mRNA, although sex steroid effects on renal 11B-OHSD may also be complicated by
the presence of a second isoform of 11B-OHSD.
The oestrus cycle in the rat extends over four to five days and three stages - pro-
oestrus, oestrus, and met-oestrus. These studies have demonstrated that 11B-OHSD
activity in female liver, kidney and hippocampus does not alter during the oestrus
cycle suggesting that physiological cyclical variations in oestrogen levels in females
do not perturb 11B-OHSD enzyme activity. This parallels the effects of 48h sex
steroid manipulations, although the effects of the oestrus cycle on 'liver-type' mRNA
expression have not been demonstrated.
In contrast to liver (and kidney), hippocampal 11B-OHSD activity and mRNA
expression were unaffected by any of the sex steroid manipulations employed. The
difference is unlikely to be due to oestradiol or testosterone not gaining access to the
brain, since both steroids readily cross the blood-brain barrier and bind to central
receptors when administered peripherally. Furthermore, although documented tissue-
specific promoter usage of the 11B-OHSD gene (Moisan et al., 1992b) might explain
the absence of sex steroid regulation in the hippocampus, work in our laboratory has
shown that liver and hippocampus predominantly employ the same promoter (Low et
al., 1993), making this an unlikely explanation for the differences in the regulation of
11B-OHSD in the two tissues. However sexually dimorphic expression of many
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genes and gene products is thought to be due to an indirect effect of sex steroids
acting on the secretory profiles of growth hormone, which differ in male and female
rats (Saunders et al., 1976; Tannenbaum & Martin 1976) as described in section
1.3.8. Furthermore, Lax et al.(1978) have shown that the actions of oestradiol on
11B-OHSD activity require an intact pituitary. Possible regulation of 11B-OHSD by
growth hormone (GH) has been investigated and described in Chapter 6. The lack of
regulation of hippocampal 11B-OHSD by sex steroids would therefore reflect a
failure of peripheral growth hormone, as with many other peptides, to cross the
blood-brain barrier, and gain access to the brain.
There are obviously several discrepancies between this, and previous studies of
the role of sex steroids in the sexual dimorphism of 11B-OHSD in rat liver and
kidney. Part of the reason for this may be that Lax et al. (1978) and Ghraf et al.
(1975a; 1975b) were looking at regulation of 11B-OHSD activity in liver and kidney
microsomes using Cortisol as substrate and NAD and co-substrate at pH 9.5.
However, Cortisol is not an appropriate substrate for rat 11B-OHSD since the
physiological glucocorticoid in the rat is corticosterone. In addition NAD is the
preferred co-factor for 11B-OHSD 2 of which there is no evidence in liver, and
although 11B-OHSD 2 is found in kidney, it is not exclusively found in microsomes
(Brown et al., 1993a). Finally, pH 9.5 is approximately optimal for looking at 'liver-
type' 11B-OHSD, while 11B-OHSD 2 prefers more physiological pH (Brown et al.,
1993a). Thus due to quite different experimental procedures, meaningful
comparisons of results between this and previous studies cannot reliably be made.
I also examined the effect of high physiological oestradiol levels during
pregnancy on 11B-OHSD activity and mRNA expression. Pregnancy is a natural
model for chronically raised oestradiol levels (Albert et al., 1992), together with
increased levels of many other steroid hormones. During pregnancy, 11B-OHSD
activity and mRNA expression in liver are both significantly raised in contrast to the
effects of chronic oestradiol treatment in either male or female animals. Similarly,
renal 11B-OHSD activity following gonadectomy and oestradiol treatment was
markedly increased, whereas during pregnancy it was significantly reduced.
Although this experiment was intended as a physiological model of raised oestrogen
levels to corroborate results of pharmacological oestrogen manipulations, opposite
directions of regulation were found in both experiments. Thus other factors in
pregnancy in addition to oestrogen must regulate 11B-OHSD. Progesterone levels are
also much higher during pregnancy (Albert et al., 1992), and progesterone is known
to inhibit 11B-OHSD, at least in placenta (Lopez-Bernal et al., 1980; Murphy, 1981).
Therefore manipulation of progesterone levels is probably the most obvious way to
begin looking at regulation of 11B-OHSD during pregnancy. It is also interesting that
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11B-0HSD activity in kidney is reduced during pregnancy. Inhibition of 11B-OHSD
by GE has been shown to result in in vivo binding of [3H] corticosterone in the
kidney in a manner indistinguishable from [3H] aldosterone binding (Edwards et al.,
1988). It is possible then, that decreased 11B-OHSD activity during pregnancy could
lead to increased exposure of renal mineralocorticoid receptors to glucocorticoids
possibly adding to the incidence of plasma volume expansion and even high blood
pressure often seen during pregnancy. There are several ways in which the role of
11B-OHSD in plasma volume expansion and raised blood pressure during pregnancy
could be considered. However, blood pressure measurements in rats are technically
difficult to do, and measurement of blood volume changes in pregnancy would be
inappropriate since blood volume increases in normal pregnancy anyway.
Nevertheless, it should be possible to look at the role of 11B-OHSD in protecting
renal mineralocorticoid receptors from exposure to glucocorticoids during pregnancy
by measuring [3H] corticosterone binding in kidney by in vivo autoradiography
following administration of tracer amounts of [3H] corticosterone to previously
adrenalectomised pregnant and non-pregnant control rats.
In summary, the studies in this chapter demonstrate that 118-OHSD is regulated
in a tissue-specific manner by sex steroids. In addition, hepatic 11B-OHSD exhibits
sexual dimorphism with higher 11B-OHSD expressed in male than female liver. The
discrepancy between oestradiol-mediated induction of 11B-OHSD activity in the
kidney in the face of almost total repression of the cloned 'liver-type' gene provide
strong support to the growing body of evidence indicating the existence of more than
one gene encoding 11B-OHSD activities. The nature of the oestrogen-induced renal
enzyme activity remains to be determined. The possibility that oestradiol regulation




GROWTH HORMONE REGULATION OF 11B-OHSD
5.1 Introduction
In Chapter 4,1 demonstrated that hepatic 11B-OHSD is sexually dimorphic with
the higher enzyme activity found in male animals. Ovariectomy of normal females
led to an increase in 11B-OHSD activity and mRNA expression towards control male
levels. This effect was reversed by oestradiol replacement but not affected by
testosterone treatment. In this chapter I examine the mechanism by which sex
steroids exert this sexually dimorphic expression on 11B-OHSD.
Many hepatic genes and gene products which typically exhibit a sexually
dimorphic pattern of expression are thought to be regulated indirectly by sex-specific
profiles of growth hormone (GH) from the pituitary (Gustafsson et al., 1983). Plasma
levels of GH in male and female rats are very similar although the secretory profiles
show significant differences between the sexes. In adult male rats, basal GH
secretion is very low but is interspersed by infrequent, high amplitude spikes. In
contrast, in the female animal GH patterns are more continuous with higher basal
levels of GH, and secretory pulses which are more frequent but of lower amplitude
(Saunders et al., 1976; Tannenbaum & Martin, 1976). In this chapter I address the
possibility that sex steroid effects on 11B-OHSD are indirect, and mediated sex
steroid-specific patterns of GH release.
Lax et al. (1978) have previously demonstrated that hypophysectomy abolishes
the sexual dimorphism of hepatic 11B-OHSD by increasing enzyme activity in
females to typical male levels indicating that the hypophysis has a repressive effect
on hepatic 11B-OHSD activity in females. Testosterone or oestradiol treatment of
hypophysectomised animals had no effect on hepatic 11B-OHSD leading the authors
to suggest that the hypophysis may have a permissive effect on the influence of sex
steroids on hepatic 11B-OHSD. Any possible active involvement of the pituitary in
maintaining sexual dimorphism of 11B-OHSD in rat liver was not investigated.
Similarly, Ghraf et al (1975b), showed that 11B-OHSD activity in rat kidney was
oestrogen repressed in female animals, and the low levels of renal 11B-OHSD could
be increased towards control male levels by ovariectomy or hypophysectomy. These
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authors did not however, examine the effects of sex steroids or pituitary hormone
replacement on renal 11B-OHSD following hypophysectomy.
In this chapter I describe experiments on the regulation of 11B-OHSD by GH in a
rat model of selective GH deficiency. This particular strain of GH deficient (dwarf)
rats are homozygous for an autosomal recessive mutation which reduces pituitary GH
to 5% of normal, and plasma GH to barely detectable levels (<5ng/ml) (Charlton et
al., 1988). The mutation originally arose spontaneously and is thought to result in
insufficient GH production by the pituitary while there is no evidence for reduced
GRF or enhanced SS production. Similarly, leutenising hormone, prolactin, thyroid
stimulating hormone, oxytocin, vasopressin and gonadal steroids are not significantly
affected in the dwarf animals compared to their heterozygous litter mates. In
addition, GH treatment of the homozygous dwarf results in significantly increased
growth rates and longitudinal bone growth (Charlton et al., 1988). However these
dwarf rats are an inbred genetic strain which may exhibit additional unexpected
abnormalities that may affect these studies. To overcome this potential problem, and
to further study the possible effects of reduced GH levels in these rats, GH and/or
oestradiol treatments following hypophysectomy have also been examined.
5.2 Results
5.2.1 Growth Hormone Regulation of 11B-OHSD in Dwarf Rats
Liver
In these experiments, the control rats used were the NIMR/AS strain which is the
parent strain from which the dwarf rats were bred. 11B-OHSD activity in normal
(AS) rat liver exhibits sexual dimorphism, with the higher enzyme activity being
expressed in male liver (50% higher than normal females) (Fig. 5.1a). There was a
smaller sex difference in dwarf rats, although dwarf males still expressed
significantly higher hepatic 11B-OHSD activity (36% higher than dwarf females).
However both sexes of dwarf rats had similar levels of hepatic 11B-OHSD activity to
normal males (Fig. 5.1a). Similarly, hepatic 11B-OHSD mRNA levels were lower in
normal females (72% lower compared to normal males), while 11B-OHSD mRNA
levels in dwarf male and female liver were not significantly different, although there
may be a trend towards lower expression in female dwarf rats (Fig. 5.1b, 5.2).
Treatment of dwarf male animals with continuous (female pattern) GH
(200(1g/day by mini osmotic pumps) for 6d led to a significant decrease in 11B-
OHSD activity (30% decrease) towards, to levels similar to those found in dwarf























(a) 11B-OHSD activity (expressed as percentage conversion [3H]-B to [3H]-A) and
(b) 'liver-type' 11B-OHSD mRNA expression (expressed as a percentage of normal
male levels) in normal and dwarf male and female rat liver, kidney and hippocampus.
*p<0.05 compared with normal males, ap<0.05 compared with dwarf males




Northern blot autoradiograph of 'liver-type' 11B-OHSD mRNA expression in normal
and dwarf male and female rat liver, kidney and hippocampus. Blots were hybridised
with 32P-labelled 11B-OHSD cDNA probes. Each lane represents total RNA from an
individual animal. 11B-OHSD mRNA expression was quantified by computer
densitometry and expressed as a ratio of the optical densities of 11B-0HSD:7S. The
11B-OHSD mRNA species in liver and hippocampus is 1.7 kb, while in kidney there
are multiple mRNA species of 1.5,1.6,1.7 and 1.9 kb.
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Effect of 6d continuous (female pattern) GH on (a) 11B-OHSD activity (expressed as
percentage conversion of [3H]-B to [3H]-A) and (b) 'liver-type' 11B-OHSD mRNA
expression (expressed as a percentage of dwarf male levels) in male dwarf rats.
















































Effect of 6d pulsatile (male pattern) GH on (a) 116-OHSD activity (expressed as
percentage conversion of [3H]-B to [3H]-A) and (b) 'liver-type' 116-OHSD mRNA
expression (expressed as a percentage of dwarf female levels) in dwarf female rat
liver, kidney and hippocampus. *p<0.05 compared to dwarf females (Duncan's
Multiple Range test). n=5/group.
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Figure 5.5:
Northern blot autoradiographs of 11B-OHSD mRNA hybridised with 'liver-type' 11B-
OHSD cDNA probes showing the effects of 6d (a) continuous (female pattern) GH in
dwarf male rats and (b) pulsatile (male-pattern) GH in dwarf female rats. Each lane
represents RNA from a single animal. 11B-OHSD mRNA expression was quantified
by computer densitometry and expressed as a ratio of the optical densities of 11B-
OHSD:7S. The 11B-OHSD mRNA species in liver and hippocampus is 1.7 kb,
while in kidney there are multiple mRNA species of 1.5,1.6,1.7 and 1.9 kb.
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3h via an automatic injection system) had no effect on hepatic 11B-OHSD activity in
dwarf female animals (Fig. 5.4a). Broadly reflecting changes in hepatic 11B-OHSD
activity, female pattern GH treatment of dwarf male animals led to a decrease (77%
fall) in 11B-OHSD mRNA expression, (Fig. 5.3b, 5.5a), while male pattern GH
treatment of dwarf female rats had no effect on hepatic 11B-OHSD mRNA expression
(Fig. 5.4b, 5.5b).
Kidney
Unlike hepatic 11B-OHSD, 11B-OHSD activity in kidney does not exhibit a
sexually dimorphic pattern of expression in either normal or dwarf rats (Fig. 5.1a).
However the levels of 11B-OHSD activity expressed in dwarf male and female
kidney were significantly lower (40% and 34% lower respectively) than those found
in parent strain animals (Fig 5.1a). In marked contrast, 'liver-type' 11B-OHSD
mRNA expression in kidney exhibited striking sexual dimorphism in both normal and
dwarf rats, with higher levels being expressed in the male animals (77% and 76%
higher respectively) (Fig. 5.1b, 5.2).
The lower renal 11B-OHSD activity in dwarf male and female rats appears to be
independent of GH since neither pattern of GH administration, continuous or
pulsatile, had any effect on 11B-OHSD activity in the kidney (Fig. 5.3a, 5.4a). In the
same way, neither pattern of GH administration had any effect on 'liver-type' 11B-
OHSD mRNA levels in dwarf male or female kidney (Fig. 5.3b, 5.4b, 5.5a, 5.5b),
although there may be a trend towards repression of 'liver-type' 11B-OHSD mRNA by
continuous GH treatment in dwarf male animals (34% decrease compared to dwarf
males) (Fig. 5.3b).
Hippocampus
Neither normal nor dwarf rats showed sexually dimorphic patterns of 11B-OHSD
activity or mRNA expression in hippocampus (Fig. 5.1a, 5.1b, 5.2), and neither
pattern of GH treatment had any effect on hippocampal 11B-OHSD (Fig. 5.3a, 5.3b;
5.4a, 5.4b, 5.5a, 5.5b).
5.2.2 Effects of Hvpophysectomy. GH and Oestradiol on 11B-OHSD
Liver
To determine whether the smaller sex differences in dwarf rats reflected lower
levels of GH, and to establish whether oestradiol had any direct effects on 11B-OHSD
in addition to those of GH, hypophysectomised male Wistar rats treated with GH
and/or oestradiol for 6d. To qualify the use of hypophysectomised male rats only, it
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was first demonstrated that 116-OHSD activity in hypophysectomised male rats was
similar to levels of activity expressed both in normal males and hypophysectomised
females (Fig. 5.6).
As expected, continuous (female pattern) GH led to a significant decrease in
hepatic 116-OHSD activity (25% fall) as did oestradiol treatment (26% fall).
Combination of oestradiol and GH treatments did not exert an additional effect
compared to each hormone alone (Fig. 5.7a). Similarly, the repressive effects of
oestradiol and/or GH treatments on hepatic 116-OHSD activity following
hypophysectomy were reflected by even greater reductions in 116-OHSD mRNA
expression (Fig. 5.7b, 5.8).
Kidnev
Since 116-OHSD activity in both normal and dwarf rats in addition to normal
Han Wistar rats does not appear to be sexually dimorphic, hypophysectomy would
not be expected to effect 116-OHSD activity in kidney. However, although levels of
116-OHSD activity in normal male and hypophysectomised male liver are similar,
hypophysectomy of female rats led to a significant decrease in 116-OHSD activity
(Fig. 5.6).
Hypophysectomised animals treated with oestradiol for 6d, showed a significant
increase in 116-OHSD activity (62% increase) compared to hypophysectomy alone
(Fig. 5.7a) in agreement with the increase in renal 116-OHSD activity observed
following oestradiol treatment of gonadectomised male and female rats (Figs. 4.1a,
4.2a). In contrast, continuous GH treatment led to a decrease in renal 116-OHSD
activity (28% fall), while a combination of oestradiol and GH treatments had no
effect on 116-OHSD activity in kidney compared to hypophysectomy alone (Fig.
5.7a). In marked contrast to the increase in renal 116-OHSD activity following
oestradiol treatment of hypophysectomised male rats, 'liver-type' 116-OHSD mRNA
levels were significantly decreased (74% decrease) (Fig. 5.7b, 5.8). Similarly,
although simultaneous oestradiol and GH treatments had no effect on renal 116-
OHSD activity, they led to a marked decrease in 'liver-type' 116-OHSD mRNA
expression in kidney (94% fall), compared to hypophysectomy alone (Fig. 5.7b, 5.8).
However, continuous GH treatment led to a fall in 'liver-type' 116-OHSD mRNA
expression, paralleling the changes in enzyme activity (Fig. 5.7b, 5.8). It is
interesting to note that the changes in 'liver-type' 116-OHSD mRNA expression in




116-OHSD activity expressed as percentage conversion of [3H]-B to [3H]-A in
normal male, hypophysectomised male and hypophysectomised female rat liver,



















Effects of 6d hypophysectomy (HPX) alone or following oestradiol treatment
(HPX+E2), GH treatment (HPX+GH) or both (HPX+E2+GH) on (a) 118-OHSD
activity (expressed as percentage conversion [3H]-B to [3H]-A) and (b) 'liver-type'
118-OHSD mRNA expression (expressed as a percentage of hypophysectomy alone)
in male rat liver, kidney and hippocampus. p<0.05 compared to hypophysectomy




Northern blot autoradiograph of 11B-OHSD mRNA hybridised with 32P-labelled
'liver-type' 11B-OHSD cDNA showing the effects of 6d hypophysectomy (HPX)
alone, or following oestradiol (HPX+E2), GH (HPX+GH) or oestradiol+GH
(HPX+E2+GH) treatments in male rat liver and kidney. Each lane represents RNA
from individual animals. 11B-OHSD mRNA expression was quantified by computer
densitometry and expressed as a ratio of the optical densities of 11B-0HSD:7S. The
11B-OHSD mRNA species in liver and hippocampus is 1.7 kb, while in kidney there
are multiple mRNA species of 1.5,1.6,1.7 and 1.9 kb.
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Hippocampus
Hypophysectomised male and female rats exhibited similar levels of hippocampal
11B-OHSD activity to normal males (Fig. 5.6).
Hypophysectomy followed by oestradiol and growth hormone treatments either
alone or in combination, had no effect on 11B-OHSD activity (Fig. 5.7a).
5.3 Discussion
In Chapter 4, I demonstrated that hepatic 11B-OHSD was expressed at lower
levels in female Han Wistar rats due to oestradiol repression of 11B-OHSD in female
liver. This sexual dimorphism in hepatic 11B-OHSD activity has now also been
demonstrated in a second normal (AS) strain of rat. These effects are likely to be
mediated at least in part, at the level of transcription, as reflected by the sexual
dimorphism of hepatic 11B-OHSD mRNA expression. Dwarf animals also exhibit
sexual dimorphism of 11B-OHSD, but to a lesser extent than parent strain rats
indicating that this may be related to GH, since this dwarf strain is not deficient in sex
steroids or any other pituitary-dependent hormones apart from GH (Charlton et al.,
1988). This hypothesis is supported by the sex-specific patterns of GH
administration in dwarf rats which indicate that female-specific GH secretion may be
responsible for repression of 11B-OHSD activity and mRNA expression in female
liver. Since dwarf female rats expressed significantly lower levels of 11B-OHSD than
dwarf males, it could be argued that repression of 11B-OHSD by continuous GH
treatment in dwarf males would be more easily observed than putative repression
resulting from pulsatile GH treatment in dwarf female animals. However, both sexes
of dwarf rats expressed significantly higher levels of hepatic 11B-OHSD activity than
normal females, and these levels were not significantly different from normal males,
indicating that there should be enough scope to observe any effects of hepatic 11B-
OHSD by pulsatile GH. Interestingly, it has recently been demonstrated that
although pituitary growth hormone production is much less in dwarf animals, the sex-
specific secretory profiles are maintained (Legraverend et al., 1992) which may
explain why sexually dimorphic expression of hepatic 11B-OHSD is still evident in
dwarf rats, but to a much lesser extent than in normal animals. This is further
supported by recent work on members of the cytochrome P450 2C gene family and
other steroid metabolising enzymes which exhibit sexually dimorphic expression
mediated by the physiological patterns of GH secretion (Gustafsson et al., 1983). In
dwarf rats where plasma growth hormone levels are 10 to 50-fold lower than normal,
the sexually dimorphic expression of the cytochrome P450 2C gene family (Bullock et
al., 1991; Legraverend et al., 1992) and 5a-reductase (Bullock et al., 1991) is
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maintained indicating that even low levels of GH are sufficient to maintain sexually
differentiated expression of many hepatic steroid metabolising enzymes including
11B-OHSD.
To address the possible effects of residual GH in the dwarf rats, and determine
any effects of oestradiol in the absence of GH, hypophysectomised male rats were
treated with continuous GH and/or oestradiol for 6d. Supporting the results in dwarf
animals, GH treatment repressed 11B-OHSD activity, and particularly mRNA
expression in rat liver. Interestingly, 6d oestradiol treatment following
hypophysectomy also led to significant repression of hepatic 11B-OHSD, which
could not be due to GH, and may therefore be a direct effect of oestradiol. However
it should be noted that the effects of oestradiol were investigated in male rat liver, and
from the results in Chapter 5, it is evident that the dose of oestradiol administered
may not result in plasma oestrogen levels similar to those found in normal females as
previously reported (Painson et al., 1992), and therefore pharmacological effects of
oestradiol on male hepatic 11B-OHSD cannot be ruled out. Thus although oestradiol
does repress 11B-OHSD in these experiments, whether this is entirely a
pharmacological effect cannot be determined from this study. It is also interesting to
note that Lax et al (1978) did not find an effect of oestradiol or testosterone on male
rat liver 11B-OHSD activity following hypophysectomy which may reflect
differential effects of oestradiol dosage. Whether oestradiol acts directly or indirectly
on hepatic 11B-OHSD remains undetermined. One experimental point which is
prominent from this study, is that following any hormone treatment, effects on 11B-
OHSD mRNA expression in liver (and kidney) appear to be magnified with respect to
the effects on 11B-OHSD activity. Since this is also the case when simply observing
11B-OHSD in males and females which have not undergone any treatment, this
suggests that northern analysis may be a more sensitive method for detecting
differences in 11B-OHSD expression. However in addition, following hormonal
treatments, it may be a reflection of initial suppression of transcription, and/or the
greater stability of existing 11B-OHSD protein than mRNA, and if the treatment
period was extended, the levels of 11B-OHSD activity may decrease in line with
mRNA expression.
The mechanism(s) of regulation of 11B-OHSD by GH are as yet unknown. The
rat cytochrome P450 2C11, 2C12 and 2C13 genes encode a testosterone 16a-
hydroxylase (Cheng & Schenkman, 1982), a steroid sulphate 15B-hydroxylase
(MacGeoch et al., 1984) and a testosterone 6B-hydroxylase (Ryan et al., 1984)
respectively. These are sex specific forms of P450 that are developmentally regulated
at a pretranscriptional level by the sexually dimorphic pattern of GH secretion
(MacGeoch et al., 1987; McClellan et al., 1989; Strom et al., 1988). In hepatocytes
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isolated from male rats, continuous (female pattern) GH added to hormone free
medium is sufficient to induce expression of the female-specific 2C12 mRNA and
protein within 4h (Guzelian et al., 1988; Toilet et al., 1990) and repress expression of
the male-specific 2C11 and 2C13 mRNAs (Legraverend et al., 1992). This indicates
that GH acts directly on the hepatocyte to regulate sex-specific expression of
cytochrome P450 2C11, 2C12 and 2C13 genes. Whether this mechanism is also
responsible for the sexual dimorphism of 11B-OHSD expression remains to be
determined.
The physiological implications of lower hepatic 11B-OHSD activity and mRNA
expression are not known. It is believed that the prominent direction of 11B-OHSD
in liver is in the reductase direction thus leading to accumulation of active
glucocorticoids (Bush et al., 1969). If, due to lower levels of hepatic 11B-OHSD,
there were lower levels of active glucocorticoids achieved in female liver, this may
explain differences in glucocorticoid-sensitive hepatic genes, such as those involved
in growth and drug and alcohol metabolism (Edenberg & Brown, 1992), as well as
perhaps having an involvement in the increased incidence of glucocorticoid-
responsive inflammatory disorders in human female liver.
Regulation of the 'liver-type' 11B-OHSD mRNA in kidney largely parallels the
changes observed in the liver. 'Liver-type' 11B-OHSD mRNA expression in kidney is
higher in normal and dwarf male rats than in normal and dwarf female rats
respectively. Similarly in parallel with the liver, continuous (female pattern) but not
pulsatile (male pattern) GH replacement led to a decrease in 'liver-type' 11B-OHSD
mRNA expression in kidney, although this did not reach significance. In marked
contrast, 11B-OHSD activity in kidney was not sexually dimorphic in normal or
dwarf animals, perhaps indicating the necessity for protection of renal
mineralocorticoid receptors from exposure to glucocorticoid exposure at all times.
However, renal 11B-OHSD activity was lower in dwarf rats and independent of GH
patterns. Collectively, the repression of all renal transcripts of the 'liver-type' 11B-
OHSD gene (Agarwal et al., 1989) suggest that this isoform of 11B-OHSD is unlikely
to be responsible for all of the substantial renal activity observed, which instead are
likely to result from the product(s) of an alternative 11B-OHSD gene(s) which is not
affected by differential patterns of GH secretion. The results of hormone replacement
following hypophysectomy emphasise the complexities of renal 11B-OHSD activity.
6d oestradiol treatment led to marked repression of the 'liver-type' 11B-OHSD mRNA
expression, despite having the opposite effect on total renal 11B-OHSD activity
presumably reflecting induction of an additional 11B-OHSD gene product by
oestradiol. Continuous GH treatment in contrast led to a slight decrease in 11B-
OHSD activity, and more marked decrease in 11B-OHSD mRNA expression, perhaps
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reflecting a more subtle regulation of the additional gene product by GH, or more
likely in light of the effects on 11B-OHSD in liver, reflecting regulation solely of the
'liver-type' 11B-OHSD isoform by GH.
Although 11B-OHSD activity and in dwarf rat kidney does not appear to be
sexually dimorphic, 11B-OHSD activity in dwarf rat kidney was significantly lower
than in normal animals. The implications of this for dwarf rats in terms of renal
mineralocorticoid function, are not known. However it may be possible to determine
the effect of lower 11B-OHSD actvitiy in dwarf kidney in terms of protection of renal
mineralocorticoid receptors from glucocorticoid exposure by comparing the in vivo
binding of [3H] corticosterone in dwarf rat kidney and normal rat kidney.
Hippocampal 11B-OHSD activity and mRNA expression did not exhibit sexual
dimorphism in normal or dwarf animals, and were not affected by either pattern of
GH administration. This could be easily explained if the effects of sex steroids were
entirely mediated through modification of patterns of GH secretion, since GH like
may other peptide hormones does not cross the blood brain barrier and would
therefore not be expected to affect hippocampal 11B-OHSD. In agreement with this,
hypophysectomy followed by 6d GH or oestradiol treatments did not affect
hippocampal 11B-OHSD activity. However hippocampal and hepatic 11B-OHSD
predominantly utilise the same promoter and produce mRNA transcripts of the same
size (Low et al., 1993; Smith et al., 1993), yet following hypophysectomy hepatic
11B-OHSD was repressed by oestradiol treatment while the hippocampal enzyme
remained unaffected. It is likely therefore that hippocampal and hepatic 11B-OHSD
are differentially regulated by as yet undetermined factors. For example subcellular
compartmentalisation of 11B-OHSD in liver and hippocampus may not be the same,
and in addition it is likely that tissue-specific transcription factors regulate expression
of 11B-OHSD in a tissue-specific manner (Williams et al, 1993), and that the
regulatory factors governing expression of 11B-OHSD in liver and hippocampus may
differ. This contention is supported by the presence of functional oestrogen receptors
in hippocampus (Bettini et al., 1992) and therefore it is possible that oestrogen
receptors are acting in the liver through an effect on another transcription factor not
present in hippocampus to differentially regulate 11B-OHSD, but this mechanism(s)
has yet to be addressed.
In conclusion, the work in this chapter demonstrates that the sexual dimorphism
of hepatic 11B-OHSD may be mediated in part by sex-specific patterns of GH
secretion. However expression of 11B-OHSD in liver can also be regulated through
an action of oestradiol, not dependent on GH. Hippocampal 11B-OHSD is not
regulated by GH, furthermore it does not appear to be regulated by oestradiol in
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contrast to liver and kidney, suggesting as yet undetermined tissue-specific
differences in the regulation of hippocampal and hepatic 11B-OHSD. Finally,
although regulation of 'liver-type' 11B-OHSD mRNA in rat kidney largely parallels
that of the liver, regulation of renal 11B-OHSD activity remains complex due to the
involvement of an additional isoform of 11B-OHSD in rat kidney contributing to the
total enzyme activity measured in this tissue.
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CHAPTER 6
REGULATION OF llli-OHSD IN INTACT MAMMALIAN CELLS
6.1 Introduction
Although 11B-OHSD activity is expressed in many tissues (Monder &
Shackleton, 1984), its physiological role is only really understood in kidney where
the enzyme protects MR from exposure to glucocorticoids. Antibodies raised against
purified rat liver 11B-OHSD (Lakshmi & Monder, 1988) failed to co-localise renal
11B-OHSD and MR leading to the suggestion that 11B-OHSD detected in proximal
tubules may regulate glucocorticoid access to MR in distal convoluted tubules and
cortical collecting ducts by a paracrine mechanism (Edwards et al., 1988; Rundle et
al., 1989). However using the cDNA encoding 11B-OHSD which was cloned from a
rat liver cDNA library (Agarwal et al., 1989), 11B-OHSD mRNA expression was
found to be high in distal as well as proximal epithelia (Yau et al., 1991).
When 11B-OHSD was purified, it was found to express only dehydrogenase
activity suggesting that the reductase component of 11B-OHSD may be a distinct
enzyme, and supporting the proposed role of 11B-OHSD as a protective mechanism
(Lakshmi & Monder, 1988). However when the cloned 11B-OHSD cDNA was
expressed in human osteosarcoma cells at relatively high levels using recombinant
vaccinia virus, 11B-OHSD was found to exhibit approximately equal amounts of
dehydrogenase and reductase activities, with p.M affinity for both corticosterone and
11-dehydrocorticosterone (Agarwal et al., 1990). Furthermore, endogenous
glucocorticoids circulate 'free' in low nM concentrations, and mineralocorticoid
receptors have a Kd for glucocorticoids which is ~0.5nM (Arriza et al., 1987;
Krozowski & Funder, 1983) making it unlikely that the 'liver-type' 11B-OHSD could
effectively compete for glucocorticoid binding. Therefore it was predicted that 11B-
OHSD would not be able to protect MR and GR from exposure to low (physiological)
concentrations of glucocorticoids, but would adequately inactivate high levels of
glucocorticoids.
Recently, a completely different cell culture system; the toad bladder cell line
(TBM 18-23) has been used to look at the direction of 11B-OHSD activity (Dupperex
et al., 1993). Stable transfection of TBM 18-23 cells with the entire coding region of
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rat liver 11B-0HSD, resulted in expression of 11 B-reductase activity suggesting that
in this intact cell system, rat liver 11B-OHSD is capable of activating inert
glucocorticoids. However dehydrogenase activity of 11B-OHSD could not be
assessed in this amphibian cell line since it was demonstratied that dexamethasone
treatment of TBM 18-23 cells increased endogenous 11B-OHSD activity in the
dehydrogenase direction. Therefore when transfected TBM 18-23 cells were treated
with dexamethasone, the resulting increase in llB-dehydrogenase activity could not
be contributed to the transfected 11B-OHSD plasmid.
'Liver-type' 11B-OHSD mRNA expression is co-localised with MR mRNA in
hippocampus (section 3.2.4, Fig. 3.6a) and may in addition, regulate access of
glucocorticoids to GR (Moisan et al., 1990b; Teelucksingh et al., 1990; Fuller &
Verity, 1990). Indeed 11B-OHSD and GR mRNAs have been demonstrated in the
same tissues (Whorwood et al., 1992; section 3.2.4, Fig. 3.6b) suggesting additional
roles for 11B-OHSD in regulating glucocorticoid access to GR in glucocorticoid
responsive tissues (eg liver) as well as to MR in tissues which express MR but
respond to physiological glucocorticoids (eg hippocampus). Therefore in order to test
the hypothesis that 'liver-type' 11B-OHSD may regulate glucocorticoid access to GR
as either a dehydrogenase or reductase, I transfected the rat 'liver-type' 11B-OHSD
cDNA into mammalian cell lines (COS-7, CV-1) and assessed the ability of 11B-
OHSD in intact cells to metabolise glucocorticoids and correlated this with 11B-
dehydrogenase activity in homogenates of the same cells. In addition, I looked at a
molecular marker for glucocorticoid activity, namely the ability of corticosterone and
11-dehydrocorticosterone to regulate MMTV-luciferase expression in the presence
and absence of 11B-OHSD.
6.2 Results
pSLl was created by cloning the 1.2kb EcoRl/Sstl fragment of rat liver 11B-
OHSD (encoding the entire open reading frame) into pJ3 (Morgenstern & Land,
1990) placing expression under the SV40 promoter (described in section 2.1.2.3).
0.1-10p.g of pSLl was transiently transfected into COS-7 cells, and 11B-OHSD
activity in both dehydrogenase and reductase directions measured in intact cells over
24h by monitoring the conversion of [3H]-corticosterone ([3H]-B) to [3H]-11-
dehydrocorticosterone ([3H]-A) or [3H]-A to [3H]-B in the cell medium (as detailed
in section 2.6.2.1). 11B-OHSD activity in homogenates of the same cells was also
measured (as described in section 2.6.2.3), for comparison with activities found in the
medium.
132
6.2.1 Efficiency of Transfection of COS-7 Cells
COS-7 cells were transiently transfected with pKC275, a plasmid constructed by
Karen Chapman, encoding B-galactosidase expression. Cells were subsequently fixed
with 4% paraformaldehyde and stained with X-Gal (as described in section 2.6.4) to
determine the number of cells typically transfected. In an average of six cell culture
dishes transfected, the percentage of cells positively stained for B-galactosidase in this
way was 45±1.5% (Fig. 6.1). COS-7 cells transfected with the control plasmid
pGEM3, showed no B-galactosidase staining by this method.
6.2.2 Rat 'Liver-Tvpe' 11B-OHSD in COS-7 Cells
Intact mock transfected COS-7 cells contained little 11B-OHSD activity in either
dehydrogenase or reductase directions. In intact cells transfected with O.l-lO^ig
pSLl, no 1 lB-dehydrogenase activity was detectable above mock transfected levels at
24h (Fig. 6.2a). In contrast, 116-reductase activity measured by conversion of [3H]-A
to [3H]-B in intact COS-7 cells was readily apparent in cells transfected with 10|ig
pSLl at 24h, and apparent to a lesser extent in cells transfected with l|ig or 3|ig of
pSLl (Fig. 6.3a).
To correlate metabolism of glucocorticoids seen in cell medium with 11B-OHSD
activity present in cell homogenates, 1 lB-dehydrogenase activity was measured in
homogenates of the same cells. In both cases, conversion of [3H]-B to [3H]-A was
apparent in cell homogenates transfected with l|j.g pSLl, and was maximal in
homogenates from cells transfected with 10|ig pSLl (Figs. 6.2b; 6.3b). In both cases
therefore, similar levels of in vitro 11B-OHSD activity were obtained indicating that
similar levels of expression of transfected plasmid result in 1 lB-reductase (Fig. 6.3a),
but not 1 lB-dehydrogenase (Fig. 6.2a) activity in intact cells. The lack of
dehydrogenase activity in intact cells cannot therefore be explained by lack of
expression of transfected pSLl.
The time course of llB-dehydrogenase and 1 lB-reductase activities in the intact
cells was also measured. As expected no 1 lB-dehydrogenase activity was detected at
any of the time points measured even at maximal levels of transfected of pSLl (Fig.
6.4a). However, 1 lB-reductase activity in cells transfected with 10|ig pSLl was
apparent within 4h of addition of [3H]-A to the medium, and by 24h, llB-reductase




X-Gal staining in situ as a measure of the efficiency of transfection. Cos-7 cells were
transfected with pKC275 (plasmid encoding 6-galactosidase), fixed in
paraformaldehyde and incubated in a solution containing X-Gal. This is a

































The ability of 'liver-type' 11B-OHSD cDNA to act as a dehydrogenase in transiently
transfected COS-7 cells, (a) 1 lB-dehydrogenase activity in intact cells measured and
expressed as percentage conversion of to [3H]-A in the cell medium, (b) 11B-
dehydrogenase activity in homogenates of the same cells, measured and expressed as
percentage conversion of to [3H]-A. Data are from a representative

















































The ability of 'liver-type' 11B-OHSD cDNA to act as a reductase in transiently
transfected COS-7 cells, (a) 1 lB-reductase activity in intact cells measured and
expressed as percentage conversion of [3H]-A to [3H]-B in the cell medium, (b) 11B-
dehydrogenase activity in homogenates of the same cells measured and expressed as
percentage conversion of [3H]-B to [3H]-A. Data are from a representative























Time couse of expression of 1 lB-dehydrogenase and 116-reductase activities of rat
'liver-type' 11B-OHSD cDNA transfected into COS-7 cells, (a) Development of 116-
dehydrogenase activity measured and expressed as percentage conversion of [3H]-B
to [3H]-A in the cell medium, (b) Development of 116-reductase activity measured
and expressed as percentage conversion of [3H]-A to [3H]-B in the cell medium. This
is a representative experiment which was repeated twice. All values are means of
duplicate measurements.
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6.2.3 Expression of Rat 'Liver-Type' 11B-OHSD in CV-1 Cells
In order to determine that predominant 11B-OHSD reductase activity in COS-7
cells was not unique to the particular cell line, similar experiments were carried out in
CV-1 cells which do not contain MR or GR (Giguere et al., 1986; Arriza et al., 1987)
or detectable 11B-OHSD activity or mRNA expression (Low et al., unpublished
observations).
In contrast to COS-7 cells, pSLl transfected CV-1 cells did show a small amount
of dehydrogenase activity in intact cells which was maximal/optimal at 3|ig (Fig.
6.5a). Reductase activity in intact cells was not measured. Despite the very low level
of dehydrogenase activity in intact cells, enzyme activity in cell homogenates was
readily detectable, and was optimal/maximal in homogenates of CV-1 cells
previously transfected 3|ig pSLl (Fig. 6.5b). Thus although 3(ig pSLl produced
maximal levels of llB-dehydrogenase activity in intact and homogenised CV-1 cells,
higher 1 lB-dehydrogenase activity in COS-7 cell homogenates and 1 lB-reductase
activity in intact COS-7 cells was observed following transfection with 10pg pSLl.
6.2.4 Influence of 11B-OHSD on Activity of a Glucocorticoid Responsive Reporter
Gene
To investigate the ability of 11B-OHSD to regulate access of glucocorticoids to
GR in vivo, COS-7 cells were transfected with a human GR expression plasmid
(Giguere et al., 1986) and a glucocorticoid responsive reporter gene (MMTV-LTR
luciferase) in the presence or absence of 11B-OHSD (pSLl). Following transfection,
corticosterone and 11-dehydrocorticosterone were added to the medium as described
in section 2.6.5.
Transfection of MMTV-LTR luciferase alone in the absence of GR or steroid
resulted in 7.5-fold induction of luciferase activity higher than background (Table
6.1). Addition of GR alone, in the absence of added steroid resulted in a 16-fold
increase in expression of MMTV-LTR luciferase. This was further increased to a 36-
fold increase in the presence of lOnM dexamethasone. Addition of pJ3 or pSLl also
led to an increase in GR induction of MMTV-LTR luciferase in the absence of added
steroid (34-fold and 34-fold increase respectively) or in the presence of lOnM
dexamethasone (144-fold and 143-fold induction respectively). At concentrations of
B below lOnM, MMTV-LTR luciferase activity in the presence of GR was similar to
MMTV-LTR luciferase activity measured in the absence of steroids (Table 6.1).




















The ability of 'liver-type' 11B-OHSD cDNA to act as a dehydrogenase in transiently
transfected CV-1 cells, (a) 116-dehydrogenase activity in intact cells measured and
expressed as percentage conversion of [3H]-B to [3H]-A in the cell medium, (b)
116-dehydrogenase activity in homogenates of the same cells measured and
expressed as percentage conversion of [3H]-B to [3H]-A. Data are from a
representative experiment which was repeated three times. All values are means of
duplicate measurements.
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Fold Induction ofMMTV-LTR luciferase (over mock
transfected cells) in the presence of
0 GR GR + pJ3 GR + pSLl
No steroid 7.5 16 34 34














The ability of corticosterone and 11-dehydrocorticosterone to regulate glucocorticoid
receptor (GR) activation of the glucocorticoid responsive gene MMTV-luciferase in
the presence (pSLl) or absence (pJ3) of 11B-OHSD in COS-7 cells. Data are
expressed as fold induction of cells transfected with GR+lOpg pJ3 in the absence of
steroid. These results are representative; each experiments was repeated three times.
Dex=dexamethasone, B=corticosterone, A=11-dehydrocorticosterone.
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LTR luciferase, although the increase was not as large as expected perhaps due to the
unexpectedly high induction of the reporter gene by GR in the absence of steroid
masking low level increases in expression (Table 6.1; 6.2). 11-dehydrocorticosterone
however, which is not able to bind to or activate mineralocorticoid or glucocorticoid
receptors, was found to induce MMTV-LTR luciferase only in the presence of pSLl,
indicating that the 'liver-type' 11B-OHSD cDNA is predominantly acting in the
reductase direction and at lfiM A, can produce sufficient B to induce MMTV-LTR
luciferase activity through activation ofGR (Table 6.1; 6.2).
Fold induction ofMMTV-LTR luciferase
activity in the presence of
lOjig pJ3 10|ig pSLl
No steroid 1 1
Dex lOnM 4.2 4.2
B lpM 2.1 3.4
A lpM 1.1 2.1
Table 6.2;
The ability of corticosterone and 11-dehydrocorticosterone to regulate glucocorticoid
receptor (GR) activation of the glucocorticoid responsive gene MMTV-luciferase in
the presence (pSLl) or absence (pJ3) of 11B-OHSD in COS-7 cells. Data are
expressed as fold induction over cells transfected with 10|ig pJ3 in the absence of
steroid. These results are representative; each experiments was repeated three times.
Dex=dexamethasone, B=corticosterone, A=11-dehydrocorticosterone.
6.3 Discussion
We and others have proposed, based on co-localisation studies, that 11B-OHSD
plays a role in vivo to protect corticosteroid receptors from exposure to
glucocorticoids. Others have demonstrated dehydrogenase and reductase activities in
mammalian cells (encoded by the 'liver-type' 11B-OHSD) in approximately equal
proportions in vitro (Agarwal et al., 1990) and in vivo (Agarwal et al., 1989). In
addition, in vivo 1 lB-reductase activity was reported in intact amphibian cells (it was
not possible due to experimental design to measure dehydrogenase activity in these
cells) (Dupperex et al., 1993). Therefore in amphibian and mammalian cells, it has
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been shown that 'liver-type' 11B-OHSD can encode 1 lB-reductase activity. In this
chapter I have shown that at least in some mammalian cell types, 1 lB-reductase
activity predominates in intact cells (despite high levels of dehydrogenase activity in
homogenates) precluding a role for the 'liver-type' 11B-OHSD in inactivating steroids.
Furthermore I have shown that co-expression of 11B-OHSD with GR permits
activation of a glucocorticoid-sensitive reporter gene by the otherwise inactive
glucocorticoid, 11-dehydrocorticosterone.
In these experiments GR alone, in the absence of added steroid, activated
MMTV-LTR luciferase activity. This was unexpected as all serum used in these
experiments was charcoal stripped to remove endogenous steroids. The stripping
procedure was 99.8% effective (assessed by removal of added [3H]-B; data not
shown). Therefore the effect of GR on the reporter gene is unlikely to be due to
glucocorticoids in the cell medium. The activation ofMMTV-LTR luciferase by GR
in the absence of steroid may have masked induction of the reporter gene by low
levels of steroid. Therefore although GR has nM affinity for B, activation of the
reporter gene in the presence of InM B is not apparent. The mechanism of MMTV-
LTR luciferase activation by GR in the absence of steroid is not known. However it
is likely to be a phenomenon peculiar to the transfection method. For instance, it has
been reported that the magnitude of several transcritional responses elicited by
transfected GR is approximately proportional to the number of GR molecules per cell
(Vanderbilt et al., 1987). Thus if there are few GR molecules per cell, then MMTV-
LTR activation by GR could be low. Alternatively, it has been shown that nuclear
factor I (NFI) is required for efficient transcription of the MMTV-LTR promoter in
JEG3 cells even after GR transfection and treatment with glucocorticoids
(Bruggemeir et al., 1990). JEG3 cells contain low levels of NFI, and transcription of
the MMTV-LTR promoter is enhanced by co-transfection with NFI cDNA
(Bruggemeir et al., 1990). Thus levels of NFI or possibly other transcription factors
in COS-7 cells may affect the transcription ofMMTV-LTR luciferase. Interestingly,
phenol red has been shown to have oestrogenic properties, and at the levels found in
normal growth mediums, this is sufficient to bind to oestrogen receptors (Berthois et
al., 1986). Whether phenol red in normal growth medium has any effects on GR is
not known.
In a recent study looking at the regulation of 11B-OHSD in intact human foreskin
fibroblasts in culture (Hammami & Siiteri, 1991), both dehydrogenase and reductase
activities of 11B-OHSD were demonstrated, the dehydrogenase component being 5-
10 times lower than its reductase counterpart. However when [3H] Cortisol was used
as substrate, in the presence of excess cortisone, higher dehydrogenase activity was
observed suggesting that in the absence of cortisone, dehydrogenase activity was
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underestimated due to the rapid back-conversion of cortisone to Cortisol. It is
possible that the reductase activity measured in COS-7 and CV-1 cells could also be
reversible and the measured activity was the result of a dynamic equilibrium between
dehydrogenase and reductase activities but this was not investigated further since the
aim of this study was to determine the direction of 11B-OHSD activity in intact
mammalian cells.
It is probable that the overall direction of the reversible hepatic 11B-OHSD
enzyme reaction is reduction (ie activation of inert glucocorticoids) (Bush et al.,
1969). In addition, results presented in this chapter provide further evidence to
suggest that the 'liver-type' 11B-OHSD acts predominantly in the reductase direction
in at least some intact mammalian cells. However in intact liver, the direction in
specific subregions is not known, and there are several functions of 11B-OHSD which
could not be rationally explained if the 'liver-type' 11B-OHSD was purely reductase.
For example, in rats 11B-OHSD antigen is expressed in leydig cells from puberty to
adult when testosterone secretion is apparent (Philips et al., 1989). This 11B-OHSD
species was shown to be identical to the 'liver-type' isoform by Western blotting
(Philips et al., 1989). However, corticosteroids directly suppress testosterone
production in rats, leading to the suggestion that 11B-OHSD inactivates
glucocorticoids and allows testosterone synthesis to take place. Therefore if 11B-
OHSD activated inert glucocorticoids, testosterone production in rats would be
attenuated and sexual development would be inhibited. Similarly in Chapter 3, it was
shown that expression of hippocampal 11B-OHSD activity and mRNA are increased
by glucocorticoids. Hippocampal neurones are very sensitive to chronic excess or
depletion of glucocorticoids, and we have suggested that 11B-OHSD regulates
glucocorticoid access to receptors in the hippocampus. However, if hippocampal
11B-OHSD which is also the same isoform as the 'liver-type' enzyme, was purely a
reductase in intact cells, then hippocampal neurones could be exposed to excess
glucocorticoids possibly leading to brain dysfunction and neuronal cell death.
Glucocorticoids are also required for lactation. 11B-OHSD in the mammary gland
decreases as pregnancy progresses and therefore has been proposed to inactivate
glucocorticoids and prevent premature milk production in females (Quirk et al.,
1990a; 1990b). As a reductase, 11B-OHSD could not fulfil this proposed role. It is
therefore likely that the overall direction of 11B-OHSD activity is determined at a
tissue-specific level, with reductase activity predominating in some cell types (eg
COS-7, liver) and dehydrogenase activity predominating in others (eg leydig cells,
hippocampus and the mammary gland). In addition it is possible that dehydrogenase
and reductase activities may both be expressed in some cell types as demonstrated in
CHO cells (Agarwal et al., 1989).
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At the cellular level several mechanisms which could regulate the overall
direction of 11B-OHSD activity. The most likely is the glycosylation state of 116-
OHSD; the 'liver-type' 11B-OHSD has two putative N-linked glycosylation sites, and
inhibition of glycosylation selectively inhibits dehydrogenase activity leaving
reductase unaffected (Agarwal et al., 1989). This mechanism could act in a cell-
specific or even compartment-specific level to give reductase activity in some cells or
both in others. However it unlikely to be the direction determining mechanism in
intact COS-7 cells. Although 11B-OHSD activity is predominantly reductase in intact
COS-7 cells, homogenates of the same cells readily express llB-dehydrogenase
activity indicating that the cells are capable of glycosylating 11B-OHSD, and yet
intact cells predominantly activate glucocorticoids. Secondly, the concentration of
NADP and NADPH may determine the relative proportion of dehydrogenase and
reductase activity, with NADP favouring dehydrogenase activity and NADPH
favouring the reductase direction (Agarwal et al., 1989). In single cells metabolism
may favour a high NADP/NADPH ratio while other cells favour a low
NADP/NADPH ratio perhaps leading to rapid local changes in the direction of 11B-
OHSD activity. However so many cellular reactions occur in which enzymes require
NADP and NADPH as co-factors, that it is unlikely the pyridine nucleotide
concentrations will change by sufficient amounts to be the sole regulator of a single
enzyme for any length of time. Thirdly, in theory pH (Deckx & De Moore, 1966)
may also have a role in determining the direction of 11B-OHSD activity. However
although pH may change sufficiently within a particular cellular compartment, pH is
unlikely to change within cells by sufficient amounts to affect the 11-hydroxy/11-oxo
ratio to any significant degree (Lakshmi & Monder, 1985; Monder & Shackleton,
1984). It is also possible that the glucocorticoid levels in tissues at particular times
could regulate the direction of 11B-OHSD activity such that when active
glucocorticoid levels are low, the enzyme is predominantly reductase, and vice versa.
In support of this hypothesis, it has recently been shown that dexamethasone
treatment of a rat hepatoma cell line containing MMTV-glycoproteins led to
increased expression of the MMTV-glycoprotein gene due to increased stability of
the gene by a post-translational modification mechanism (Goodman & Firestone,
1993). Whether glucocorticoids also increase the stability of 11B-OHSD and in
particular dehydrogenase verus reductase components of 11B-OHSD, remains to be
determined.
An interesting question arising from this study is the possible physiological
relevance of llB-reductase activity particularly in kidney derived cell lines such as
COS-7. In kidney, 11B-OHSD 2 is believed to rapidly inactivate all glucocorticoids
passing through the distal nephron. However, 'liver-type' 11B-OHSD mRNA (Yau et
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al., 1991) and immunoreactivity (Edwards et al., 1988) is also found in kidney
tubules. In addition it is known that the renal tubule contains glucocorticoid receptors
(Farman et al., 1991; Katz, 1990) which mediate glucocorticoid-specific effects in the
kidney including effects on renal haemodynamics, acid and water excretion,
gluconeogenesis, and sodium-potassium ATPase (Katz, 1990; Kinsella, 1990).
Therefore, complete inactivation of glucocorticoids may be detrimental to normal
kidney function, and may explain the relevance of llB-reductase activity even in
kidney-derived cell lines.
In conclusion, the rat 'liver-type' 11B-OHSD cDNA transiently transfected into
COS-7 mammalian cells acts predominantly as a reductase as shown by conversion of
[3H] 11-dehydrocorticosterone to [3H] corticosterone in intact cells and activation of
a glucocorticoid-responsive gene by the inactive 11-dehydrocorticosterone only in the
presence of 11B-OHSD. In addition it has been shown that 'liver-type' 11B-OHSD




11B-OHSD was first shown to be a potential mechanism for regulating
glucocorticoid access to renal mineralocorticoid receptors in 1988, when it was
shown that inhibition of 11B-OHSD abolished selective aldosterone binding to renal
mineralocorticoid receptors (Edwards et al., 1988; Funder et al., 1988). Since that
time our understanding of the physiology of 116-OHSD has developed rapidly to
provide solutions to many questions, and of course to reveal many more problems
and possible research proposals for the future.
It is now known that 11B-OHSD is found in numerous tissues in close proximity
to both mineralocorticoid and glucocorticoid receptors strongly suggesting that 116-
OHSD may influence corticosteroid-dependent processes in all tissues in which it is
found. Thus in mineralocorticoid responsive tissues such as kidney, 116-OHSD is
proposed to inactivate glucocorticoids therefore allowing selective access of
aldosterone to the otherwise non-selective mineralocorticoid receptors. In contrast, in
glucocorticoid receptor rich tissues, or tissues expressing both types of corticosteroid
receptor, 116-OHSD is thought to play a more regulatory role to optimise
glucocorticoid levels by activating or inactivating circulating glucocorticoid levels
appropriately.
The obvious question which arises from these mechanisms of action is how 116-
OHSD could be regulated to play such tissue-diverse roles. Part of the answer to this
question has been revealed from several studies recently indicating the existence of a
second isoform of 116-OHSD which is NAD-dependent and found in kidney (Rusvai
et al., 1993) and a similar or the same NAD-dependent isoform found in human
placenta (Brown et al., 1993). Characterisation and partial purification of human
placental 116-OHSD has revealed that it encodes purely dehydrogenase activity in the
absence of reductase, and has nM affinity for Cortisol and corticosterone. Thus this
isoform of 116-OHSD is highly suited to the protective role required in both placenta
and kidney. Definitive characterisation of human placental and/or renal 116-OHSD
will however only be possible with purification of the protein(s) and cDNA(s) and
gene(s) which encode them.
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In contrast to mineralocorticoid responsive tissues, tissues expressing both
corticosteroid receptors, or predominantly glucocorticoid receptors, generally express
'liver-type' 11B-OHSD activity, mRNA expression and immunoreactivity which in
contrast to the NAD-dependent isoform is thought to be a reversible enzyme. Indeed
previous studies have shown that 'liver-type' 11B-OHSD cDNA encodes both
reductase, and dehydrogenase activities (Agarwal et al., 1989; 1990). The same
studies also suggested that glycosylation status and co-factor concentrations regulated
the predominant direction of 11B-OHSD activity such that glycosylation and high
NADP concentrations favour dehydrogenase activity, while the non-glycosylated,
high NADPH state favours reductase activity (Agarwal et al., 1990). However
transfection studies presented here would tend to disagree with the importance of the
glycosylation state as a direction con tolling mechanism in intact cells, since 11B-
OHSD activity in homogenates can be driven in the dehydrogenase direction
although reductase activity predominates in the intact cells. Nevertheless it would be
interesting to look the influence of glycosylation status on the activity of 11B-OHSD
by site-directed mutagenesis of one or other or both putative N-linked glycosylation
sites on the 'liver-type' 11B-OHSD cDNA followed by transfection into cells and
measurement of 11B-OHSD activity in both the dehydrogenase and reductase
directions. It should also be possible to determine the influence of co-factor status on
the reversibility of 11B-OHSD by manipulating NADP/NADPH levels or measuring
the relative dehydrogenase and reductase activities of 11B-OHSD in primary cultures
of cells such as hepatocytes which are known to have high co-factor reserves, and
hippocampal neurones which have much lower co-factor levels. An added
complication in these experiments which was also noted in the transfection studies
here, would be the effect of different cell types on the reversibility of 11B-OHSD.
Thus although COS-7 cells expressed no llB-dehydrogenase activity even when
transfected with 10jj.g 11B-OHSD which produced high levels of llB-reductase
activity, CV-1 cells (from which COS-7 cells are derived) did convert a little
corticosterone to 11-dehydrocorticosterone and this effect was optimal in cells
transfected with 3pg 11B-OHSD plasmid. Thus the predominant direction of 11B-
OHSD may also be regulated in a cell-specific manner, and it would be enlightening
to look at various other cell lines transfected with 11B-OHSD plasmids to determine
if this was indeed the case. Finally, glucocorticoid levels themselves could possibly
regulate the direction of 11B-OHSD activity. In Chapter 3,1 demonstrated that 11B-
OHSD activity and 'liver-type' mRNA expression were up-regulated in liver and
hippocampus by both dexamethasone and chronic stress. However how these
manipulations affect the reductase component of 11B-OHSD, or the direction of 11B-
OHSD activity in vivo is not known. Transfection experiments were carried out at
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only one glucocorticoid concentration, and it may therefore be interesting to look at
the influence of different levels of glucocorticoids on the direction of 11B-OHSD
activity in intact cells.
Studies on the regulation of 11B-OHSD in this thesis have led to several
interesting findings. Firstly 11B-OHSD is regulated in a tissue-specific manner.
Thus although liver and hippocampus are regulated by glucocorticoids, 11B-OHSD in
kidney was unaffected by adrenal steroid manipulations. In contrast, hippocampal
11B-OHSD was unaffected by gonadal steroids or growth hormone, whereas 11B-
OHSD in liver and kidney showed potent regulation by both. It is therefore likely
that tissue-specific factors affect the actions of 11B-OHSD in vivo. One of the most
compelling pieces of evidence for this is the demonstration that 11B-OHSD in liver
and hippocampus predominantly utilise the same transcription start-site, yet 11B-
OHSD in liver is repressed by oestrogen, while hippocampal 11B-OHSD is
unaffected by oestrogen manipulations. In addition, oestrogen has free access to the
brain, oestrogen receptors have been demonstrated in hippocampus, and it has been
shown here that oestrogen may have a direct effect on 11B-OHSD in liver. Tissue-
specific factors in liver and hippocampus which bind to the 'liver-type' 11B-OHSD
could be measured in band shift assays, and the areas of DNA to which these putative
factors bind could be determined by footprinting analyses.
11B-OHSD activity in liver of control animals was high, and similar to levels
observed following chronic dexamethasone treatment, while in hippocampus, 11B-
OHSD activity in sham-operated controls was low, and similar to levels expressed in
adrenalectomised animals. This suggests a fundamental difference in the manner in
which liver and hippocampus are exposed to glucocorticoids under basal conditions.
This may be a function of the reversiblity of 'liver-type' 11B-OHSD which is thought
to be a reductase in liver (Bush et al., 1968), and is proposed to be dehydrogenase in
hippocampus (Moisan et al., 1990a). However the predominant direction of 11B-
OHSD in vivo is not known, and measuring this is technically difficult. However
initial liver perfusion studies have indicated that 11B-OHSD activity in liver is indeed
predominantly reductase (Pendek et al., unpublished observations). Manipulation of
brain slices through the hippocampus in a similar way, by application of either [3H]-
corticosterone or [3H] 11-dehydrocorticosterone to one side of the brain slice and
collection of the tritiated products on the other tissue face may produce slightly more
physiological data about the direction of 11B-OHSD activity in hippocampus in vivo.
It has been demonstrated here, and previously, that hepatic 11B-OHSD is
expressed in a sexually dimorphic manner with higher levels of activity present in
male than female rats. What is the physiological significance of lower 11B-OHSD in
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female liver? Since 11B-0HSD in liver is thought to be predominantly reductase,
lower 11B-OHSD activity in females may explain the higher incidence of
glucocorticoid-responsive inflammatory disorders of the liver in females. In addition,
sexual dimorphism of other steroid metabolising and drug metabolising enzymes may
explain the differences in drug and alcohol metabolism between males and females,
but why this sexual dimorphism exists is not known. However, a possible way of
determining the importance of 11B-OHSD in normal liver function was revealed from
sex steroid manipulation studies. Although the silastic capsules containing oestradiol
had been reported to produce oestrogen levels not significantly different from those in
control female rats, oestradiol replacement significantly repressed 11B-OHSD in liver
below levels found in control female rats indicating that this dose of oestradiol is in
fact pharmacological and not physiological. Thus lOd oestradiol treatment almost
completely abolished 'liver-type' 11B-OHSD mRNA expression, and significantly
repressed 11B-OHSD activity. It is assumed that longer treatment periods would
eventually abolish both 11B-OHSD activity and mRNA expression. At this point it
would be very interesting to look at how liver function is affected by the absence of
11B-OHSD by looking at the expression of glucocorticoid-responsive genes such as
angiotensinogen, tyrosine amino transferase (TAT) and phosphoenol pyruvate
carboxykinase (PEPCK).
The sexual dimorphism of hepatic 11B-OHSD activity and mRNA expression was
revealed to be due at least in part by the female-specific pattern of GH secretion. As
expected, GH did not affect 11B-OHSD in hippocampus probably partly due to
problems of access from the periphery to the brain. However in light of the
differential regulation of hippocampus and liver by oestrogen, it may be worthwhile
to look at possible regulation of 11B-OHSD by GH to further characterise tissue-
specific regulation of 11B-OHSD. This could be achieved by intracerebroventricular
cannulation followed by the same dose of GH administered in either continuous or
pulsatile patterns, followed by measurement of 11B-OHSD activity and mRNA
expression.
In vivo manipulation of steroids and hormones do not always provide definitive
information on the mechanism of action. Thus although female-pattern GH represses
hepatic 11B-OHSD, whether this is due to a direct action of GH or requires the
presence of other factors such as insulin-like growth factors is not known. However
this information could be obtained by looking at primary hepatocytes in culture
treated with GH alone or in combination with other factors followed by measurement
of changes in 11B-OHSD mRNA levels.
Finally as a direct result of regulation studies in this thesis, it would be
informative to know how the isoform of 11B-OHSD found in kidney which is
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potently induced by oestrogen, but appears to be unaffected by GH, is regulated, both
in kidney and in other tissues which contain the same isoform. However apart form
looking at levels of NAD-dependent activity following the same hormonal
manipulations, this is not possible at the moment and will require complete
purification and cloning of the corresponding cDNA before definitive studies can be
performed.
In summary, these studies have demonstrated tissue-specific regulation of 11B-OHSD
in rat liver, kidney and hippocampus. It has been shown that liver and hippocamus
are probably exposed to different glucocorticoid levels under basal conditions, and
this may be a function of the predominant direction of 11B-OHSD activity in the two
tissues. In addition, hepatic 11B-OHSD demonstrates sexually dimorphic expression
due at least in part to the sexually differentiated patterns of GH secretion in male and
female rats. Sex steroid and growth hormone manipulation studies also provided
further evidence suporting the presence of a second isoform of 11B-OHSD found in
kidney. Finally, it was shown that 'liver-type' 11B-OHSD cDNA encodes reductase
but not dehydrogenase activity in at least some intact mammalian cells, and as such
may regulate the access of active glucocorticoids to glucocorticoid receptors in some
cell types and tissues.
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ABSTRACT
The enzyme 11 (3-hydroxysteroid dehydrogenase (11P-
HSD) catalyses the conversion of physiological gluco¬
corticoids to inactive products, thus modifying the
access of glucocorticoids to glucocorticoid and miner-
alocorticoid receptors. Glucocorticoids may affect
ovarian function both indirectly and via binding to
ovarian receptors. We have demonstrated 11P-HSD
bioactivity and mRNA expression in rat ovary in
vitro. The enzyme was localized to oocytes and luteal
bodies immunohistochemically using two antibodies
raised against purified rat liver 11 P-HSD. These data
are supported by in-situ hybridization studies, which
also localized 11 P-HSD mRNA expression to oocytes
and luteal bodies. The results suggest that 11 P-HSD
may modulate the effects of glucocorticoid on ovarian
function.
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INTRODUCTION
Glucocorticoid hormones are important regulators of
cell function in many tissues. Recent evidence suggests
that glucocorticoids affect ovarian physiology. Thus
systemic administration of exogenous glucocorticoids
has been shown to reduce ovarian weight (Inazu,
Iwata & Satoh, 1990) and to inhibit ovulation
(Baldwin & Sawyer, 1974). Although the inhibition
of ovulation is thought to reflect glucocorticoid
actions at the anterior pituitary, where they inhibit
the preovulatory luteinizing hormone (LH) surge
(Baldwin & Sawyer, 1974), the presence of glucocort¬
icoid receptors (Schreiber, Nakamura & Erickson,
1982) and glucocorticoid-responsive gene products
(Malbon & Hadcock, 1988; Albiston, Lock, Burger
& Krozowski, 1990) in the ovary suggests that direct
effects also occur. In support of this, glucocorticoids
have been shown to inhibit follicle-stimulating hor¬
mone (FSH)-stimulated aromatase activity (Hsueh &
Erickson, 1978) and to augment progesterone accu¬
mulation (Adashi, Jones & Hsueh, 1981) in granulosa
cells in vitro. Similarly, glucocorticoids stimulate the
production of plasminogen activator by isolated
Journal of Endocrinology (1992) 135, 53-58 © 1992 Journal of E
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granulosa cells (Wang & Leung, 1989; Jia & Hsueh,
1990), an action thought to be important in the
control of ovulation (Reich, Miskin & Tsafriri, 1985).
Both protein purification and more recent molecu¬
lar cloning studies have demonstrated the existence
of two types of glucocorticoid receptor, type-I (high-
affinity or mineralocorticoid receptor) and type-II
(low-affinity or glucocorticoid receptor). Although
the type-I and -II receptors show well-described hier¬
archies of affinity for the various physiological and
synthetic glucocorticoids in vitro, ligand access to
receptors in many tissues in vivo is regulated by 11P-
hydroxysteroid dehydrogenase (11 P-HSD). This mic¬
rosomal enzyme catalyses the reversible conversion of
physiological glucocorticoids (Cortisol in man,
corticosterone in the rat) to inactive products (corti¬
sone or 11-dehydrocorticosterone). The 11-dehydro
products have very low affinities for either type-I or
type-II receptors. The activity of 11 P-HSD appears to
be responsible for the in-vivo aldosterone selectivity
of the otherwise non-selective renal type-I receptor
(Edwards, Stewart, Burt et al. 1988; Funder, Pearce,
Smith & Smith, 1988) and modulates glucocorticoid
access to type-II receptors in the skin (Teelucksingh,
crinology Ltd Printed in Great Britain
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Mackie, Burt et al. 1990) and cerebellum (Moisan,
Seckl, Brett et al. 1990a). Within reproductive tissues,
11 P-HSD is present in the placenta where it is thought
to protect the fetus from the deleterious effects of
exposure to maternal glucocorticoids (Beitins,
Bayard, Ances et al. 1973; Lopez Bernal, Anderson
& Turnbull, 1982) and the enzyme has been demon¬
strated in the testis where it may regulate Leydig cell-
glucocorticoid interactions which are critical in the
control of testosterone production and the onset of
puberty (Phillips, Lakshmi & Monder, 1989).
By analogy with the testis, the ovary might be
expected to contain 11 P-HSD which could regulate
glucocorticoid access to receptors and thus modulate
corticosteroid effects in vivo. Although previous stud¬
ies have not found 11 P-HSD bioactivity in the rat
ovary (Ghraf, Vetter, Zandveld & Schriefers, 1975),
human ovaries have been shown to be able to convert
Cortisol to cortisone (Murphy, 1981a), and to contain
mRNA encoding 11 P-HSD (Tannin, Agarwal,
Monder et al. 1991). Therefore, we have re-examined
whether 11 P-HSD bioactivity and mRNA expression
are present in the ovary of the rat, and have deter¬




Ovaries, obtained from adult female Wistar rats
(240 g; « = 3-4) in pro-oestrus, were homogenized in
Krebs-Ringer bicarbonate buffer (118 mmol NaCl/1,
3-8 mmol KC1/1, 1 ■ 19 mmol KH^P04/1, 2-54 mmol
CaCl2-2H20/l, 119 mmol MgS04-7H20/l, 25 mmol
NaHC03/l) using a Dounce tissue grinder. The total
protein content was estimated colorimetrically (Bio-
Rad protein assay kit, Hemel Hempstead, Herts,
U.K.), using a sample of the homogenate. The
incubation was carried out in duplicate with
0-0625 g, 0- 25 g and 0- 5 g protein/1 and a final concen¬
tration of 200 pmol NAD/1 and 12 nmol [1,2,6,7-
3H]corticosterone/l (specific activity: 84Ci/mmol;
Amersham International pic, Little Chalfont, Bucks,
U.K.) in Krebs-Ringer buffer (+0-2% bovine serum
albumin and glucose) for 10, 20 and 60 min at 37 °C.
The total volume was 250 pi. Rat kidney, known to
have very high 11 P-HSD bioactivity, was used as a
positive control (at 0-25 g protein/1 for 10 min), whilst
incubation of buffer alone provided an assay blank.
After incubation, steroids were extracted with ethyl
acetate and separated by high-pressure liquid chro¬
matography (HPLC). The percentage conversion of
[3H]corticosterone to [3H] 11-dehydrocorticosterone
was calculated from the radioactivity of each fraction.
Results are expressed as means ± s.e.m.
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Reductase component
For preparation of [3H] 11-dehydrocorticosterone,
[3H]corticosterone (Amersham) was incubated with
rat kidney homogenate for 2 h at 37 °C in the presence
of 200 pmol NAD/1. After incubation, the steroids
weie extracted with ethyl acetate and separated by
thin-layer chromatography. Extraction yield was 42%
and purity >93% as assessed by HPLC. Ovarian
homogenate was prepared as above (n = 3), and 0-25 g
protein/1 incubated with 12 nmol [3H] 11-dehydro-
corticosterone/1 for 10 min at 37 °C in the presence of
200 pmol NADH/1 in Krebs- Ringer buffer as above.
Steroids were separated and assayed by HPLC as for
dehydrogenase activity.
Northern analysis
Ovary, hippocampus, kidney and liver were rapidly
removed from female Wistar rats (240 g) after cervical
dislocation, snap-frozen and stored at —85 °C. Total
RNA was extracted from each tissue by the acid guan-
idinium thiocyanate method, as previously described
(Chomczynski & Sacchi, 1987). Approximately 20 pg
ovary 15 pg hippocampus and 10 pg kidney and liver
total RNA were fractionated on a 1-2% agarose-
0-7 mol formaldehyde gel/1 and blotted on to nitrocel¬
lulose (Hybond C extra; Amersham International
pic) by capillary transfer overnight. Hybridization
was performed at 42 °C overnight in 50% formamide
with a randomly primed 32P-labelled 11 p-HSD cDNA
probe cloned from a rat liver cDNA library (Agarwal,
Monder, Eckstein & White, 1989), consisting of the
excised pi 1DH insert. The membrane was washed to
a final stringency of 0-2xSSC (lxSSC equals
0-5 mol NaCl and 0 015 mol sodium citrate per litre),
01% sodium dodecyl sulphate at 60 °C and exposed
to Kodak XAR film for 2 days as previously described
(Moisan, Seckl & Edwards, 19906).
Immunohistochemistry
Adult Wistar rats (240 g) were deeply anaesthetized
with pentobarbitone and perfused through the
ascending aorta with 250 ml ice-cold saline followed
by 500 ml ice-cold paraformaldehyde (4 mol/1) in
phosphate buffer (0-1 mol/1, pH 7-4). Ovaries were
removed and post-fixed overnight. As previously
described (Moisan et al. 1990a) sections (4 pm) were
cut and immunostained using two separate polyclonal
rabbit antisera (5 125 at 1:50 dilution and 5-126 at
1:100 dilution) raised against purified rat liver 11 [3-
HSD as described elsewhere (Monder & Lakshmi,
1990). Detection was by the peroxidase-antiperoxid-
ase method (Sternberger, Hardy, Cuculis & Meyer,
1970) using reagents from Dako Ltd, High Wycombe,
Bucks, U.K. Control sections were immunostained
using preimmune rabbit serum.
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In-situ hybridization
Adult Wistar rats (240 g) were killed by cervical dis¬
location, the ovaries rapidly removed and immedi¬
ately frozen on dry ice. Cryostat sections (10 pm) were
mounted on to gelatin- and poly-L-lysine-coated
microscope slides and stored at -85 °C. Tissue sec¬
tions were post-fixed in 4% paraformaldehyde/phos-
phate (0-1 mol/1) buffer and washed in three changes
of 2 x SSC containing 0 02% diethylpyrocarbonate.
T3 RAN polymerase (Promega Ltd, Southampton,
Hants, U.K.) was used to transcribe a 598 bp anti-
sense cRNA probe containing 35S-labelled UTP from
Sty I-linearized pBluescript vector containing the
1265 bp 11 (3-HSD cDNA insert (Agarwal et a/. 1989).
The probe was denatured and added at a final concen¬
tration of 10 x 106c.p.m./ml to hybridization buffer
(50% formamide, 0-6 mol NaCl/1, 10 mmol Tris/1,
pH 7-5, 0-02% Ficoll, 0-02% polyvinylpyrrolidone,
0-1% bovine serum albumin, 1 mmol EDTA/1, 0-1 g
salmon sperm DNA/1, 0-1 g yeast tRNA/1, 100 g dex-
tran sulphate/1 and 10 mmol dithiothreitol/1) as pre¬
viously described (Yau, Van Haarst, Moisan et al.
1991). In brief, 65 pi aliquots of probe were pipetted
on to sections and covered with a coverslip
(22 x 50 mm) which was sealed with DPX mounting
medium. Slides were incubated overnight at 50 °C.
After hybridization, coverslips were removed by rin¬
sing three to four times in 2 x SSC at room tempera¬
ture, sections treated with RNAase A (30 g/1, 45 min
at 37 °C) (Boehringer Mannheim, Lewes, East Sussex,
U.K.) and washed in reducing salt concentrations to
a final stringency of 0-1 x SSC/14 mmol 2-mercapto-
ethanol/1 at 60 °C. After dehydration in increasing
concentrations of ethanol in 0-3 mol sodium acetate/
1, slides were dried in air, dipped in photographic
emulsion (Ilford Mobberley, Knutsford, Cheshire,
U.K.) and exposed in light-tight boxes at 4 °C for 21
days before being developed (D19, Ilford) and coun-
terstained with haematoxylin-eosin. Controls were
hybridized with non-complementary 'sense' probes of
the same specific activity under identical conditions.
RESULTS
11P-HSD activity
11 P-HSD activity in the dehydrogenase direction was
found in all ovarian homogenates and increased lin¬
early with protein concentration up to 0-5 g/1 (data
not shown). The time curves for the three different
protein concentrations (Text-fig. 1) indicate linearity
with respect to time for up to 10 min. At a protein
concentration of 0-25 g/1 incubated for 10 min, ovar¬
ian activity was 10% of kidney activity (ovary,
n = 3: 179-6±30-5 fmol product formed; kidney,
n = 2: 1742-4±44-1 fmol product formed). No
conversion of [3H]ll-dehydrocorticosterone to
[3H]corticosterone was found.
Northern blots
A single band hybridizing to the 11 P-HSD probe was
detected in ovarian total RNA which corresponded
to the major 11 P-HSD mRNA species demonstrated
in rat liver and hippocampus. There was no evidence
of expression ofmultiple 11 P-HSD mRNA species as
found in rat kidney (Text-fig. 2).
Immunohistochemistry
Using either antiserum to purified rat liver 11 P-HSD,
a consistently strong positive immunostaining was
found in the oocyte (PI. 1). Additionally, positive
immunostaining of moderate or low intensity was
detected in cells comprising the luteal bodies (not
shown). This varied between the luteal masses rather
than within a given luteal body, presumably reflecting
their varying stages of maturation. No staining was
observed in the granulosa cells, theca cells, stroma or
other ovarian components (PI. 1). No staining of any
ovarian subregion was demonstrated with preimmune
serum.
In-situ hybridization
11 P-HSD mRNA expression was localized to oocytes
and was also found to a variable extent over the luteal
bodies, varying between luteal masses rather than
within individual bodies and parallelling the immu-
nohistochemical findings (PI. 2).
DISCUSSION
Previous studies on ovarian 11 P-HSD are few. Ghraf
et al. (1975) reported no 11 P-HSD bioactivity in the
rat ovary but, in contrast, Murphy (1981a) found
considerable bioactivity in human ovaries; both stud¬
ies used similar methods.
We now report high 11 p-HSD bioactivity in homo¬
genized whole ovaries, in agreement with the findings
of Murphy (1981a). The reason for the discrepancy
between our data and those of Ghraf et al. (1975) is
unclear but may relate to the very high pH (9-5) used
in the latter study. The presence of 11 P-HSD bioactiv¬
ity is supported by the clear expression of mRNA
encoding the 'liver-type' isoform of the enzyme. Using
both immunohistochemistry and in-situ hybridization
we have localized 11 P-HSD mRNA antigen to
oocytes and, to a lesser extent, to luteal bodies. The
Journal of Endocrinology (1992) 135, 53 58
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text-figure 1. 11 |3-Hydroxysteroid dehydrogenase bioactivity (measured as fmol [3H]ll-dehy-
drocorticosterone formed from [3H]corticosterone) in whole ovarian homogenates at protein
concentrations of 0-0625 g/1 (O; n = 3), 0-25 g/1 (□; n = 4) and 0-5 g/1 ( A ; n = 3). Values are
means ±s.e.m.
18S
text-figure 2. Autoradiograph of a Northern blot of
total mRNA hybridized with 32P-labelled cDNA probes
to 11 P-hydroxysteroid dehydrogenase mRNA. 0 = ovary,
H = hippocampus, K = kidney, L = liver. Note the presence
of a single band in ovary corresponding to the one found
in hippocampus and liver. Kidney shows multiple hybrid¬
izing mRNA species.
concordance of immunoreactivity and mRNA expres¬
sion is in contrast to distal renal tubule (Edwards
el al. 1988; Rundle, Funder, Lakshmi & Monder,
1989; Yau et al. 1991), where mRNA expression
and bioactivity (Naray-Fejes-Toth, Watlington &
Fejes-Toth, 1991) are found, but immunoreactivity
(liver-type) is not detected. On the other hand, in
hippocampus, cerebellum and vasculature, 11P-HSD
mRNA expression colocalizes with immunoreactivity
(Moisan et al. 1990a,b; Walker, Yau, Brett et al.
1991). It is thus likely that ovarian luteal bodies and
oocytes express the liver-type mRNA and protein
which may modulate glucocorticoid access to recep¬
tors rather than the distal convoluted tubule isoform
which is completely protective of the colocalized
mineralocorticoid receptor.
The interesting finding of high bioactivity localized
to the oocyte itself, as indicated by in-situ hybridiza¬
tion and immunohistochemistry, implies modification
of the oocyte glucocorticoid exposure and makes the
presence of steroid receptors within the oocyte likely,
as is the case in other 11 P-HSD locations. Although
glucocorticoids are believed to inhibit ovulation by
inhibiting the preovulatory LH surge, our findings
point to a possible local role of glucocorticoids in
ovulation and/or oocyte differentiation. Interestingly,
the specificity of 11(3-HSD for 11 P-hydroxyproges-
terone and 11 P-hydroxypregnenolone as well as their
a-counterparts is much higher than for Cortisol or
corticosterone (Murphy, 1981fi), raising the intrigu¬
ing possibility that the substrate for ovarian 11 p-HSD
is not necessarily a glucocorticoid.
We were unable to find any indication of the
presence of 11 P-HSD in the granulosa cells, which
Journal of Endocrinology (1992) 135, 53-58
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previously have been shown to contain glucocorticoid
receptors (Schreiber et al. 1982) and to be metabolic-
ally regulated by glucocorticoids (Hsueh & Erickson,
1978; Adashi et al. 1981; Wang & Leung, 1989). This
absence of 11P-HSD expression in the granulosa cells
could be the result of aromatase activity generating
oestrogen, which has been shown to inhibit potently
activity of the liver-type 11 P-HSD (Monder & Shack-
leton, 1984), as present in the ovary. Similarly, we did
not demonstrate the presence of 11 P-HSD in theca
cells, although dexamethasone has been shown to
alter their metabolism (reducing carbonyl reductase
content) (Inazu et al. 1990). Our finding of 11 P-HSD
immunoreactivity and mRNA expression in the luteal
cells but not the theca cells may be another example
of cellular ontogeny, as we have shown in the skin
(Teelucksingh et al. 1990), where 11 P-HSD is not
detected in the basal cell layer but is located in cells
of the upper epidermis.
In summary, we have found 11 P-HSD gene expres¬
sion and bioactivity in the rat ovary, localized mainly
in the oocyte and luteal masses. This suggests that
glucocorticoids may exert a local modulatory role on
ovarian function, which can be altered by cell-specific
metabolism of steroids. The importance of 11 P-HSD
in ovarian function remains to be determined.
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DESCRIPTION OF PLATES
Plate 1
figure 1. Immunostaining of rat ovary using antiserum
to purified rat liver 11 P-hydroxysteroid dehydrogenase,
displaying marked staining of the oocyte (x400).
figure 2. Control using preimmune serum, showing no
immunostaining (x400).
Plate 2
figure 3. In-situ hybridization showing a concentration
of silver grains over the oocyte indicating hybridization
of the cRNA probe containing 35S-labelled UTP to 1 ip-
hydroxysteroid dehydrogenase mRNA (x600).
figure 4. In-situ hybridization using 'sense' probe, show¬
ing no silver grain concentration (x600).
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ABSTRACT
Steroid-metabolizing enzymes modulate the effects of
androgens on brain differentiation and function, but
no similar enzymatic system has been demonstrated
for adrenocorticosteroids which exert feedback con¬
trol on the hypothalamus. 11 P-Hydroxysteroid de¬
hydrogenase (lip-OHSD) rapidly metabolizes
physiological glucocorticoids (corticosterone, Corti¬
sol) to inactive products, thereby regulating gluco¬
corticoid access to peripheral mineralocorticoid and
glucocorticoid receptors in a site-specific manner.
Using in-situ hybridization, we found expression of
1 lp-OHSD mRNA in neurones of the hypothalamic
paraventricular nucleus (PVN) where corticotrophin-
releasing factor-41 (CRF-41) is synthesized and from
where it is released into hypophysial portal blood.
Administration of glycyrrhetinic acid (GE), a potent
lip-OHSD inhibitor, decreased CRF-41 release into
hypophysial portal blood in the presence of
unchanged circulating glucocorticoid levels, sug¬
gesting that 11P-OHSD regulates the effective corti¬
costerone feedback signal to CRF-41 neurones. These
effects of GE were not observed in adrenalectomized
animals, demonstrating dependence on adrenal
products. In contrast, GE led to two- to threefold
increases in arginine vasopressin and oxytocin release
into portal blood, effects also dependent upon intact
adrenal glands. These results suggest that 11 P-OHSD
in the PVN, and possibly other sites, may represent a
novel and important control point of corticosteroid
feedback on CRF-41 release in vivo.
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INTRODUCTION
The neural control of pituitary corticotrophin
(ACTH) secretion is mediated by corticotrophin-
releasing factor-41 (CRF-41) and arginine vasopres¬
sin (AVP), and under certain circumstances oxytocin,
synthesized in the hypothalamic paraventricular
nucleus (PVN) (Antoni, 1986; Rivier & Plotsky,
1986; Fink et al. 1988; Tannahill et al. 1991). Cortico¬
steroids, released in response to ACTH, complete the
regulatory loop by a negative feedback action at the
brain pituitary level. However, the mechanism of
corticosteroid negative feedback remains imperfectly
understood with differences in the effects of physio¬
logical and synthetic glucocorticoids and the condi¬
tions (acute or chronic) of the experiment (Plotsky
& Vale, 1984; Plotsky el al. 1986; Rivier & Plotsky,
1986; Plotsky & Sawchenko, 1987; Fink et al. 1988;
Dallman et ai 1989; Sheward & Fink, 1991;
Tannahill et al. 1991). Corticosteroid actions are med¬
iated by intracellular glucocorticoid receptors (GR,
type II) and mineralocorticoid receptors (MR, type
I) (McEwen et al. 1986u). GR are highly expressed in
anterior pituitary corticotrophs and in the PVN,
where they co-localize with CRF-41-immunoreactive
cells (Fuxe et al. 1985). MR-like binding sites are also
found in pituitary and hypothalamus and MR mRNA
expression has been detected in the PVN (McEwen et
al. 1986ft; Swanson & Simmons, 1989).
GR and MR show a high degree of structural
homology. Indeed, in vitro, MR bind the mineralocor¬
ticoid aldosterone and the physiological glucocorti¬
coids Cortisol and corticosterone with equal affinity
(Arriza et al. 1988). In vivo, aldosterone selectivity of
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MR in the kidney in the face of a 1000-fold excess of
circulating glucocorticoid is secured by 11 (3-hydroxy-
steroid dehydrogenase (lip-OHSD) which rapidly
converts corticosterone or Cortisol into inactive 11-
keto products (11-dehydrocorticosterone or cortisone
respectively), thereby preventing these physiological
glucocorticoids from gaining access to peripheral GR
and MR (Edwards et al. 1988; Funder et al. 1988;
Teelucksingh etal. 1990; Yau et al. 1991). lip-OHSD
bioactivity and mRNA expression are also present in
various subregions of the brain, including the hypo¬
thalamus (Moisan et al. 1990b) where some MR are
selective for aldosterone in vivo (McEwen et al.
1986a). The aim of the present study was to determine
(i) whether 1 lp-OHSD is expressed in the PVN and
(ii) if so, whether it plays a role in the negative feed¬
back regulation by corticosterone of hypothalamic
CRF-41 secretion into hypophysial portal plasma.
MATERIALS AND METHODS
In-situ hybridization histochemistry
To determine whether mRNAs encoding 1 lp-OHSD
and MR are expressed in PVN cells, in-situ hybridiz¬
ation was performed using non-isotopic cRNA probes
as previously described (Yau et al. 1991). Briefly,
fresh frozen coronal brain sections (10 pm) were post-
fixed in 4% paraformaldehyde/phosphate buffer
(0-1 mol/1) and washed twice in 2 x standard sodium
citrate (SSC) prior to hybridization. T3 polymerase
(Gibco BRL, Paisley, Strathclyde, U.K.) was used to
transcribe 598 bp antisense cRNA probes from Styl-
linearized pBluescript vector containing lip-OHSD
cDNA (Agarwal et al. 1989). For MR mRNA probes,
a 513 bp EcoRl fragment of rat cDNA in pGEM4
(Arriza et al. 1988) was linearized with Hindlll and
transcribed with SP6 polymerase. Biotin-11-UTP
(1 mmol/1) was added to the in-vitro transcription
reaction. Hybridization and high stringency washes
were performed as described (Yau et al. 1991). Biotin
was detected by exposure to avidin-biotin peroxidase
complex (ABC; Vector Laboratories, Peterborough,
Cambs, U.K.) for 30 min. Sensitivity was increased by
subsequent incubation with biotinylated anti-avidin
(1 :250) for 60 min and repeat exposure to ABC. 3,3'-
Diaminobenzidine was added as chromogen. Cell
nuclei were counterstained with methyl green. Con¬
trols sections were (i) hybridized with identically
labelled 'sense' RNA probes and (ii) incubated in
buffer alone (i.e. without cRNA probes) to determine
the endogenous biotin signal. Positive controls were
provided by determining, in the same section, hybrid¬
ization of the cRNA probes to the overlying dorsal
hippocampus, which expresses both lip-OHSD and
MR mRNAs highly (Moisan et al. 19906; Seckl et al.
1990).
Hypophysial portal blood sampling
Male Wistar rats (200 g body weight) were main¬
tained under conditions of controlled temperature
(22 °C) and lighting (lights on 05.00 19.00 h) and
allowed free access to diet and tap water. Animals
were anaesthetized with sodium pentobarbitone
(36 40 mg/kg body weight, i.p.) and the hypophysial
portal vessels exposed by a transpharyngeal approach
as previously described (Fink et al. 1988; Sheward &
Fink, 1991; Tannahill et al. 1991). Rats were then
injected subcutaneously with glycyrrhetinic acid (GE;
Aldrich Chemical Company, Gillingham, Dorset,
U.K.; 5 mg in ethanol, n = 10) or ethanol vehicle (n =
15) at 0 and 45 min. Glycyrrhetinic acid, the active
component of liquorice, inhibits central lip-OHSD
potently (Moisan et al. 1990a). Portal blood was col¬
lected, from 0 min, for two consecutive 45-min
periods into ice-cold tubes containing aprotinin
(10 pl/100 pi blood).
In order to determine whether the effects of GE
were dependent on the presence of endogenous
corticosteroids which are substrates for lip-OHSD,
a second study was carried out in which rats were
adrenalectomized under halothane anaesthesia and
then injected daily with 0-9% (w/v) NaCl («= 16)
or dexamethasone (Sigma, Poole, Dorset, U.K.;
0-2 mg/kg, s.c., n — 6) for 10 days. Adrenalectomized
animals were given saline (containing 2% dextrose)
instead of tap water to drink. Rats were then anaes¬
thetized with sodium pentobarbitone and injected
with GE as above (eight adrenalectomized rats and
all dexamethasone-treated animals) or ethanol vehicle
(the remaining eight adrenalectomized rats) immedi¬
ately before each hypophysial portal blood sampling
period.
Portal blood samples were centrifuged and plasma
was stored at —40 °C before peptide assay. CRF-41,
AVP and oxytocin were estimated in portal plasma
using specific and sensitive radioimmunoassays (Fink
et al. 1988). Peripheral blood samples were obtained
at the beginning of the experiment for estimation of
plasma ACTH (to ensure successful adrenalectomy)
and at the end of the study for measurement of plasma
corticosterone, osmolality and glucose. ACTH and
corticosterone were estimated by specific radio¬
immunoassays (Fink et al. 1988), plasma osmolality
and glucose were measured using the freezing-point
depression and glucose oxidase/peroxidase methods
respectively. Data were compared by analysis of vari¬
ance or unpaired Student's t-tests, as appropriate.
Significance was set at P<0 05. Values are
means ±s.e.m.
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RESULTS
In-situ hybridization histochemistry showed lip-
OHSD mRNA expression in 70 ±5% of magnocellu-
lar PVN neurones (out of a total of 267 magnocellular
cells counted in five separate sections) and 72 ± 8% of
153 parvicellular PVN neurones (Plate). MR mRNA
was expressed in 68 ±7% of 151 magnocellular and
66±7% of 262 parvicellular PVN neurones (Plate).
There was high expression of MR and 11P-OHSD
mRNAs in the dorsal hippocampus (expression was
found in the vast majority of dentate gyrus granule
cells and pyramidal cells of the cornu ammonis; data
not shown). Sense RNA probes did not hybridize to
cells in the PVN (Plate) or hippocampus (data not
shown) and there was little or no 'endogenous biotin'
signal in control sections (Plate).
Administration of GE significantly reduced the
amount ofCRF-41 released into portal blood by more
than 50% (Text-fig. 1), although peripheral plasma
corticosterone levels remained unchanged (Table 1).
In contrast, GE treatment was associated with a 2-5-
to 3-5-fold increase in portal plasma AVP and oxy¬
tocin levels (Text-fig. 2) which could not be explained
by changes in plasma osmolality or glucose (Table 1).
To determine whether the GE-mediated changes in
portal peptide content were due to 11 P-OHSD inhibi¬
tion and thus dependent on the presence of circulating
substrate (corticosterone), GE was administered to
chronically (10 days) adrenalectomized rats, some of
which were also treated with the synthetic glucocor¬
ticoid dexamethasone which is not metabolized by
11 P-OHSD. Adrenalectomized controls received vehi¬
cle instead of GE. Adrenalectomy alone led to eleva¬
ted CRF and AVP, but not oxytocin content in portal
blood when compared with intact controls (Text-figs
1 and 2). Adrenalectomy prevented the fall in portal
CRF-41 and the rise in AVP and oxytocin caused by
GE (Text-figs 1 and 2) and GE administration did
not exert any effect significantly different from adren¬
alectomy alone, demonstrating that the effect of GE
was dependent on the normal secretion of endogenous
adrenal products and suggesting that the effect of GE
is not a direct pharmacological one or simply stress-
related. Further evidence that the lack of response to
GE in adrenalectomized rats was due to the absence
of endogenous glucocorticoids was provided by the
fact that the hypothalamic-pituitary-adrenal axis
remained responsive to glucocorticoid negative feed¬
back, as shown by the significant reduction of CRF-
41, AVP and oxytocin release into portal blood (Text-
fig. 1) in adrenalectomized animals treated with GE
plus dexamethasone when compared with adrenal¬
ectomy alone (or adrenalectomy plus GE).
DISCUSSION
These results show that 11 P-OHSD mRNA is




□ Adx + GE
I"! Adx + Dex + GE
0 45 min 45 90 min
text-figure. 1. Effects of glycyrrhetinic acid (GE; 5 mg s.c. at 0 and
45 min, n = 10) or vehicle («= 15) on the output of corticotrophin-
releasing factor-41 (CRF-41) into hypophysial portal blood collected
over two consecutive 45-min periods in rats anaesthetized with sodium
pentobarbitone. Further rats were adrenalectomized (Adx) and given
dexamethasone (Dex; 0-2 mg/kg per day) replacement or vehicle for 10
days prior to portal blood sampling (/? = 6 8 per group). Values are
meansis.e.m. */><005 compared with control; tp<0-05 compared
with adrenalectomized animals.
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table 1. Effects of glycyrrhetinic acid (GE; 5 mg; administered s.c. at 0 and 45 min) or
vehicle on peripheral plasma corticosterone, osmolality and glucose concentrations after
90 min in anaesthetized rats. Control and GE-treated rats were adrenally intact. Further
animals were adrenalectomized (Adx) and were given vehicle, GE or dexamethasone
replacement (Dex) and GE. Values are means ±s.e.m. (« = 6 8 per group)
Control GE Adx Adx + GE Adx + Dex + GE
Corticosterone (fag/1) 344±16 274±64 <DL <DL <DL
Osmolality (mosm/kg) 295 ±2 295 ±3
Glucose (mmol/1) 10±0-7 9-7±l-9
< DL = below assay detection limit.
and parvicellular neurones of the PVN and suggest
that the activity of lip-OHSD affects glucocorticoid
negative feedback. This assertion is based on (i) our
in-situ hybridization data and (ii) the fact that inhibi¬
tion of 1 ip-OHSD by GE in intact rats reduced CRF-
41 release into portal blood. The latter occurred in
the absence of any significant change in plasma
corticosterone concentrations and GE had no signifi¬
cant effect on CRF-41 release in adrenalectomized
rats. This suggests that the reduced CRF-41 release
in intact rats treated with GE was due to the negative
feedback of corticosterone which accumulated as a
consequence of decreased metabolism to its inactive
11-dehydro products. Although it is possible that the
increased hypothalamic drive brought about by
adrenalectomy is sufficient to overcome a direct effect
(i.e. not via corticosteroid metabolism) of GE seen in
intact rats, the effect of GE on CRF-41 release is
similar in magnitude to that seen with chronic high-
dose dexamethasone treatment of adrenalectomized
rats, suggesting that lip-OEISD provides a potent
and important degree of regulation of corticosteroid
feedback on CRF-41.
Dexamethasone is a more potent GR-specific lig-
and than corticosterone but has little effect on MR
and since dexamethasone does not appear to exert
any short-term regulatory influence on portal CRF-
41 release (Fink et al. 1988), it is probable that the
effect of corticosterone on unstimulated CRF-41
release is mediated via MR. This accords with previ¬
ous studies of the effects of corticosteroid in the brain
where dexamethasone is less effective than cortico¬
sterone in inhibiting ACTF1 secretion (Levin et al.
1988; Dallman et al. 1989). Physiological cortico¬
sterone feedback on the hypothalamic-pituitary-
adrenal axis, during both the diurnal peak and trough,
is mediated, at least in part, by MR (Dallman et al.
1989; Ratka et al. 1989), aldosterone is selectively
concentrated in the hypothalamus (Yongue & Roy,
1987) and excess corticosterone cannot displace hypo¬
thalamic aldosterone binding in adrenalectomized
rats (McEwen et al. 1986b), providing further evi¬
dence to suggest that lip-OHSD protects hypothal¬
amic MR from corticosterone in vivo.
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Although GE potently inhibits both peripheral and
central lip-OHSD (Edwards et al. 1988; Moisan et
al. 1990a), 1 ip-OHSD is fairly widely distributed in
the brain and since GE is a highly lipophilic steroid¬
like substance, and is therefore also likely to be widely
distributed in the brain, the present studies do not
pin-point precisely where the enzyme exerts its effect
on the corticosteroid control of CRF-41 release. Flow-
ever, as (i) the PVN produces about 90% of the CRF-
41 released into hypophysial portal blood (Antoni et
al. 1990), (ii) stimulation of the PVN, perhaps rather
than other brain areas, results in CRF-41 release into
portal blood (Tannahill et al. 1991) and (iii) the PVN
contains lip-OHSD and GR (Fuxe et al. 1985) as
well as MR (Swanson & Simmons, 1989 and Plate) it
is likely that the PVN represents a major, although
not necessarily the only, site at which lip-OHSD
exerts a controlling influence on the corticosteroid
negative feedback system.
The stimulation of AVP and oxytocin release into
portal blood by GE is puzzling, but as in the case of
the GE-induced decrease in CRF-41 release, the effect
was not seen in adrenalectomized rats and, therefore,
would appear to depend on an adrenal product;
indeed GE tended to decrease portal plasma AVP
content in adrenalectomized animals. In addition to
inhibiting lip-OHSD, GE also inhibits 5P-reductase
and 3P-hydroxysteroid dehydrogenase (Latif et al.
1990) which would result in the increased accumula¬
tion of aldosterone, 5a-dihydroxyaldosterone and
possibly other steroids in the brain. Although these
products bind to MR (Latif et al. 1990), and might
therefore be expected merely to amplify any effect
of corticosterone on 1 ip-OHSD-protected MR, they
might also conceivably stimulate rather than inhibit
AVP and oxytocin release, perhaps via MR at other
sites or by GR antagonism. Dissociation between
CRF-41, AVP and oxytocin release into portal blood
is not unique, in that clear-cut dissociation between
the release of these three neuropeptides into portal
blood has been found to occur under several condi¬
tions (Rivier & Plotsky, 1986; Plotsky & Sawchenko,
1987; Fink et al. 1988; Antoni et al. 1990; Sheward
et al. 1990; Tannahill et al. 1991). Although neurones









0-45 min 45 -90 min
text-figure 2. Effects of glycyrrhetinic acid (GE; 5 mg s.c. at 0 and
45 min, n = 10) or vehicle (n= 15) on the output of (a) AVP and (b)
oxytocin into hypophysial portal blood collected over two consecutive 45-
min periods in rats anaesthetized with sodium pentobarbitone. Further
rats were adrenalectomized (Adx) and given dexamethasone (Dex;
0-2mg/kg per day) replacement or vehicle for 10 days prior to portal
blood sampling (n = 6-8 per group). Values are meansis.e.m. *P<005
compared with control; t/><0 05 compared with adrenalectomized
animals.
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from both parvicellular PVN (AVP- and CRF-
containing cells projecting to the median eminence)
and magnocellular PVN and supraoptic nucleus
(AVP and oxytocin cells projecting to the neurohypo¬
physis) contribute to AVP in portal plasma (Antoni et
al. 1990), there is no evidence that GE affects plasma
osmolality or glucose (present data) or blood pressure
(Seckl et al. 1991), excluding conventional magno¬
cellular AVP activators (osmotic challenge, hypogly-
caemia, hypotension) which might explain increased
AVP and oxytocin release. Thus, the GE-stimulated
release of AVP and oxytocin is an intriguing and
potentially important finding which requires further
investigation.
In summary, the present data imply that lip-
OHSD and possibly other corticosteroid-metabolizing
enzymes in the brain play a major role in the negative
feedback control by corticosteroids ofCRF-41 release
into hypophysial portal blood. The unexpected find¬
ing that GE can stimulate AVP and oxytocin release
in adrenal intact, but not adrenalectomized, rats is
another example of the dissociation between the
release of CRF-41 and the neurohypophysial
peptides.
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DESCRIPTION OF PLATE
High magnification ( x 650) views of paraventricular
nucleus showing in-situ hybridization with biotinylated
cRNA probes. Expression of 11 P-hydroxysteroid dehydro¬
genase (lip-OHSD) mRNA in (Fig. 1) magnocellular
and (Fig. 2) parvicellular paraventricular nucleus; (Fig. 3)
control section incubated with biotinylated lip-OHSD
'sense' RNA probe and (Fig. 4) control section incubated
with hybridization buffer without cRNA probe showing
low 'endogenous biotin' signal. Mineralocorticoid receptor
(MR) mRNA in expression in (Fig. 5) magnocellular and
(Fig. 6) parvicellular paraventricular nucleus. Note pres¬
ence of dark peroxidase product, derived from hybridiz¬
ation of biotinylated cRNA antisense probes to respective
mRNAs, in both magnocellular (m) and parvicellular (p)
neurones. Nuclei are counterstaincd with methyl green.
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ABSTRACT
11 p-Hydroxysteroid dehydrogenase (11P-OHSD)
catalyses the reversible conversion of corticosterone
to inactive 11-dehydrocorticosterone, thus regulating
glucocorticoid access to mineralocorticoid and per¬
haps glucocorticoid receptors in vivo. 11P-OHSD has
been purified from rat liver and an encoding cDNA
isolated from a liver library. However, several lines of
indirect evidence suggest the existence of at least two
isoforms of 11 P-OHSD, one found predominantly in
glucocorticoid receptor-rich tissues and the other
restricted to aldosterone-selective mineralocorticoid
target tissues and placenta. Here we have examined
the effects of chronic (10 day) manipulations of sex-
steroid levels on 11 P-OHSD enzyme activity and
mRNA expression in liver, kidney and hippocampus
and present further evidence for the existence of a
second 11 P-OHSD isoform in kidney.
Gonadectomized male and female rats were given
testosterone, oestradiol or blank silicone elastomer
capsules, controls were sham-operated. In male liver,
gonadectomy+oestradiol treatment led to a dramatic
decrease in both 11 P-OHSD activity (69 ± 8% de¬
crease) and mRNA expression (97 ± 1% decrease).
Gonadectomy and testosterone replacement had no
effect on male liver 11 P-OHSD. However, in female
liver, where 11 p-OHSD activity is approximately 50%
of that in male liver, gonadectomy resulted in a
marked increase in 11 P-OHSD activity (120 ±37%
rise), which was reversed by oestradiol replacement
but not testosterone treatment.
In male kidney, gonadectomy + oestradiol treat¬
ment resulted in a marked increase in 11 P-OHSD
activity (103 ±4% rise). By contrast, 11 P-OHSD
mRNA expression was almost completely repressed
(99 ±0-1% decrease) by oestradiol treatment. This
effect of oestradiol was reflected in a loss of 11P-
OHSD mRNA in all regions of the kidney showing
high expression by in-situ hybridization. In female
kidney, oestradiol replacement also led to an increase
in 11 P-OHSD activity (70 ± 15% rise) while mRNA
expression fell by 95 ± 3%. None of the treatments
had any effect on enzyme activity or mRNA ex¬
pression in the hippocampus, although transcription
starts from the same promoter as liver.
We conclude that (i) sex steroids regulate lip-
OHSD enzyme activity and mRNA expression in a
tissue-specific manner and (ii) the concurrence of
increased enzyme activity with near absent 11P-
OHSD mRNA expression in the kidney following
oestradiol treatment suggests that an additional gene
product is responsible, at least in part, for the high
renal activity observed.
Journal of Endocrinology (1993) 139, 27-35
INTRODUCTION
11 P-Hydroxysteroid dehydrogenase (lip-OHSD) is
an intracellular enzyme, found in almost all tissues
(Monder & Shackleton, 1985), which catalyses the
reversible conversion of corticosterone to inactive
11-dehydrocorticosterone in the rat, or Cortisol to
cortisone in man (Lakshmi & Monder, 1985). 11P-
OHSD activity is high in aldosterone-selective miner¬
alocorticoid tissues such as kidney, where, despite a
100- to 1000-fold molar excess of circulating corticos¬
terone, the otherwise non-selective mineralocorticoid
receptor in the distal convoluted tubules and cortical
collecting ducts selectively binds aldosterone due to
the activity of 11 P-OHSD (Edwards et al. 1988;
Funder et al. 1988). 11 P-OHSD activity is also present
Journal of Endocrinology (1993) 139, 27-35 © 1993 Journal of Endocrinology Ltd Printed in Great Britain
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in tissues containing predominantly glucocorticoid
receptors, including, liver, colon (Fuller & Verity,
1990), skin (Teelucksingh et al. 1990) and cerebellum
(Moisan et al. 1990«), and in tissues which express
mineralocorticoid receptors but respond to physio¬
logical glucocorticoids in vivo, such as hippocampus
(Reul & DeKloet, 1985; Moisan et al. 1990b). Re¬
cently, a cDNA encoding 11 (3-OHSD activity has
been isolated from a rat liver library (Agarwal et al.
1989) and this has been used to demonstrate the
presence of a single 1 1 P-OHSD mRNA species in the
majority of tissues including liver, but multiple species
in kidney (Krozowski et al. 1990). Furthermore, we
have demonstrated tissue-specific promoter usage of
the rat 11P-OHSD gene leading to a single major
transcript in liver, but two additional transcripts in
the kidney, explaining the multiple RNA species
detected (Moisan et al. 1992a). 11 P-OHSD also ex¬
hibits tissue-specific ontogenesis (Moisan et al.
1992b), suggesting that 11 P-OHSD is not constitutive
but regulated. Several previous studies have examined
sex-steroid regulation of 11 P-OFISD activity in
liver and kidney (Ghraf et al. 1975; Lax et al. 1978;
Smith & Funder, 1991) but since 1 lp-OHSD activity
could result from a number of enzyme isoforms, these
studies are no longer definitive. The aim of this
study was, therefore, to examine the effects of sex
steroids on 1 lp-OHSD activity and mRNA encoding
the liver 11P-OHSD isoform and to correlate mRNA
levels (all hybridizing species) with enzyme activity
in liver, kidney and hippocampus following chronic




Male and female rats (Han Wistar, 200-250 g) were
maintained under conditions of controlled lighting
(lights on from 07.00 to 19.00 h) and temperature
(22 °C) with water and food available ad libitum.
Groups of animals (« = 5-6 per group) were
gonadectomized or sham-operated under halo-
thane anaesthesia. Gonadectomized animals were
implanted subdermally with silicone elastomer
capsules (1-98 mm internal diameter, 3-17 mm
external diameter) containing testosterone propi¬
onate or 17P-oestradiol, which produce levels of
testosterone (Naville et al. 1992) and oestradiol
(Painson et al. 1991) not significantly different from
those found in the plasma of control males and
females. The remainder and sham-operated animals
received blank capsules. Rats were killed 10 days
after surgery.
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Assay of 11 P-OHSD enzyme activity
Rats were decapitated and the hippocampus, liver
and kidneys removed and dissected on ice. Tissues
were homogenized in Krebs-Ringer bicarbonate
buffer (118 mmol NaCl/1, 3 8 mmol KC1/1, 119 mmol
KH2P04/1, 2-54 mmol CaCl2 . 2H20/1, 119 mmol
MgS04 . 7H230/1, 25 mmol NaHC03/l and 0-2% glu¬
cose, pH 7-4) and assayed as described previously
(Moisan et al. 1990n). Briefly, after estimating the
total protein concentration colorimetrically (Bio-Rad
protein assay kit, Hemel Hempstead, Herts, U.K.), an
aliquot of homogenate was incubated with 200 pmol
NADP+/1 and 12nmol [1,2,6,7 3H]corticosterone/l
(specific activity, 88 Ci/mmol; Amersham Inter¬
national pic, Amersham, Bucks, U.K.) in Krebs-
Ringer buffer ( + 0-2% bovine serum albumin) for 10
min at 37 °C. The protein concentration in each
reaction was adjusted such that additional protein
produced a linear increase in 11 P-OHSD enzyme
activity. This was found to be 50 mg/1 liver, 25 mg/1
kidney and 500 mg/1 hippocampus. After incubation,
steroids were extracted with ethyl acetate and
separated by thin-layer chromatography. The con¬
version of [3H]corticosterone to [3H] 11-dehydro-
corticosterone was calculated from the radioactivity
of each fraction.
Analysis of mRNA
Total RNA was extracted from hippocampus, liver
and kidney by the guanidinium thiocyanate method
as described (Chomczynski & Sacchi, 1987). Briefly,
tissue was homogenized in 4 mol guanidinium thio-
cyanate/1, 0-025 mol sodium citrate/1, 0-5% sarcosyl
and 0-1 mol P-mercaptoethanol/1. DNA was precipi¬
tated by the addition of 0-2 mol sodium acetate/1 (pH
4) and protein removed by phenol-chloroform extrac¬
tion. The aqueous phase containing RNA was pre¬
cipitated twice with isopropanol and resuspended
in diethylpyrocarbonate-treated water. RNA concen¬
tration and purity was assayed spectrophotometri-
cally and aliquots stored at — 70 °C prior to use.
Aliquots of total RNA from hippocampus (15 pg),
liver (10 pg) and kidney (10 pg) were fractionated on
1-2% agarose-2-2 mol formaldehyde/1 gels and blotted
onto nitrocellulose or nylon (Hybond C extra or
Hybond N, Amersham International pic) by capillary
transfer at 4 °C overnight. Membranes were pre-
hybridized in 50% formamide, 5 x SSPE (20 x
SSPE=6 mol NaCl/1, 018 mol NaH2P04/l, 20 mmol
EDTA/1; pH 7-4), 5 x Denhardt's solution (5 x
Denhardt's = 0T% bovine serum albumin, 0-1%
Ficoll, 0-1% polyvinylpyrolidone), 0-2 g denatured
herring testes DNA/1, 01% sodium dodecyl sulphate
(SDS) and 1 mmol EDTA/1. Hybridization was
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performed in identical buffer containing radiolabeled
11 P-OHSD probe. A 1-2 kb EcoRl fragment encod¬
ing 11 P-OHSD cDNA (Agarwal et al. 1989) was
labelled with [32P]dCTP (3000 Ci/mmol; Amersham
International pic) to a specific activity of 1-2 x
109c.p.m./pg DNA and diluted in hybridization
buffer (3-6 x 106 c.p.m./ml). Hybridization was per¬
formed at 42 °C overnight and the membrane was
washed to a final stringency of 0-2 x SSC (1 x
SSC= 0-5 mol NaCl/1 and 0-015 mol sodium citrate/1),
01% SDS at 60 °C and exposed to Kodak XAR film
for varying lengths of time adjusted to the linear
range of the film. Filters were stripped and rehybrid-
ized under identical conditions with similarly labelled
7S cDNA probes (Balmain et al. 1982) which does not
vary in non-dividing cells (Seckl & Fink, 1992). Films




H GDX + T
□ GDX + OE
(a)
In-situ hybridization
Male rats were gonadectomized and implanted
with silicone elastomer capsules containing oestradiol
or blank. Ten days later they were decapitated and
the brains rapidly removed and frozen on dry ice.
Coronal sections (10 pm) were mounted onto gelatin-
coated poly-l-lysine-treated slides and stored at
- 70 °C prior to hybridization as previously de¬
scribed (Moisan et al. 1990b). Briefly, tissue sections
were post-fixed in 4% paraformaldehyde/0-1 mol
phosphate buffer/1 and washed in 2 x SSC. T3 RNA
polymerase (NBL, Cramlington, Northumberland,
U.K.) was used to transcribe 597 bp 35S-labelled
antisense cRNA probes from Styl linearized Blue-
script vectors containing the 11 p-OHSD cDNA insert
(Agarwal et al. 1989). The [ SJcRNA probe was
denatured and added at a final concentration of
10 x 106 c.p.m./ml lo hybridization buffer (50%
formamide, 0-6 mol NaCl/1, 10 mmol Tris-HCl/1
(pH 7-5), 0-02% Ficoll, 0-02% polyvinylpyrrolidine,
0-1% bovine serum albumin, 1 mmol EDTA/1, 0-1 g
denatured salmon sperm DNA/1, 0-5 g total yeast
tRNA/1, 0-1 mg dextran sulphate/1 and 10 mmol
dithiothreitol/1) and applied to the sections. Slides
were incubated overnight in sealed boxes at 50 °C.
Following hybridization, slides were rinsed twice in
2 x SSC for 15 min at room temperature prior to
RNase A digestion (30 mg/1 for 45 min at 37 °C).
Slides were washed to a maximum stringency of
01 x SSC at 60 °C for 1 h. After air drying, sec¬
tions were exposed to Hyperfilm Pmax (Amersham
International pic) for 10 days and developed. To
demonstrate specificity of the 11P-OHSD probe,
sections were hybridized with a sense probe


















figure 1. Effect of chronic (10 days) sex-steroid
manipulations on (a) 1 lfi-hydroxysteroid dehydrogenase
(11 P-OHSD) enzyme activity and (b) 11 P-OHSD mRNA
expression in male rat liver, kidney and hippocampus.
Data are expressed as a percentage of activity or mRNA
levels in sham-operated controls. GDX = gonadectomy,
GDX+T=gonadectomy + testosterone replacement,
GDX +OE=gonadectomy + oestradiol treatment. *T<0-05
compared with sham-operated controls (Student's r-test).
Primer extension and RNase protection analyses
A synthetic oligonucleotide complimentary to bases
+ 74 to +36 (Agarwal et al. 1989; Moisan et al. 1992a)
was 5' end-labelled with 32P-y-[ATP] (Amersham
International pic) and T4 polynucleotide kinase
(Boehringer Mannheim, Lewes, E. Sussex, U.K.) to a
high specific activity (1-2 x 109 c.p.m./mg). Approxi¬
mately 5 x 105c.p.m. were hybridized in solution to
total hippocampal (100 pg), liver (20 pig) and kidney
(20 pg) RNA samples at 60 °C for 1 h in annealing
buffer (100 mmol KC1/1, 10 mmol MgCL/l, 25 mmol
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figure 2. Northern blot autoradiograph hybridized with 32P-labelled 11 (Vhydroxysteroid dehydrogenase (ll(3-OHSD)
cDNA probe showing the effects of sham-operation (C), gonadectomy (G), gonadectomy+testosterone replacement (T),
gonadectomy + oestradiol treatment (E) for 10 days on 11 P-OHSD mRNA expression in male rat liver, kidney and
hippocampus.
Tris-HCl/1, pH 8 5) in a final volume of 12 pi. Primer
extension reactions were carried out in 40 pi of
30 mmol KC1/1, 8 mmol MgCl2/l, 50 mmol Tris-
HC1/1, 500 pmol each dNTP/1, 50~g actinomycin D/l,
20 units RNase inhibitor (NBL) and 50 units ofAMV
reverse transcriptase (Promega, Southampton, Hants,
U.K.) at 42 °C for 60 min. After phenol-chloroform
extraction and ethanol precipitation, the size of the
reaction product was estimated on a 6% denaturing
polyacrylamide gel by comparison with a sequencing
reaction.
For RNase protection, 32P[CTP]-labelled antisense
RNA probes were synthesized from linear DNA
templates using either T7 or T3 RNA polymerases.
Templates were degraded using DNase I. RNA probe
(1-5 x 106 c.p.m.) was hybridized to hippocampal
(70 pg), liver (20 pg) and kidney (20 pg) RNA samples
overnight at 47 °C in 80% formamide, 0-4 mol NaCl/1,
40 mmol Pipes/1 (pH 6-7) and 1 mmol EDTA/1. Non-
hybridized RNA was degraded by the addition of
RNase A (40 mg/1) and T1 (2 mg/1) for 1 h at 30 °C.
Following proteinase K treatment and phenol-
chloroform extraction, the samples were ethanol-
precipitated and analysed on a 6% polyacrylamide gel
in parallel with a sequencing reaction.
Statistics
Data were compared by analysis of variance
(ANOVA) followed by Student's unpaired /-test. Sig¬




In male rats, gonadectomy alone and following
testosterone replacement did not affect hepatic 11P-
OHSD activity (Fig. la). However, oestradiol admin¬
istration for 10 days produced a large decrease in
enzyme activity of 69 ± 8% in male liver (Fig. la). In
parallel, oestradiol administration for 10 days led to a
dramatic decrease in 11P-OHSD mRNA expression
of 97 ± 1%. As with enzyme activity, no other ma¬
nipulation altered 11P-OHSD mRNA expression
(Figs lb and 2).
In female rats in contrast (where 11 P-OHSD activ¬
ity is approximately 50% of that expressed in male
liver), gonadectomy resulted in a marked increase in
lip-OHSD activity (120 ±37% increase) which was
not affected by testosterone treatment (108 ± 24%
increase compared with controls) but was reversed by
oestradiol replacement (Fig. 3a). However, ovari¬
ectomy either alone or following testosterone treat¬
ment had no effect on 11 p-OHSD mRNA expression,
while oestradiol replacement resulted in a significant
decrease in mRNA levels (to 82 ± 10% of control
levels) (Fig. 3b).
Kidney
Sex-steroid manipulations were associated with
marked changes in both 11 P-OHSD enzyme activity
and mRNA expression in kidney. Gonadectomy of
male rats resulted in a rise in enzyme activity of
72 ± 5% (Fig. la). Testosterone replacement pre¬
vented the gonadectomy-induced increase in enzyme
activity by 10 days (Fig. la). Oestradiol treatment of
gonadectomized rats led to a large increase in 11 p-
OHSD activity (103 ±4% rise) (Fig. la). In striking
contrast, 11 P-OHSD mRNA expression was virtually
undetectable after 10 days (Figs lb and 2). The
oestradiol-induced suppression of 11 P-OHSD gene
transcripts affected all mRNA species expressed in the
kidney.
In female kidney, 11 P-OHSD activity was increased
by 10 days of oestradiol replacement (91 ± 15% rise)
Journal of Endocrinology (1993) 139, 27-35
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figure 3. Effect of chronic (10 day) sex-steroid
manipulations on (a) 11 (3-hydroxysteroid dehydrogenase
(11P-OHSD) enzyme activity and (b) 11 P-OHSD mRNA
expression in female rat liver, kidney and hippocampus.
Data are expressed as a percentage of activity or mRNA
levels in sham-operated controls. OVX=ovariectomy,
OVX+T=ovariectomy with testosterone treatment,
OVX+OE = ovariectomy with oestradiol replacement.
*R<0-05 compared with sham-operated controls
(Student's t-test).
but not by ovariectomy either alone or following
testosterone treatment, in parallel to the changes in
11 P-OHSD activity in males (Fig. 3a). Again, oestra¬
diol treatment resulted in a dramatic decrease in
11 P-OHSD mRNA levels (89±6% decrease) despite
the induction of lip-OHSD activity (Fig. 3b).
Hippocampus
None of the sex-steroid manipulations had any effect
on hippocampal lip-OHSD activity (Figs la and 3a)
or mRNA expression (Figs 1 b, 2 and 3b) in male or
female rats.
In-situ hybridization of lip-OHSD mRNA in kidney
Ten days after gonadectomy lip-OHSD mRNA was
highly expressed in the kidney, localized predomi¬
nantly to the inner cortex and outer medulla, as
previously shown in control kidney (Yau et al. 1991).
Oestradiol treatment for 10 days markedly attenuated
lip-OHSD mRNA expression in all kidney regions
(Fig. 4). Controls hybridized with sense RNA showed
no specific hybridization (data not shown).
Identification of 11P-OHSD transcription start sites
To eliminate the possibility that the lack of regulation
by sex steroids in hippocampus was due to differential
promoter regulation, primer extension analysis was
carried out on RNA isolated from the hippocampus
from untreated animals to determine the start point(s)
of transcription. Extension of the oligonucleotide
(complimentary to bases +74 to +36 within exon 1)
indicated that the major start site in the hippocampus
is the same as the major start site in liver - and is also
used in the kidney (data not shown). These findings
were confirmed using RNase protection (Fig. 5). The
hippocampal transcription start site is 105 base pairs
5' of the start of translation in the liver in agreement
with published findings (Agarwal et al. 1989). This
result, taken with the presence of a single band on
Northern analysis, indicates that the +1 transcription
start site in liver is also used in the hippocampus.
DISCUSSION
11P-OHSD has previously been shown to be regu¬
lated in a complex manner by various hormones
including thyroxine (Hellman et al. 1961; Koerner &
Hellman, 1964; Lax et al. 1979; Zumoff et al. 1983),
insulin (Hammami & Siiteri, 1991; Siiteri et al. 1991)
and glucocorticoids (Moisan et al. 1990c; Hammami
et al. 1991; Smith & Funder 1991). Here we demon¬
strate that hepatic 11P-OHSD enzyme activity and
mRNA expression are sexually dimorphic, showing
repression by oestradiol treatment, whereas gona¬
dectomy or testosterone replacement have no effect
on either enzyme activity or mRNA levels in males,
while gonadectomy in females results in an induction
of 11 P-OHSD activity which is reversed by oestra¬
diol replacement. Hippocampal lip-OHSD enzyme
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figure 4. Autoradiograph of longitudinal rat kidney sections hybridized with
35S-labelled 11 p-hydroxysteroid dehydrogenase (lip-OHSD) cRNA probes
showing lip-OHSD mRNA expression following (a) gonadectomy or (b)
gonadectomy+oestradiol treatment for 10 days.
TCGAHKL Y
figure 5. RNase protection assay. L=liver total RNA; K=kidney total RNA; H = hippocampal total RNA; Y=yeast
RNA; run with a sequencing reaction. The arrowhead indicates the presence of the major transcription start site ( + 1)
at the same position in liver and hippocampus. This start site is also used in kidney.
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activity and mRNA expression are not affected by
any of the sex-steroid manipulations employed. In
contrast to liver and hippocampus, changes in renal
11 P-OHSD mRNA expression do not parallel enzyme
activity; oestradiol treatment results in near complete
loss of 11 P-OHSD mRNA expression but induction
of enzyme activity in both males and females.
Previous studies have shown lip-OHSD enzyme
activity to be regulated by sex steroids in liver (Lax et
al. 1978) and kidney (Smith & Funder, 1991) and that
lip-OHSD enzyme activity is higher in male than
female rat liver (Hoff et al. 1973; Lax et al. 1979).
These studies could not address changes in 11P-
OHSD mRNA expression. We found that following
chronic (10 days) administration of oestradiol to
gonadectomized male rats, liver lip-OFISD enzyme
activity was significantly decreased, in agreement with
previous work (Lax et al. 1978). We have also shown
that oestradiol replacement in female rat liver reverses
the gonadectomy-induced increase in lip-OHSD
activity. In addition, oestradiol treatment markedly
decreased liver 11P-OHSD mRNA expression in
both males and females, suggesting that oestrogen
represses 11 P-OHSD biosynthesis in vivo, explaining
the higher basal levels of 11 P-OHSD activity in male
liver (Lax et al. 1978).
In contrast to liver, hippocampal lip-OHSD en¬
zyme activity and mRNA expression were not altered
by any of the sex-steroid manipulations employed.
This difference is unlikely to be due to failure of access
of oestradiol or testosterone to the brain since both
steroids readily cross the blood-brain barrier and
bind to central receptors when administered periph¬
erally. Furthermore, although the documented tissue-
specific promoter usage of the 11 P-OHSD gene
(Moisan et al. 1992a) might explain the absence of
sex-steroid regulation in hippocampus, we found that
liver and hippocampus predominantly employ the
same promoter, making this unlikely. However,
sexually dimorphic expression of many genes and
gene products is thought to be due to an indirect effect
of sex steroids acting on the secretory profiles of
growth hormone, which differ in male and female rats
(Saunders et al. 1976; Tannenbaum & Martin, 1976).
Thus, genes encoding the major urinary proteins of
mice are expressed at five- to ten-times higher levels in
male than female mouse liver (Hastie et al. 1979;
Mcintosh & Bishop, 1989); this dimorphism can be
reversed by administration of testosterone to females
(Szoka & Paigen, 1978; Clissold et al. 1984) and
represents an indirect effect of testosterone acting to
modify growth hormone secretory patterns (Knopf
et al. 1983; Norstedt & Palmiter, 1984). Similarly,
testosterone induction of the hepatic isoform of 3p-
hydroxysteroid dehydrogenase is mediated by andro¬
gen suppression of growth hormone and can be
reversed by high constant (female-type) growth hor¬
mone replacement (Naville et al. 1991). Since the
effects of oestradiol on 11 P-OHSD activity in kidney
require an intact hypophysis (Ghraf et al. 1975; Lax
et al. 1978), the actions of sex steroids on 11 P-OHSD
may also be growth hormone-mediated. The lack of
regulation of hippocampal 11 P-OHSD by sex steroids
may reflect the failure of peripheral growth hormone,
as with many other peptides, to access the brain.
Recent work has shown that kidney 11 P-OHSD
enzyme activity in increased by chronic (10 day)
oestradiol treatment, but is not regulated by gonadec-
tomy or testosterone replacement (Smith & Funder,
1991). We now show that gonadectomy induces 11P-
OHSD activity in males, an effect which is reversed by
testosterone replacement, and that chronic oestradiol
administration markedly induces 11 P-OHSD enzyme
activity, but almost completely represses 11 P-OHSD
mRNA expression in both males and females. There
are several possible explanations for the discrepancy
between renal 11 P-OHSD mRNA expression and
enzyme activity, (i) This might represent differences in
turnover/half-life of mRNA and protein. However,
given the degree of transcriptional repression it is very
unlikely that increased enzyme activity represents
enhanced translation of any remaining mRNA. Nor,
at least from the liver 11 P-OHSD data presented here,
do such gross differences between mRNA and protein
half-life seem likely explanations for the opposite
changes in mRNA levels and enzyme activity seen in
kidney, (ii) Previous studies using 11 P-OHSD cDNA
probes encoding 'liver-type' lip-OHSD have shown
multiple mRNA species in the kidney (Krozowski et
al. 1990), including a cDNA encoding a truncated
protein which contains the putative active sites of the
enzyme. However, it appears unlikely that any one of
these mRNA species is responsible for the high
enzyme activity in the kidney since all result from
differential promoter usage of the same gene (Moisan
et al. 1992a) and all were repressed following oestra¬
diol treatment, (iii) Alternatively, a second gene prod¬
uct might be responsible for oestradiol-induced renal
11 P-OHSD enzyme activity. The second gene would
presumably produce mRNA which hybridizes very
weakly or not at all on Northern analysis with the
cloned 'liver-type' 11 P-OHSD cDNA. This hypoth¬
esis is supported by several studies which suggest the
presence of a second 11 P-OHSD in kidney. Western
blots have demonstrated three immunoreactive com¬
ponents in the kidney (Monder & Lakshmi, 1990),
while kinetic studies have indicated the presence of an
11 p-OHSD with a Km two orders of magnitude lower
than the hepatic species (Naray-Fejes-Toth et al.
1991). Histochemical studies performed on rat kidney
have identified an NAD+-requiring species (Mercer &
Krozowski, 1991), while we have shown NAD + -
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dependence of human and rat placental and rat renal
11 p-OHSD and have, in addition, partially purified
the human placental isoform of 11 P-OHSD, which
has a much higher glucocorticoid affinity (Aim low
nmol/1) than the liver isoform, suggesting that the
NAD+-dependent enzyme present in rat kidney may
be more suited to 'protect' renal mineralocorticoid
receptors from circulating glucocorticoids (Brown et
al. 1993a,6). Finally, during development, lip-OHSD
activity in the kidney is high from postnatal day 1
whereas 'liver-type' 11 P-OHSD mRNA expression is
low and does not reach adult levels until postnatal
day 15 (Moisan et al. 1992b).
These experiments demonstrate that 11 P-OHSD is
regulated by sex steroids in a tissue-specific manner.
The discrepancy between oestradiol-mediated induc¬
tion of 11 P-OHSD activity in the kidney in the face of
near complete repression of all known mRNA tran¬
scripts of the cloned 'liver-type' 11 P-OHSD gene lend
strong support to suggestions that more than one
gene encodes 11 P-OHSD activities. The nature of
the oestrogen-induced renal enzyme remains to be
determined.
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